var title_f30_53_31568="Categories of idiopathic pediatric acute liver failure";
var content_f30_53_31568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Categories of idiopathic pediatric acute liver failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The etiology of pediatric acute liver failure (PALF) is identified in approximately 55 percent of cases, leaving an indeterminate cause in 45 percent. Indeterminate cases are likely composed of a number separate conditions including immune dysregulation, with the latter condition having a variety of manifestations.",
"    <div class=\"footnotes\">",
"     %: percent; APAP: acetaminophen (paracetamol).",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Suchy FJ, Sokol RJ, Balistreri WF, Eds. Liver Disease in Children, 4th Ed. Cambridge University Press, New York, 2012. Copyright &copy; 2012 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31568=[""].join("\n");
var outline_f30_53_31568=null;
var title_f30_53_31569="Patient information: Frostbite (The Basics)";
var content_f30_53_31569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/6/109\">",
"         Patient information: Hypothermia (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Frostbite (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1823182349\">",
"      <span class=\"h1\">",
"       What is frostbite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Frostbite is damage to a body part caused by cold. It can be mild or severe.",
"     </p>",
"     <p>",
"      Frostbite is most common on the ears, nose, cheeks, chin, fingers, and toes. Skin affected by frostbite might look white and feel numb or hard.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182364\">",
"      <span class=\"h1\">",
"       What are the symptoms of frostbite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cold, numb skin &ndash; Skin might look white or gray and feel hard or waxy.",
"       </li>",
"       <li>",
"        Trouble moving the affected area - For example, fingers with frostbite might feel clumsy.",
"       </li>",
"       <li>",
"        Blisters with fluid or blood inside",
"       </li>",
"       <li>",
"        Areas of black skin &ndash; This is a sign of severe frostbite.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182379\">",
"      <span class=\"h1\">",
"       How can I help a person who might have frostbite?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you think you or someone you are with might have frostbite, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Move the person to a warmer place as soon as possible",
"       </li>",
"       <li>",
"        Take off any wet clothing",
"       </li>",
"       <li>",
"        Try to warm up the affected area. To do this, you can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Put it in warm water &ndash; The water should feel comfortable when you touch it with unaffected skin. Do NOT use hot water.",
"       </li>",
"       <li>",
"        Use body heat &ndash; For example, you can hold cold, numb fingers under the armpits.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid things that could cause worse damage. For example:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Try not to walk on feet that have frostbite, unless you have to walk to get to a warm place.",
"       </li>",
"       <li>",
"        Do not warm the area if it might get cold again before you see a doctor or nurse.",
"       </li>",
"       <li>",
"        Do not rub the area.",
"       </li>",
"       <li>",
"        Do not use a stove or fire to warm the area, because numb skin can get burned by accident.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If frostbite symptoms don&rsquo;t get better after taking these steps, get to a hospital as soon as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182396\">",
"      <span class=\"h1\">",
"       How is frostbite treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warming the affected area in water &ndash; This can hurt, but doctors can give medicines to help with pain.",
"       </li>",
"       <li>",
"        Medicine to help with blood flow &ndash; Frostbite can cause blood clots in affected body parts. If the clots could cause serious damage, doctors might give a medicine called &ldquo;tPA&rdquo; to help the blood flow normally again. But tPA increases the risk of severe bleeding, including bleeding in the brain. So doctors only give it to people with a low risk of bleeding.",
"       </li>",
"       <li>",
"        Tetanus shot &ndash; Tetanus is a germ (bacteria) that lives in the soil. It can get into tissue that is damaged by frostbite. A tetanus shot prevents people from getting sick.",
"       </li>",
"       <li>",
"        Antibiotics &ndash; Tissue that is damaged by frostbite is more likely to get infected. If this happens, doctors can give antibiotic medicines.",
"       </li>",
"       <li>",
"        Surgery &ndash; Severe frostbite can kill tissue. The dead tissue sometimes falls off by itself, but doctors sometimes need to remove it. Some people with severe frostbite need a kind of surgery called &ldquo;amputation,&rdquo; to remove a damaged body part.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182413\">",
"      <span class=\"h1\">",
"       Can frostbite be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. In most cases, you can prevent frostbite by being careful not to stay out in the cold for too long. Be sure to dress warmly enough. It can be good to wear:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A hat",
"       </li>",
"       <li>",
"        Face protection, such as a ski mask",
"       </li>",
"       <li>",
"        Sunglasses or goggles",
"       </li>",
"       <li>",
"        Mittens &ndash; Mittens keep hands warmer than gloves.",
"       </li>",
"       <li>",
"        Warm, water-resistant shoes or boots",
"       </li>",
"       <li>",
"        Layers of clothing - These might include long underwear, fleece or wool clothing, and a coat and pants that protect against wind, rain, and snow.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It can also help to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat enough when you are out in the cold",
"       </li>",
"       <li>",
"        Avoid alcohol and smoking",
"       </li>",
"       <li>",
"        Avoid contact with water or metal &ndash; These can be very cold.",
"       </li>",
"       <li>",
"        Know the weather &ndash; If it gets very cold and windy, frostbite can happen more quickly (in a few minutes).",
"       </li>",
"       <li>",
"        Tell people where you are going",
"       </li>",
"       <li>",
"        Carry emergency supplies in case you are outside longer than you planned",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people put lotion or ointment on the skin to prevent frostbite. But this might actually make frostbite more likely.",
"     </p>",
"     <p>",
"      Most people think frostbite only happens outside. But putting cold objects on the skin, such as ice packs, can cause frostbite. Only use an ice pack (or other cold object) for 15 minutes every 1 or 2 hours. Put a cloth or towel between the ice and your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182437\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=see_link\">",
"       Patient information: Hypothermia (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?30/53/31569?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86011 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31569=[""].join("\n");
var outline_f30_53_31569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182349\">",
"      What is frostbite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182364\">",
"      What are the symptoms of frostbite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182379\">",
"      How can I help a person who might have frostbite?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182396\">",
"      How is frostbite treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182413\">",
"      Can frostbite be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182437\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=related_link\">",
"      Patient information: Hypothermia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31570="First degree AV block IV";
var content_f30_53_31570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Marked first degree AV block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram of leads V1, II, and V5 showing marked first degree AV block. The P waves are indicated by the arrows. The PR interval is 0.84 sec and the QRS duration is 0.08 sec. The P wave is almost obscured by the preceding T wave in leads II and V5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rory Childers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31570=[""].join("\n");
var outline_f30_53_31570=null;
var title_f30_53_31571="Herpes zoster rash 1 PI";
var content_f30_53_31571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50627%7EPI%2F66249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50627%7EPI%2F66249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Shingles (herpes zoster)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shingles (herpes zoster)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31571=[""].join("\n");
var outline_f30_53_31571=null;
var title_f30_53_31572="PKDL macules";
var content_f30_53_31572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Post kala-azar dermal leishmaniasis macules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive hypopigmented macular PKDL in an 8 year old girl in Bangladesh. She had a history of kala-azar that resolved with sodium stibogluconate treatment 28 months prior to the onset of the rash.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Caryn Bern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31572=[""].join("\n");
var outline_f30_53_31572=null;
var title_f30_53_31573="Ferric gluconate: Drug information";
var content_f30_53_31573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferric gluconate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/39/39539?source=see_link\">",
"    see \"Ferric gluconate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/37/13909?source=see_link\">",
"    see \"Ferric gluconate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;;",
"     </li>",
"     <li>",
"      Nulecit&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3958031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Iron-deficiency anemia, hemodialysis patients:",
"     </b>",
"     I.V.: 125 mg elemental iron per dialysis session. Most patients will require a cumulative dose of 1 g elemental iron over approximately 8 sequential dialysis treatments to achieve a favorable response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A test dose of 2 mL diluted in NS 50 mL administered over 60 minutes was previously recommended (not in current manufacturer labeling). Doses &gt;125 mg are associated with increased adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cancer-/chemotherapy-associated anemia (unlabeled use):",
"     </b>",
"     I.V. infusion: 125 mg over 1 hour; maximum: 250 mg/infusion. Repeat dose every week for 8 doses. Test doses (25 mg slow I.V. push or infusion) are recommended in patients with iron dextran hypersensitivity or those with other drug allergies (NCCN guidelines, v.2.2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/37/13909?source=see_link\">",
"      see \"Ferric gluconate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Iron-deficiency anemia, hemodialysis patients:",
"     </b>",
"     Children &ge;6 years: I.V.: 1.5 mg/kg of elemental iron (maximum: 125 mg/dose) per dialysis session. Doses &gt;1.5 mg/kg are associated with increased adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14313378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14313379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Elemental iron 12.5 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrlecit&reg;: Elemental iron 12.5 mg/mL (5 mL) [contains benzyl alcohol, sucrose 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nulecit&trade;: Elemental iron 12.5 mg/mL (5 mL [DSC]) [contains benzyl alcohol, sucrose ~20%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.: Iron-deficiency anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Dilute in NS 25 mL: Administer over 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Avoid rapid administration. May administer diluted in 100 mL NS over 1 hour. If administered undiluted, infuse slowly at a rate of up to 12.5 mg/minute.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F170726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable with 0.9% sodium chloride; do not mix with parenteral nutrition solutions or other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of iron-deficiency anemia in patients undergoing hemodialysis in conjunction with erythropoietin therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cancer-/chemotherapy-associated anemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ferric gluconate may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported in adults unless otherwise noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension (children 35%; adults 29%), hypertension (children 23%; adults 13%), tachycardia (children 17%; adults 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (children 24%; adults 7%), dizziness (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (adults &le;35%; children 11%), nausea (adults &le;35%; children 9%), diarrhea (adults &le;35%; children 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Erythrocytes abnormal (11% [changes in morphology, color, or number])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site reaction (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Cramps (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (10%), syncope (6%), edema (5%), angina pectoris, bradycardia, hypervolemia, MI, peripheral edema, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (10%), fever (children 9%; adults 5%), fatigue (6%), agitation, chills, consciousness decreased, lightheadedness, malaise, rigors, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (6%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (6%), hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (children 9%; adults 6%), anorexia, dyspepsia, eructation, flatulence, GI disorder, melena, rectal disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Menorrhagia, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombosis (children 6%), anemia, leukocytosis, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps (10%), weakness (7%), paresthesias (6%), arm pain, arthralgia, back pain, leg edema, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Arcus senilis, conjunctivitis, diplopia, puffy eyelids, redness of eyes, rolling of eyes, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (children 9%), cough (6%), rhinitis (children 6%), upper respiratory infections (6%), pneumonia, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Abscess, carcinoma, diaphoresis, flu-like symptoms, infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reaction, anaphylactic reactions, convulsion, facial flushing, hemorrhage, hypertonia, hypoesthesia, loss of consciousness, shock, skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ferric gluconate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Clinically significant hypotension may occur; usually resolves within 1-2 hours. May augment hemodialysis-induced hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylactoid reactions, have occurred. Monitor during administration and for &ge;30 minutes after administration until clinically stable. Avoid rapid administration. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates (not indicated for use in this population).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use only in patients with documented iron deficiency; caution with hemoglobinopathies or other refractory anemias as iron overload may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ferrlecit Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/mL (5 mL): $38.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Na Ferric Gluc Cplx in Sucrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg/mL (5 mL): $38.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferrous Gluconate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 (27 Fe) mg (100): $1.91",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin and hematocrit, serum ferritin, iron saturation; vital signs; signs and symptoms of hypersensitivity (monitor for &ge;30 minutes following the end of administration and until clinically stable)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NKF K/DOQI guidelines recommend that iron status should be monitored monthly during initiation through the percent transferrin saturation (TSAT) and serum ferritin.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3889017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CKD patients should have sufficient iron to achieve and maintain hemoglobin of 11-12 g/dL. To achieve and maintain this target Hgb, sufficient iron should be administered to maintain a TSAT of 20%, and a serum ferritin level &gt;100 ng/mL (nondialysis chronic kidney disease and peritoneal dialysis chronic kidney disease) or serum ferritin level &gt;200 ng/mL (hemodialysis chronic kidney disease).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F855042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Efecient (IN);",
"     </li>",
"     <li>",
"      Ferritin Oti (PT);",
"     </li>",
"     <li>",
"      Ferrlecit (CZ, DE, HN, IL);",
"     </li>",
"     <li>",
"      Fu-Iron (TW);",
"     </li>",
"     <li>",
"      Ladyline (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplies a source to elemental iron necessary to the function of hemoglobin, myoglobin and specific enzyme systems; allows transport of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: Bound iron: 1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/53/31573/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/53/31573/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 2.2010.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):529-30. Available at file://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm or  file://www.kidney.org/professionals/KDOQI",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8936 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31573=[""].join("\n");
var outline_f30_53_31573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855041\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170721\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958031\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170715\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170707\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14313378\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14313379\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170691\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170676\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170693\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170726\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170692\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349544\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170728\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170719\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170696\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170680\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299320\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170685\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170687\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170697\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789331\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323148\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170689\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3889017\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855042\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170679\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170695\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8936\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8936|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/39/39539?source=related_link\">",
"      Ferric gluconate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/37/13909?source=related_link\">",
"      Ferric gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31574="Electrical stimulation for gastroparesis";
var content_f30_53_31574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrical stimulation for gastroparesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31574/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31574/contributors\">",
"     William L Hasler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31574/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31574/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31574/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31574/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/53/31574/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroparesis is defined as a delay in gastric emptying that produces nausea, vomiting, bloating, early satiety, and discomfort. In severe cases, nausea and vomiting may cause weight loss, dehydration, electrolyte disturbances, and malnutrition due to inadequate caloric and fluid intake.",
"   </p>",
"   <p>",
"    Management of gastroparesis consists of supportive measures (eg, hydration and nutrition), optimizing glycemic control in patients with diabetes mellitus, medications, and occasionally surgical therapy. The limited efficacy of these options for patients with severe gastroparesis has provided a rationale for the development of novel approaches for treatment.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the methods of electrical stimulation of gastric motor activity for gastroparesis and their efficacy in treating gastroparesis. The pathophysiology, etiology, diagnosis, and treatment of gastroparesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link\">",
"     \"Pathogenesis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYOELECTRIC CONTROL OF GASTRIC MOTOR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emptying of gastric contents after a meal is controlled by specific motor and myoelectric activities of different regions of the stomach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximal stomach exhibits changes in tone in response to eating, which serve initially to accommodate the ingested bolus and then, as digestion progresses, to regulate delivery of food particles into the distal stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The distal stomach exhibits a fed motor pattern consisting of phasic contractions that propagate from the gastric body to the pylorus at a maximal frequency of three cycles per minute (cpm). These serve to grind and mix the food into a fine particulate suspension [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Impairment of normal phasic motor activity in the distal stomach produces the clinical condition of gastroparesis. The frequency and direction of the phasic motor activity is regulated by the gastric slow wave, a rhythmic electrical oscillation, which is believed to be generated by the interstitial cells of Cajal in the proximal gastric body, the \"pacemaker\" zone of the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/4\">",
"     4",
"    </a>",
"    ]. The slow wave is ubiquitously present at a frequency of 3 cpm, regardless of the contractile state of the stomach. During motor quiescence, the slow wave exhibits a plateau potential of low amplitude. Phasic contractions are generated when the slow wave plateau potential increases in amplitude or when action potentials are stimulated by meal-induced neurohumoral activators [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300680411\">",
"    <span class=\"h1\">",
"     GASTRIC ELECTRICAL STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal methods of gastric electrical stimulation are high frequency gastric electrical stimulation and gastric electrical pacing. The former has limited evidence of efficacy and is available for humanitarian treatment in patients with gastroparesis that is refractory to other therapies, while the latter is at present too large for implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300680277\">",
"    <span class=\"h2\">",
"     High frequency gastric electrical stimulation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2044925\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of high frequency gastric electrical neurostimulation at 12 cpm is uncertain, but probably does not relate to stimulation of gastric emptying. Little or no consistent acceleration of solid phase emptying has been observed in clinical trials of neurostimulation. In one retrospective review of 63 patients, gastric stimulation reduced gastric retention at four hours by only 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Low energy, high frequency neurostimulation also has no effect on basal gastric electrical activity and has no effect on dysrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However, it enhances slow wave amplitude and propagation velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/8\">",
"     8",
"    </a>",
"    ]. Gastric neurostimulation modifies sympathovagal activity and modulates activity in thoracic spinal neurons that are responsive to gastric distention [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H591275\">",
"    <span class=\"h3\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized controlled crossover studies have been reported in patients with diabetic and idiopathic gastroparesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first suggested that there was significant benefit with treatment on versus off in a combined group of idiopathic and diabetic gastroparesis with the predominant benefit in those with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, the second controlled study in diabetic gastroparesis showed no difference between on and off treatment periods after an initial six weeks unblinded on treatment phase [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/15\">",
"       15",
"      </a>",
"      ]. However, following the on and off treatment periods all patients had their stimulators turned on and all had improvements in subjective and objective parameters with chronic stimulation after 12 months of gastric electrical stimulation, compared with baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of small uncontrolled studies have reported clinically important benefits of gastric electrical stimulation including an improvement in nausea and vomiting in patients with diabetic and idiopathic gastroparesis, and gastroparesis due to other causes (eg, after fundoplication for gastroesophageal reflux disease, esophagectomy for esophageal carcinoma, Roux-en-Y gastric bypass for morbid obesity, chronic intestinal pseudoobstruction, and transplantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/16-27\">",
"     16-27",
"    </a>",
"    ]. The response rates to gastric neurostimulation in these uncontrolled studies range from 50 to 92 percent with continued reduction in gastroparesis symptoms for up to ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/15,28,29\">",
"     15,28,29",
"    </a>",
"    ]. However, the potential role of gastric electrical stimulation is not clear given the less convincing benefit in randomized controlled crossover trials [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/14,30\">",
"     14,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies have also reported an improvement in body mass index, HbA1c, serum albumin, and reduction in the need for prokinetic medication and supplemental nutrition with gastric electrical stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/18,19,22,31\">",
"     18,19,22,31",
"    </a>",
"    ]. Gastric stimulation has also been associated with an improvement in physical and mental quality of life scores and reduction in the need for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/18,19,21\">",
"     18,19,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H591135\">",
"    <span class=\"h3\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of high-frequency gastric electrical stimulation including infection, lead dislodgement, and bowel obstruction, have necessitated removal of the device in more than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/17\">",
"     17",
"    </a>",
"    ]. Battery life has not been well defined, although some series report a need for repeat surgery for battery replacement less than 10 years after initial device implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H591226\">",
"    <span class=\"h3\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have attempted to identify factors that predict a response to gastric neurostimulation in patients with gastroparesis. In one study, patients with nausea and vomiting and those without narcotic dependence prior to placement of the stimulator had a more favorable clinical response than those with bloating or abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with diabetes exhibited greater symptom reductions than patients with idiopathic disease. Energy requirements in patients with postsurgical gastroparesis are higher than for other causes of disease, suggesting this group may be less responsive to neurostimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590950\">",
"    <span class=\"h3\">",
"     Potential candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with documented gastroparesis and severe nausea and vomiting (occurring on average at least once daily) refractory to aggressive antiemetic and prokinetic drug therapy for at least one year may be candidates for electrical stimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Evaluation of patients with suspected gastric stasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gastric electrical neurostimulator (Enterra Therapy system, Medtronic, Inc., Minneapolis, MN) is not approved by the US Food and Drug Administration (FDA) for unrestricted marketing for the treatment of gastroparesis. However, it is approved as a humanitarian use device (HUD). In addition, because of probable benefit rather than established effectiveness, the device has also received humanitarian device exemption (HDE) approval for the treatment of refractory diabetic and idiopathic gastroparesis, documented by objective measures of gastric emptying of solids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Scintigraphic gastric emptying'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neurostimulator has not been documented to reduce pain, fullness, bloating, or acid reflux symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/23\">",
"     23",
"    </a>",
"    ]. As a result, it is uncertain if the therapy will be beneficial if these symptoms predominate. Because of the risk of infection after surgery, patients on immunosuppressive therapy may not be optimal candidates for this technology. The effects of neurostimulation on the developing fetus are unknown; thus gastric neurostimulation should not be performed during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastric pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric pacing aims to reset a regular slow-wave rhythm. It involves giving the gastric wall a pulse stimulus with a constant current lasting 30 to 500 ms during a nonrefractory period to generate an extra slow wave which propagates along the gastric wall. The benefits of gastric pacing have been suggested in small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/9,33\">",
"     9,33",
"    </a>",
"    ]. However, this method of stimulation is impractical at the present time as the external current source needed to generate the energy to entrain the slow wave is too large for implantation.",
"   </p>",
"   <p>",
"    An early trial of gastric pacing in patients with postoperative gastroparesis observed entrainment of the intrinsic slow wave in 10 of 16 patients; however, this method did not accelerate gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/34\">",
"     34",
"    </a>",
"    ]. In an open label trial of gastric pacing, nine patients with prokinetic medication-resistance gastroparesis (five diabetic, three idiopathic, one postvagotomy) received high energy, electrical stimulation at a rate slightly higher than the normal slow wave frequency through surgically implanted electrodes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/33\">",
"     33",
"    </a>",
"    ]. When delivered just before and after meals, the pacing stimuli entrained the slow wave in all individuals and underlying rhythm disturbances were reversed in the two patients with spontaneous slow wave dysrhythmias. After one month, gastroparetic symptoms were markedly improved and eight patients no longer required jejunal tube feedings. Furthermore, solid phase gastric emptying was significantly enhanced compared to prestimulation values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;New approaches to gastric electrical stimulation continue to be developed. Progress in nonoperative methods of electrode insertion, device miniaturization, battery technology, and the development of devices that deliver variable stimuli may extend the range of options available to patients with severe gastroparesis that is unresponsive to medications.",
"   </p>",
"   <p>",
"    Techniques of electrode implantation that avoid the need for laparotomy or laparoscopy may broaden the applicability of gastric neurostimulation methods. Use of endoscopically-placed temporary stimulating electrodes has been proposed to help predict who might respond to a permanently implanted device [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/35\">",
"     35",
"    </a>",
"    ]. A percutaneous electrode system has been developed to deliver neurostimulating pulses [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/36\">",
"     36",
"    </a>",
"    ]. With this technique, a cannula with an internal needle is introduced percutaneously and advanced to the gastric submucosal region. A self-anchoring electrode is then placed through the needle. This method has been used to deliver electrical stimuli for up to eight weeks in patients with gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/37\">",
"     37",
"    </a>",
"    ]. Electrodes that can be placed during percutaneous gastrostomy placement have also been devised [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/38\">",
"     38",
"    </a>",
"    ]. These electrodes have been proposed as a means of delivering high energy pacing stimuli from external current sources.",
"   </p>",
"   <p>",
"    Gastric pacing has the disadvantage of requiring a large external current source to deliver the high energy impulses needed to stimulate gastric contractions. Several multichannel stimulation protocols have been devised to deliver high energy pulses in sequential fashion that evoke propagating contractions and enhance gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Some groups have used stimulus protocols that entrain intrinsic slow wave activity, while others advocate high energy stimuli that stimulate gastric neural activity independently of intrinsic electrical oscillations. In one study, stimulation energies for four-channel pacing were only 1 percent of the levels needed for single-channel pacing, suggesting that implantable pacemakers might be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/40\">",
"     40",
"    </a>",
"    ]. Two-channel pacing has shown efficacy in stimulating gastric emptying and reducing symptoms in patients with severe diabetic gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another area of investigation relates to development of devices that deliver variable stimuli, which exert beneficial effects both on symptoms and gastric emptying. In canine studies, stimulation with low energy pulses of short duration alternating with high energy pulses of long duration exerted antiemetic effects and reversed slow wave dysrhythmias elicited by the emetic stimulus vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31574/abstract/43\">",
"     43",
"    </a>",
"    ]. Such dual stimulation protocols combine the effective features of both gastric neurostimulation and pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9577030\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The principal methods of gastric electrical stimulation are high frequency gastric electrical stimulation and gastric electrical pacing. (See",
"      <a class=\"local\" href=\"#H1300680411\">",
"       'Gastric electrical stimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High frequency gastric electrical stimulation has no effect on basal gastric electrical activity and has no effect on dysrhythmias but modifies sympathovagal activity and thereby gastric distention. While a number of small uncontrolled studies suggest clinically important benefits of gastric electrical stimulation including an improvement in nausea and vomiting associated with gastroparesis, sham controlled trials have not consistently demonstrated a decrease in the frequency of vomiting in patients with gastroparesis. (See",
"      <a class=\"local\" href=\"#H2044925\">",
"       'Mechanism of action'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H591275\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe nausea and vomiting (occurring on average at least once daily), which have proven refractory to aggressive antiemetic and prokinetic drug therapy for at least one year in duration may be candidates for gastric neurostimulation.",
"      <br/>",
"      <br/>",
"      In the United States, the gastric electrical neurostimulator (Enterra Therapy system, Medtronic, Inc., Minneapolis, MN) has been approved as a humanitarian exemption device only for diabetic and idiopathic gastroparesis. (See",
"      <a class=\"local\" href=\"#H590950\">",
"       'Potential candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nausea and vomiting and those without narcotic dependence prior to placement of the stimulator have a more favorable clinical response than those with bloating or abdominal pain. As compared to patients with idiopathic disease, patients with diabetes have greater symptom reduction with gastric electrical stimulation. Patients with postsurgical gastroparesis may be less responsive to neurostimulation. (See",
"      <a class=\"local\" href=\"#H591226\">",
"       'Predictors of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of high frequency gastric electrical stimulation including infection, lead dislodgement, and bowel obstruction. (See",
"      <a class=\"local\" href=\"#H591135\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric pacing involves giving the gastric wall a pulse stimulus with a constant current lasting 30 to 500 ms during a nonrefractory period to generate an extra slow wave which propagates along the gastric wall. The benefits of gastric pacing have been suggested in small uncontrolled studies. However, this method of stimulation is impractical at the present time as the external current source needed is too large for implantation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Gastric pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progress in nonoperative methods of electrode insertion, device miniaturization, battery technology, and the development of devices that deliver variable stimuli may extend the range of options available to patients with severe gastroparesis that is unresponsive to medications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Future directions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/1\">",
"      Ahluwalia NK, Thompson DG, Barlow J. Effect of distension and feeding on phasic changes in human proximal gastric tone. Gut 1996; 39:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/2\">",
"      Collins PJ, Horowitz M, Chatterton BE. Proximal, distal and total stomach emptying of a digestible solid meal in normal subjects. Br J Radiol 1988; 61:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/3\">",
"      Rees WD, Go VL, Malagelada JR. Antroduodenal motor response to solid-liquid and homogenized meals. Gastroenterology 1979; 76:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/4\">",
"      Hinder RA, Kelly KA. Human gastric pacesetter potential. Site of origin, spread, and response to gastric transection and proximal gastric vagotomy. Am J Surg 1977; 133:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/5\">",
"      Morgan KG, Szurszewski JH. Mechanisms of phasic and tonic actions of pentagastrin on canine gastric smooth muscle. J Physiol 1980; 301:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/6\">",
"      Lin Z, Hou Q, Sarosiek I, et al. Association between changes in symptoms and gastric emptying in gastroparetic patients treated with gastric electrical stimulation. Neurogastroenterol Motil 2008; 20:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/7\">",
"      Xing J, Brody F, Rosen M, et al. The effect of gastric electrical stimulation on canine gastric slow waves. Am J Physiol Gastrointest Liver Physiol 2003; 284:G956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/8\">",
"      Lin Z, Forster J, Sarosiek I, McCallum RW. Effect of high-frequency gastric electrical stimulation on gastric myoelectric activity in gastroparetic patients. Neurogastroenterol Motil 2004; 16:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/9\">",
"      Chen JD, Qian L, Ouyang H, Yin J. Gastric electrical stimulation with short pulses reduces vomiting but not dysrhythmias in dogs. Gastroenterology 2003; 124:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/10\">",
"      Liu J, Qiao X, Chen JD. Vagal afferent is involved in short-pulse gastric electrical stimulation in rats. Dig Dis Sci 2004; 49:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/11\">",
"      Xing JH, Brody F, Brodsky J, et al. Gastric electrical stimulation at proximal stomach induces gastric relaxation in dogs. Neurogastroenterol Motil 2003; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/12\">",
"      McCallum RW, Dusing RW, Sarosiek I, et al. Mechanisms of high-frequency electrical stimulation of the stomach in gastroparetic patients. Conf Proc IEEE Eng Med Biol Soc 2006; 1:5400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/13\">",
"      Qin C, Chen JD, Zhang J, Foreman RD. Modulatory effects and afferent pathways of gastric electrical stimulation on rat thoracic spinal neurons receiving input from the stomach. Neurosci Res 2007; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/14\">",
"      Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003; 125:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/15\">",
"      McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010; 8:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/16\">",
"      O'Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg 2009; 33:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/17\">",
"      Abell TL, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002; 66:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/18\">",
"      Forster J, Sarosiek I, Lin Z, et al. Further experience with gastric stimulation to treat drug refractory gastroparesis. Am J Surg 2003; 186:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/19\">",
"      Abell T, Lou J, Tabbaa M, et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr 2003; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/20\">",
"      Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil 2005; 17:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/21\">",
"      Lin Z, McElhinney C, Sarosiek I, et al. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci 2005; 50:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/22\">",
"      Lin Z, Sarosiek I, Forster J, McCallum RW. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil 2006; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/23\">",
"      Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci 2008; 53:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/24\">",
"      McCallum R, Lin Z, Wetzel P, et al. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005; 3:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/25\">",
"      Salameh JR, Schmieg RE Jr, Runnels JM, Abell TL. Refractory gastroparesis after Roux-en-Y gastric bypass: surgical treatment with implantable pacemaker. J Gastrointest Surg 2007; 11:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/26\">",
"      Andersson S, L&ouml;nroth H, Simr&eacute;n M, et al. Gastric electrical stimulation for intractable vomiting in patients with chronic intestinal pseudoobstruction. Neurogastroenterol Motil 2006; 18:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/27\">",
"      Filichia LA, Cendan JC. Small case series of gastric stimulation for the management of transplant-induced gastroparesis. J Surg Res 2008; 148:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/28\">",
"      Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion 2007; 75:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/29\">",
"      McCallum RW, Lin Z, Forster J, et al. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 2011; 9:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/30\">",
"      McCallum RW, et al. Enterra gastric electrical stimulation for idiopathic gastroparesis: Results from a multicenter randomized study (abstract). Gastroenterology 2010; 138:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/31\">",
"      van der Voort IR, Becker JC, Dietl KH, et al. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes 2005; 113:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/32\">",
"      Abidi N, Starkebaum WL, Abell TL. An energy algorithm improves symptoms in some patients with gastroparesis and treated with gastric electrical stimulation. Neurogastroenterol Motil 2006; 18:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/33\">",
"      McCallum RW, Chen JD, Lin Z, et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/34\">",
"      Hocking MP, Vogel SB, Sninsky CA. Human gastric myoelectric activity and gastric emptying following gastric surgery and with pacing. Gastroenterology 1992; 103:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/35\">",
"      Ayinala S, Batista O, Goyal A, et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc 2005; 61:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/36\">",
"      Elfvin A, Andersson S, Abrahamsson H, et al. Percutaneous implantation of gastric electrodes - a novel technique applied in animals and in patients. Neurogastroenterol Motil 2007; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/37\">",
"      Abrahamsson H, L&ouml;nroth H, Simr&eacute;n M. Progress in gastric electrical stimulation. Gastrointest Endosc 2008; 67:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/38\">",
"      Sallam HS, Chen JD, Pasricha PJ. Feasibility of gastric electrical stimulation by percutaneous endoscopic transgastric electrodes. Gastrointest Endosc 2008; 68:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/39\">",
"      Mintchev MP, Sanmiguel CP, Amaris M, Bowes KL. Microprocessor-controlled movement of solid gastric content using sequential neural electrical stimulation. Gastroenterology 2000; 118:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/40\">",
"      Chen JD, Xu X, Zhang J, et al. Efficiency and efficacy of multi-channel gastric electrical stimulation. Neurogastroenterol Motil 2005; 17:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/41\">",
"      Zhu H, Sallam H, Chen DD, Chen JD. Therapeutic potential of synchronized gastric electrical stimulation for gastroparesis: enhanced gastric motility in dogs. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/42\">",
"      Lin Z, Sarosiek I, Forster J, et al. Two-channel gastric pacing in patients with diabetic gastroparesis. Neurogastroenterol Motil 2011; 23:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31574/abstract/43\">",
"      Song GQ, Hou X, Yang B, et al. A novel method of 2-channel dual-pulse gastric electrical stimulation improves solid gastric emptying in dogs. Surgery 2008; 143:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2578 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31574=[""].join("\n");
var outline_f30_53_31574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9577030\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYOELECTRIC CONTROL OF GASTRIC MOTOR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1300680411\">",
"      GASTRIC ELECTRICAL STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1300680277\">",
"      High frequency gastric electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2044925\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H591275\">",
"      - Benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H591135\">",
"      - Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H591226\">",
"      - Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H590950\">",
"      - Potential candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastric pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9577030\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=related_link\">",
"      Pathogenesis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31575="Etiology of the Budd-Chiari syndrome";
var content_f30_53_31575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of the Budd-Chiari syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Stephen C Hauser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31575/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/53/31575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in an interruption or diminution of the normal flow of blood out of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, as commonly used, the Budd-Chiari syndrome implies thrombosis of the hepatic veins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the intrahepatic or suprahepatic inferior vena cava. An alternative nomenclature that recognizes an obliterative process involving principally the inferior vena cava (\"obliterative hepatocavopathy\") has also been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/3\">",
"     3",
"    </a>",
"    ]. The term is usually distinguished from two other conditions that interfere with hepatic venous flow: sinusoidal obstruction syndrome (hepatic veno-occlusive disease) and right heart failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders that involve the microscopic centrilobular veins and small sublobular veins within the liver are usually due to nonthrombotic fibrous occlusion and obliteration of these small veins. The distinct anatomic location, pathology, and conditions (eg, ingestion of toxic pyrrolizidine alkaloids or exposure to high doses of radiation or chemotherapeutic agents) with which sinusoidal obstruction syndrome is associated allow it to be placed in its own category [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although disorders of the heart may present clinically as the Budd-Chiari syndrome (eg, constrictive pericarditis, chronic right-sided heart failure with severe tricuspid insufficiency), the pathogenesis and treatment of these disorders are quite different from those usually considered typical of the Budd-Chiari syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link\">",
"       \"Congestive hepatopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the Budd-Chiari syndrome is due to occlusion or partial occlusion of one, two, or all three of the major hepatic veins (right, middle, and left)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occlusion or partial occlusion of the inferior vein cava (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, several small veins that enter the inferior vena cava directly from the posterior surface of the caudate lobe and occasionally from the right and left hepatic lobes may or may not be involved by the occlusive process.",
"   </p>",
"   <p>",
"    This topic review will discuss the major causes of the Budd-Chiari syndrome. The symptoms, diagnosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An underlying disorder can be identified in over 80 percent of patients with the Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. More than one thrombotic risk factors are present in many patients; 46 percent had more than one risk factor in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/14\">",
"     14",
"    </a>",
"    ]. Many of these disorders are characterized by a hypercoagulable state, which is important to consider when treating the Budd-Chiari syndrome (eg, the importance of anticoagulation after shunt surgery) (",
"    <a class=\"graphic graphic_table graphicRef79884 \" href=\"UTD.htm?39/22/40299\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A 2009 guideline from the American Association for the Study of Liver Diseases recommends the following approach for investigating causes of Budd-Chiari Syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate for space occupying lesions or malignant tumors compressing or invading the hepatic venous outflow tract with sonography, CT scan, or MRI.",
"     </li>",
"     <li>",
"      Seek evidence for ulcerative colitis, celiac disease, and systemic diseases.",
"     </li>",
"     <li>",
"      Routinely evaluate for multiple, concurrent risk factors for thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Myeloproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of all cases of the Budd-Chiari syndrome may be due to an underlying chronic myeloproliferative disorder (eg, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia) and an accompanying hypercoagulable state. Peripheral blood evidence for myeloproliferation may not be present if portal hypertension, splenomegaly, and a hypersplenic state accompany the Budd-Chiari syndrome.",
"   </p>",
"   <p>",
"    The combination of a myeloproliferative disorder (occult or overt) associated with a hypercoagulable state (or states) is common [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/14,16-18\">",
"     14,16-18",
"    </a>",
"    ]. In one of the largest published series (involving 237 patients evaluated at four centers between 1984 and 2001), 23 percent had an overt myeloproliferative disorder (polycythemia vera in 45 patients and essential thrombocytosis in nine patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/19\">",
"     19",
"    </a>",
"    ]. In another large series, 49 percent of 103 patients who underwent testing had a myeloproliferative disorder, the most common of which was polycythemia vera [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous erythroid colony formation in the presence of low serum erythropoietin levels, increased megakaryocyte colony growth, and clonal karyotypic abnormalities all have been reported in patients with Budd-Chiari syndrome due to myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/20\">",
"     20",
"    </a>",
"    ] and in some so-called \"idiopathic\" cases of Budd-Chiari syndrome, suggesting the presence of an occult myeloproliferative syndrome in these persons [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/16,17,21-24\">",
"     16,17,21-24",
"    </a>",
"    ]. In one study, for example, spontaneous endogenous erythroid colony formation in vitro",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow biopsies suggested that a primary myeloproliferative disorder was present in 78 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JAK2 tyrosine kinase (V617F) mutations have been described in 26 to 59 percent of patients with Budd-Chiari syndrome, many of whom had negative results from standard testing for myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/14,18,24-26\">",
"     14,18,24-26",
"    </a>",
"    ]. A JAK2 mutation is present in almost all patients with polycythemia vera and approximately 50 percent of patients with essential thrombocythemia or chronic idiopathic myelofibrosis. One report described Budd-Chiari syndrome associated with hypereosinophilic syndrome and a JAK2 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/27\">",
"     27",
"    </a>",
"    ]. We suggest that patients diagnosed with Budd-Chiari syndrome in whom no underlying disorder can be identified be tested for a JAK2 mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Mutations in PV, ET, and PMF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, some data suggest that the liver may produce erythropoietin during the acute phase of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/28\">",
"     28",
"    </a>",
"    ]. Such a change could contribute to the apparent spontaneous erythroid colony formation in cultured bone marrow or peripheral blood mononuclear cells demonstrated in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies account for approximately 10 percent of cases of the Budd-Chiari syndrome. Direct compression or invasion of vascular structures and the hypercoagulable state associated with malignancy can result in venous thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .) Hepatocellular carcinomas are found most often, followed by cancer of the adrenal gland or kidney, sarcomas of the right atrium, inferior vena cava or hepatic veins, and cancers of the lung, pancreas, and stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infections and benign lesions of the liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections or benign space-occupying lesions of the liver can, like tumors, compress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombose vascular structures, accounting for nearly 10 percent of cases of Budd-Chiari syndrome. Some of these disorders also may be accompanied by a hypercoagulable state. These lesions include hepatic cysts and abscesses, hepatic adenoma, hepatic cystadenoma, syphilitic gumma, invasive aspergillosis, zygomycosis (mucormycosis), and aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oral contraceptives and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 20 percent of cases of the Budd-Chiari syndrome occur in women who have been on oral contraceptives (for as little as two weeks), are pregnant, or have delivered a child within the previous two months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. It is presumed that the hypercoagulable state in these women is responsible for this association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other hypercoagulable states",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other hypercoagulable states have been associated with the Budd-Chiari syndrome. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G1691A factor V (Leiden) gene mutation, which produces activated protein C resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/35-38\">",
"       35-38",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      G20210A factor II gene mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/39\">",
"       39",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antiphospholipid syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/40-44\">",
"       40-44",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antithrombin deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/45,46\">",
"       45,46",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein C deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/47-49\">",
"       47-49",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein S deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paroxysmal nocturnal hemoglobinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/50\">",
"       50",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link\">",
"       \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperhomocysteinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The factor V Leiden mutation, the most frequent cause of hereditary thrombophilia, may be particularly important. This mutation was present in approximately 25 percent of patients in three series that included a total of 126 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/37,51,52\">",
"     37,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of thrombosis may be greatest when the factor V Leiden mutation occurs in combination with another predisposing disorder or condition, such as pregnancy, the administration of oral contraceptives, or a myeloproliferative syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/35,53\">",
"     35,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    That the interaction of one or more predisposing conditions may coexist was also supported in a study that included 32 patients with Budd-Chiari syndrome in whom the presence of most of the known prothrombotic conditions was investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/54\">",
"     54",
"    </a>",
"    ]. A myeloproliferative disorders was detected in 17 patients of whom 7 (41 percent) also had one or more prothrombotic coagulation disorders. Of 11 other patients without a myeloproliferative disorder, 9 had a single prothrombotic coagulation disorder (82 percent). The G20210A factor II gene mutation was observed in 6 percent of patients, a similar frequency to what was observed in a separate cohort of patients with portal vein thrombosis (14 percent) and higher than healthy controls (1 to 5 percent). The prevalence of homozygous C677TMTHFR (methylene-tetrahydrofolate-reductase) gene mutation was 12.5 percent, which was similar to the healthy controls (approximately 10 percent).",
"   </p>",
"   <p>",
"    In one of the studies described above [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/51\">",
"     51",
"    </a>",
"    ], the presence of combined (acquired and inherited) risk factors was 25, 49, 19, and 7 percent of the group having zero, one, two, or three risk factors, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional prothrombotic conditions that may contribute to venous thrombosis (such as high levels of factor XII) continue to be described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/55\">",
"     55",
"    </a>",
"    ]. Whether they are associated with the Budd-Chiari syndrome requires further investigation. A single case-control study suggests that impaired fibrinolysis, partially caused by elevated plasminogen activator inhibitor 1 levels, may play a role in the pathogenesis of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Behcet's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is an important feature of Behcet's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .) In one study of 493 cases, 53 had one or more large vessel thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/57\">",
"     57",
"    </a>",
"    ]. Fourteen of these 53 patients had hepatic vein thrombosis, eight also had inferior vena cava thrombosis, and two had both inferior vena cava and portal vein thrombosis. Only two patients had isolated hepatic vein thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Membranous webs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous obstruction (partial or complete) of the inferior vena cava (MOVC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the hepatic veins is an unusual but potentially treatable cause of the Budd-Chiari syndrome in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/58\">",
"     58",
"    </a>",
"    ] but is much more common in South Africa, India, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These web-like lesions, which usually are found just cephalad to the entrance of the right hepatic vein into the inferior vena cava, may be the result of a congenital anomaly. However, they are more often attributable to an acquired thrombotic process such as a myeloproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to diagnose MOVC or so-called short-length hepatic vein stenoses [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/62\">",
"     62",
"    </a>",
"    ] because of the availability of treatment options (eg, anticoagulation, angioplasty, or stenting) that are usually not germane to other causes of the Budd-Chiari syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miscellaneous associations with the Budd-Chiari syndrome include systemic lupus erythematosus, mixed-connective tissue disease, Sj&ouml;gren's syndrome, inflammatory bowel disease, hypereosinophilic syndrome, idiopathic granulomatous venulitis, sarcoidosis, protein-losing enteropathy, minimal change nephrotic syndrome, neurofibromatosis, alpha-1 antitrypsin deficiency, trauma (including laparoscopic cholecystectomy) or torsion of the liver, and rare familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/9,63\">",
"     9,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, up to 20 percent of cases of the Budd-Chiari syndrome are listed as idiopathic. As more and more conditions which predispose to Budd-Chiari syndrome, such as occult myeloproliferative disease and factor V Leiden mutation, are recognized, the percentage of cases described as idiopathic will continue to decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the cause, patients with Budd-Chiari syndrome develop postsinusoidal portal hypertension, which leads to complications similar to those observed in patients with cirrhosis. However, the systemic hemodynamic effects differ than those that are observed classically in patients with cirrhosis.",
"   </p>",
"   <p>",
"    The most detailed study evaluated systemic and cardiopulmonary hemodynamics, plasma renin activity, aldosterone and norepinephrine levels, and plasma volume in patients with Budd-Chiari syndrome who were admitted for complications of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31575/abstract/64\">",
"     64",
"    </a>",
"    ]. Systemic, cardiopulmonary pressures, and cardiac indices in patients with Budd-Chiari syndrome were within the normal range for most patients but were significantly different compared with a matched group of cirrhotic patients. Despite normal systemic vascular resistance there was activation of the neurohumoral vasoactive systems and plasma volume expansion. Normal pressures were not observed in all patients; in about one-third (mostly those with longer duration of illness) systemic vascular resistance was decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365876928\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in an interruption or diminution of the normal flow of blood out of the liver.",
"     </li>",
"     <li>",
"      An underlying disorder can be identified in over 80 percent of patients with the Budd-Chiari syndrome. Many of these disorders are characterized by a hypercoagulable state, which is important to consider when treating the Budd-Chiari syndrome (eg, the importance of anticoagulation after shunt surgery) (",
"      <a class=\"graphic graphic_table graphicRef79884 \" href=\"UTD.htm?39/22/40299\">",
"       table 1",
"      </a>",
"      ). As a general rule, work-up should include hepatic imaging and evaluation for inflammatory, immunologic, and thrombotic disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the cause, patients with Budd-Chiari syndrome develop postsinusoidal portal hypertension, which leads to complications similar to those observed in patients with cirrhosis. However, the systemic hemodynamic effects differ from those that are observed classically in patients with cirrhosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hemodynamic consequences'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/1\">",
"      Valla DC. Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut 2008; 57:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/2\">",
"      Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/3\">",
"      Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/4\">",
"      Zafrani ES, von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/5\">",
"      Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/6\">",
"      Saint-Marc Girardin MF, Zafrani ES, Prigent A, et al. Unilobar small hepatic vein obstruction: possible role of progestogen given as oral contraceptive. Gastroenterology 1983; 84:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/7\">",
"      Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/8\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 51-1987. Progressive abdominal distention in a 51-year-old woman with polycythemia vera. N Engl J Med 1987; 317:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/9\">",
"      Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982; 61:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/10\">",
"      Powell-Jackson PR, Melia W, Canalese J, et al. Budd-Chiari Syndrome: clinical patterns and therapy. Q J Med 1982; 51:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/11\">",
"      Gupta S, Blumgart LH, Hodgson HJ. Budd-Chiari syndrome: long-term survival and factors affecting mortality. Q J Med 1986; 60:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/12\">",
"      Murphy FB, Steinberg HV, Shires GT 3rd, et al. The Budd-Chiari syndrome: a review. AJR Am J Roentgenol 1986; 147:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/13\">",
"      Maddrey WC. Hepatic vein thrombosis (Budd-Chiari syndrome). Hepatology 1984; 4:44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/14\">",
"      Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/15\">",
"      DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/16\">",
"      Hirshberg B, Shouval D, Fibach E, et al. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000; 32:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/17\">",
"      Amitrano L, Guardascione MA, Ames PR, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/18\">",
"      Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/19\">",
"      Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/20\">",
"      Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/21\">",
"      Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. Q J Med 1990; 76:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/22\">",
"      Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995; 55:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/23\">",
"      De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/24\">",
"      Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/25\">",
"      Qi X, Yang Z, Bai M, et al. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011; 33:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/26\">",
"      Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120:4921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/27\">",
"      Mishchenko E, Tadmor T, Schiff E, et al. Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what? Am J Hematol 2011; 86:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/28\">",
"      Levy VG, Ruskone A, Baillou C, et al. Polycythemia and the Budd-Chiari syndrome: study of serum erythropoietin and bone marrow erythroid progenitors. Hepatology 1985; 5:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/29\">",
"      Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/30\">",
"      Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 1983; 28:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/31\">",
"      Lalonde G, Th&eacute;oret G, Daloze P, et al. Inferior vena cava stenosis and Budd--Chiari syndrome in a woman taking oral contraceptives. Gastroenterology 1982; 82:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/32\">",
"      Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med 1980; 68:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/33\">",
"      Perarnau JM, Bacq Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis 2008; 28:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/34\">",
"      Shetty S, Ghosh K. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis--a concise review. Thromb Res 2011; 127:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/35\">",
"      Fickert P, Ramschak H, Kenner L, et al. Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation. Gastroenterology 1996; 111:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/36\">",
"      Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/37\">",
"      Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/38\">",
"      Hoffman R, Nimer A, Lanir N, et al. Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients. Liver Transpl Surg 1999; 5:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/39\">",
"      Laposata M. The prothrombin G20210A mutation: a new high-prevalence congenital risk factor for thrombosis. Gastroenterology 1999; 116:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/40\">",
"      Saca LF, Szer IS, Henar E, et al. Budd-Chiari syndrome associated with antiphospholipid antibodies in a child: report of a case and review of the literature. J Rheumatol 1994; 21:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/41\">",
"      Mackworth-Young CG, Melia WM, Harris EN, et al. The Budd-Chiari syndrome. Possible pathogenetic role of anti-phospholipid antibodies. J Hepatol 1986; 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/42\">",
"      Van Steenbergen W, Beyls J, Vermylen J, et al. 'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature. J Hepatol 1986; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/43\">",
"      Pomeroy C, Knodell RG, Swaim WR, et al. Budd-Chiari syndrome in a patient with the lupus anticoagulant. Gastroenterology 1984; 86:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/44\">",
"      Espinosa G, Font J, Garc&iacute;a-Pagan JC, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) 2001; 80:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/45\">",
"      Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/46\">",
"      McClure S, Dincsoy HP, Glueck H. Budd-Chiari Syndrome and antithrombin III deficiency. Am J Clin Pathol 1982; 78:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/47\">",
"      Sugano S, Suzuki T, Makino H, et al. Budd-Chiari syndrome attributed to protein C deficiency. Am J Gastroenterol 1996; 91:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/48\">",
"      Majluf-Cruz A, Hurtado Monroy R, Sansores Garc&iacute;a L, Labardini-M&eacute;ndez J. The incidence of protein C deficiency in thrombosis-related portal hypertension. Am J Gastroenterol 1996; 91:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/49\">",
"      Bourli&egrave;re M, Le Treut YP, Arnoux D, et al. Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency. Gut 1990; 31:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/50\">",
"      Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987; 93:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/51\">",
"      Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/52\">",
"      Mohanty D, Shetty S, Ghosh K, et al. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001; 34:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/53\">",
"      Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/54\">",
"      Denninger MH, Cha&iuml;t Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/55\">",
"      Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/56\">",
"      Hoekstra J, Guimar&atilde;es AH, Leebeek FW, et al. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010; 115:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/57\">",
"      Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Beh&ccedil;et's disease. Am J Gastroenterol 1997; 92:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/58\">",
"      Rector WG Jr, Xu YH, Goldstein L, et al. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985; 64:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/59\">",
"      Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982; 82:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/60\">",
"      Wang Z. Budd-Chiari syndrome. 430 case experiences. Asian J Surg 1996; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/61\">",
"      Sevenet F, Deramond H, Hadengue A, et al. Membranous obstruction of the inferior vena cava associated with a myeloproliferative disorder: a clue to membrane formation? Gastroenterology 1989; 97:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/62\">",
"      Valla D, Hadengue A, el Younsi M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology 1997; 25:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/63\">",
"      Young ID, Clark RN, Manley PN, et al. Response to steroids in Budd-Chiari syndrome caused by idiopathic granulomatous venulitis. Gastroenterology 1988; 94:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31575/abstract/64\">",
"      Hern&aacute;ndez-Guerra M, L&oacute;pez E, Bellot P, et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology 2006; 43:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3624 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-A590A08E48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31575=[""].join("\n");
var outline_f30_53_31575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365876928\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Myeloproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infections and benign lesions of the liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oral contraceptives and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other hypercoagulable states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Behcet's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Membranous webs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HEMODYNAMIC CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365876928\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3624|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/22/40299\" title=\"table 1\">",
"      Causes of Budd Chiari syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31576="Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials";
var content_f30_53_31576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31576/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/53/31576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revascularization of stable patients with multivessel atherosclerotic coronary artery disease (CAD) has evolved significantly due in part to advances in both percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p>",
"    The goals of medical therapy and revascularization are to delay or prevent the complications of coronary disease in an effort to prolong life, decrease cardiac morbidity, and alleviate symptoms. Patient age, left ventricular function, and the severity of atherosclerosis and symptoms frequently affect the outcome and can influence the choice of a particular management strategy. The decision to proceed with intervention, with either PCI or CABG, is usually made in three groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with activity-limiting symptoms despite optimal medical therapy.",
"     </li>",
"     <li>",
"      Those with anatomy for which revascularization has a proven survival benefit.",
"     </li>",
"     <li>",
"      Active patients who prefer revascularization for improved quality of life compared to medical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"       \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of which method of revascularization is used for patients in these three groups, progression of native coronary disease is an important determinant of clinical outcome with time. This was illustrated in an analysis from the BARI trial which compared PCI with angioplasty to CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/1\">",
"     1",
"    </a>",
"    ]. At five years, progression of disease in previously untreated vessels accounted for two-thirds of the increase in myocardium at risk, regardless of whether PCI or CABG had originally been performed.",
"   </p>",
"   <p>",
"    This observation demonstrates the importance of aggressive risk factor reduction in all patients with CHD, including those undergoing revascularization. This includes low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , reaching treatment goals for hypertension and serum lipids, avoidance of smoking, and, in diabetics, controlling the serum glucose. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major clinical trials that have compared bypass surgery to PCI in the management of stable angina pectoris will be reviewed here. The recommended approach to individual patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PCI VERSUS CABG FOR SINGLE VESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with single vessel disease not involving the left anterior descending artery (LAD), there is no evidence to suggest that outcomes would be better after CABG.",
"   </p>",
"   <p>",
"    The relative efficacy of PCI and CABG, including minimally invasive CABG, in patients with isolated disease of the LAD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link&amp;anchor=H468899215#H468899215\">",
"     \"Management of significant proximal left anterior descending coronary artery disease\", section on 'Patients with single vessel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BALLOON ANGIOPLASTY VERSUS CABG FOR MULTIVESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of revascularization in appropriately selected patients with multivessel disease was demonstrated in a systematic review of individual patient data from seven randomized trials that compared CABG to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/2\">",
"     2",
"    </a>",
"    ]. CABG was associated with a significant reduction in mortality at five years (10.2 versus 15.8 percent) and 10 years (26.4 versus 30.5 percent). The benefit was primarily seen in intermediate to high risk patients (ie, left main disease, three vessel disease, or two vessel disease with at least a 75 percent stenosis in the proximal LAD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'CABG versus medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequently, a number of randomized trials compared the efficacy and complications of balloon angioplasty and CABG in patients with multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]. The major finding in these trials is that survival is similar with CABG and balloon angioplasty, but that repeat intervention is much more common with balloon angioplasty. Although the follow-up in the trials was less than five years, a prolonged follow-up of almost 2000 patients in an observational series showed similar results: no differences in adjusted survival at 10 and 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/14\">",
"     14",
"    </a>",
"    ]. Repeat intervention was more common with balloon angioplasty in the first year, but became more common with initial CABG after seven to eight years due to loss of graft patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limitations to the trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are, however, a number of important limitations concerning the potential applicability of the trial results to current clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of patients entered into these trials was only a small percentage of the number screened and was therefore not likely to be reflective of the general population. As an example, most patients had preserved left ventricular function and focal atherosclerotic coronary disease. Thus, extrapolation of these data to patients with diffuse disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left ventricular dysfunction is inappropriate.",
"     </li>",
"     <li>",
"      The physicians in the trials were highly experienced in both bypass surgery and angioplasty.",
"     </li>",
"     <li>",
"      The initial trials are probably not relevant to current clinical practice because of the lack of use of stents during PCI, which reduce restenosis, or of internal mammary artery rather than saphenous vein grafts during CABG, which improve both long-term graft patency and patient survival (",
"      <a class=\"graphic graphic_figure graphicRef72584 graphicRef69211 \" href=\"UTD.htm?32/16/33038\">",
"       figure 1A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/15\">",
"       15",
"      </a>",
"      ]. Although these concerns were overcome in ARTS and SoS, these trials did not use drug-eluting stents, which are now used in most PCIs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As PCI with stenting has replaced balloon angioplasty in the overwhelming majority of patients who undergo PCI, the landmark trials of balloon angioplasty versus CABG are presented only briefly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     BARI trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bypass Angioplasty Revascularization Investigation (BARI) compared the effectiveness of CABG versus balloon angioplasty in 1829 highly symptomatic patients with two or three vessel coronary disease and an anatomy that was deemed equally suitable for revascularization with either technique. Outcomes have been published at 5, 7, and 10-year follow-up. Important findings are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in cumulative survival between CABG and balloon angioplasty (89 versus 86, 84 versus 81, and 73 versus 71 percent, respectively) or cardiac survival between the two groups. Survival rates in the two treatment arms were similar in most patient subgroups, with the exception of diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H25#H25\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Balloon angioplasty versus CABG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Revascularization occurred significantly less often in the CABG group (8 versus 54, 13 versus 60, and 23 versus 77 percent, respectively).",
"     </li>",
"     <li>",
"      Angina occurred less frequently in the CABG group in the first year, with the difference attenuating thereafter. The rate was equivalent at 10 years (16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     BARI registry data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BARI trial registry included 2010 patients who did not consent to randomization and were treated with balloon angioplasty or CABG based upon physician preference [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/19\">",
"     19",
"    </a>",
"    ]. Among those who were revascularized, twice as many patients were treated with balloon angioplasty than with CABG (66 versus 34 percent). Similar to the randomized trial, the mortality at seven years was the same after adjustment for baseline differences (13.9 versus 14.2 percent for CABG). In contrast to the randomized trial, the seven-year mortality with balloon angioplasty was lower in the registry (14 versus 19 percent in the randomized trial), but was the same as the randomized trial among those undergoing CABG (14.2 versus 15.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     RITA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Randomized Intervention Treatment of Angina (RITA) trial randomly assigned 1011 patients, 45 percent of whom had single vessel disease, to either balloon angioplasty or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. After a median follow-up of 6.5 years, the rates of death or nonfatal infarction for balloon angioplasty or CABG were the same (17 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/20\">",
"     20",
"    </a>",
"    ]. Angina was consistently higher in the balloon angioplasty group, 26 percent of whom required CABG, and 19 percent of whom required another balloon angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     GABI trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The German Angioplasty Bypass Surgery Investigation (GABI) was a multicenter study of patients in whom complete revascularization of at least two major vessels supplying different myocardial regions was deemed clinically necessary and technically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Patients with totally occluded arteries supplying viable myocardium were excluded. At 12 months, no significant differences existed between the two groups with respect to Q wave MI, severe angina, or freedom from angina. However, the total reintervention rate was, as in other trials, much lower with surgery (6 versus 44 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     EAST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Emory Angioplasty versus Surgery Trial (EAST) nearly 400 patients with multivessel disease (most patients had normal left ventricular function) were randomly assigned to either balloon angioplasty or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. At three-year follow-up no significant differences were found with respect to the combined end-point of mortality, Q-wave MI, or large thallium perfusion defect. However, patients treated with CABG had fewer additional procedures at three years (2 versus 23 percent). After eight year follow-up, the combined end-point was the same in the two groups (79 versus 83 percent for CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CABRI trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Europe-based multicenter Coronary Angioplasty versus Bypass Revascularization Investigation (CABRI) compared CABG to balloon angioplasty in 1054 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/11\">",
"     11",
"    </a>",
"    ]. There was a similar mortality rate (2.7 versus 3.9 percent) in the two groups at one year. However, patients assigned to balloon angioplasty required more repeat procedures (34 versus 7 percent) and had a higher incidence of clinically significant angina (relative risk 1.54). Restenosis after balloon angioplasty only partially accounted for this difference; of greater importance was the higher likelihood of residual disease after balloon angioplasty compared with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     STENTING VERSUS CABG FOR MULTIVESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of either bare metal (BMS) or drug eluting stents (DES) has markedly reduced the incidence of restenosis and target vessel revascularization compared to balloon angioplasty, including patients with multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bare-metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trials that compare BMS to CABG are probably not applicable to current practice since they did not use drug-eluting stents that further reduce the risk of restenosis, which is the main determinant of clinical outcome with stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     ARTS I trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ARTS I trial, 1205 patients (17 percent diabetics) with multivessel disease were randomly assigned to undergo BMS implantation or bypass surgery, usually with an arterial graft, when a cardiac surgeon and an interventional cardiologist agreed that the same extent of revascularization could be achieved with either procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/23\">",
"     23",
"    </a>",
"    ]. In this trial, approximately 70 percent of patients had two-vessel and 30 percent of patients had three-vessel disease; patients with left main coronary disease were not enrolled. Complete revascularization was significantly more likely to be achieved with CABG (84 versus 71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was no difference in mortality (8.0 versus 7.6 percent) or the rate of the combined end point of death, MI, or stroke (18.2 versus 14.9 percent) at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/28\">",
"     28",
"    </a>",
"    ]. However, event-free survival was lower with stenting due to a significant increase in the need for repeat revascularization (21 versus 4 percent at one year, 27 versus 7 percent at three years, and 30 versus 9 percent at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/23,28,29\">",
"     23,28,29",
"    </a>",
"    ]. Among stented patients in the ARTS I trial, two groups had worse outcomes: those with incomplete revascularization and patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H24#H24\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'PCI versus CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional problem is that only 3.5 percent of patients in ARTS were treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, which was used in higher risk patients undergoing elective PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/30\">",
"     30",
"    </a>",
"    ] at that time in the absence of pretreatment with potent P2Y12 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     SoS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Stent or Surgery (SoS) trial randomly assigned 988 patients with multivessel coronary disease to CABG or PCI with bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/26\">",
"     26",
"    </a>",
"    ]. At a median follow-up of two years, PCI was associated with a significantly higher rate of repeat revascularization (21 versus 6 percent) with CABG. At six years, mortality was significantly higher in the PCI group (10.9 versus 6.8; hazard ratio 1.66, 95% CI 1.08 to 2.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/31\">",
"     31",
"    </a>",
"    ]. It is not clear if this difference was at least in part by chance since there was a larger number of cancer deaths in the stenting group. In addition, only 78 percent of all lesions undergoing PCI received stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses have evaluated patients treated with either CABG or PCI:",
"   </p>",
"   <p>",
"    A 2008 meta-analysis evaluated outcomes after either CABG or PCI with bare-metal stenting in over 3000 patients with multivessel disease from the ARTS I, SOS, ERACI-II trials (which included patients with unstable angina) and MASS-II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/32\">",
"     32",
"    </a>",
"    ]. At five years the cumulative incidence of death, MI, and stroke was similar in the two groups (16.9 versus 16.7 percent, respectively) but revascularization was significantly less frequent after CABG (7.9 versus 29 percent).",
"   </p>",
"   <p>",
"    A 2009 meta-analysis evaluated patient level data from 7812 individuals enrolled in ten trials of CABG versus PCI using either bare-metal stents (37 percent) or balloon angioplasty (63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/33\">",
"     33",
"    </a>",
"    ]. After more than five years, there was no significant difference in mortality (15 versus 16 percent; hazard ratio 0.91, 95% CI 0.82-1.02 for CABG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) have led to a marked reduction in the incidence of restenosis, thereby potentially reducing or eliminating an important difference between CABG and PCI. The results of the SYNTAX trial and ARTS II and New York state registries, represent the most current and applicable evidence upon which recommendations are formed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     SYNTAX trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SYNTAX trial randomly assigned 1800 patients with three-vessel or left main coronary artery disease (approximately 60 and 40 percent, respectively) to either CABG or PCI with the paclitaxel-eluting stent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients were eligible for either procedure and were treated with the intention of complete revascularization. The SYNTAX score, an angiographic tool used to grade the extent of disease and lesion complexity, was assigned to each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H468900345#H468900345\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'SYNTAX score and SYNTAX score II'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted after 12 months of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The composite primary end point (death from any cause, stroke, MI or repeat revascularization) was significantly higher in the PCI group (17.8 versus 12.4 percent). This result was driven by primarily by more frequent revascularization with PCI (13.5 versus 5.9 percent).",
"     </li>",
"     <li>",
"      Although the secondary end point of the rate of death, stroke or MI was comparable (7.6 for PCI versus 7.7 for CABG), the stroke rate was significantly higher in the CABG group (2.2 versus 0.6 percent).",
"     </li>",
"     <li>",
"      More complete revascularization was achieved with CABG (63 versus 57 percent).",
"     </li>",
"     <li>",
"      Patients with lower SYNTAX scores had lower event rates than those with higher scores. Secondary analyses suggested that among patients with low SYNTAX scores, the clinical outcomes were comparable with PCI and CABG (13.6 versus 14.7, respectively), whereas in patients with intermediate (16.7 versus 12.0, respectively) and high (23.4 versus 10.9 percent, respectively) SYNTAX scores outcomes were better with CABG.",
"     </li>",
"     <li>",
"      Angina frequency, as assessed with the angina frequency subsection of the Seattle Angina Questionnaire, was evaluated in a prospective quality of life (QOL) substudy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/37\">",
"       37",
"      </a>",
"      ]. Using this QOL tool, a score of 100 represents no angina, 70 to 90 represents monthly angina, and 0 to 60 represents daily or weekly angina. At 12 months, there was higher mean anginal frequency score with CABG (93.8 versus 92.4). Although the difference between the two groups represented a statistically significant decrease in anginal frequency with CABG, we view the clinical import of this difference as small, particularly as most patients in both groups had few anginal episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three- and five-year results of the SYNTAX trial have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Comparing PCI to CABG: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After three years and five years, the composite primary end point remained significantly higher (28.0 versus 20.2 percent and 37.3 versus 26.9 percent, respectively). These results were attributable primarily to higher rates of repeat revascularization and MI. &nbsp;",
"     </li>",
"     <li>",
"      After three years, there was no difference in the rates of the composite safety end point of",
"      <span class=\"nowrap\">",
"       death/stroke/MI",
"      </span>",
"      (14.1 versus 12.0 percent), stroke (2.0 versus 3.4 percent, respectively), or all-cause death (8.6 versus 6.7 percent). After five years, there was no difference in the rates all-cause death (13.9 versus 11.4 percent) or stroke (3.7 versus 2.4 percent).",
"     </li>",
"     <li>",
"      Outcomes were further evaluated based on anatomic disease complexity. After five years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a SYNTAX score &lt;23, there was no difference in the composite primary end point (32.1 and 28.6 percent), irrespective of whether unprotected left main disease was present or not.",
"     </li>",
"     <li>",
"      For patients with a SYNTAX score of 23 to 32, outcomes between PCI and CABG were similar if unprotected left main disease was present (32.7 and 32.3 percent, respectively). However, in patients with three-vessel disease, the primary composite outcome was higher with PCI (37.9 versus 22.6 percent; p = 0.0008).",
"     </li>",
"     <li>",
"      For patients with a SYNTAX score &ge;33, the primary composite outcome occurred more frequently in patients with and without unprotected left main disease (46.5 versus 29.7 [p = 0.003] and 41.9 versus 24.1 percent [p = 0.0005], respectively).",
"     </li>",
"     <li>",
"      The end points of all-cause death and MI, which were components of the primary composite outcome, were &nbsp;lower with CABG (11.4 versus 19.2 percent; hazard ratio 1.84, 95% CI 1.19-2.83 and 3.9 versus 10.1 percent; hazard ratio 2.57; 95% CI 1.31-5.06, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of the SYNTAX trial need to be interpreted in the context of its limitations, including male predominance (78 percent), suboptimal use of medical therapy in the CABG cohort, and use of a paclitaxel-eluting stent, which has a higher rate of angiographic and clinical restenosis than either the sirolimus-or second generation drug-eluting stents. In addition, analyses by SYNTAX score and by individual end points were not prespecified and, thus, findings should be considered hypothesis generating. However, in formulating our recommendations, we have taken this potential mortality benefit into account. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term surveillance for stent thrombosis is particularly important, given the high average number of stents (4.1) and long mean stent length (86 mm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SYNTAX trial is the most contemporary randomized comparison of PCI to CABG in patients with multivessel or left main coronary artery disease. The discussion of the impact of SYNTAX on our recommendations for such patients is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H6#H6\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Drug-eluting stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H468900345#H468900345\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'SYNTAX score and SYNTAX score II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16727687\">",
"    <span class=\"h3\">",
"     Evidence from registries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/44\">",
"     44",
"    </a>",
"    ], studies of patients enrolled in registries have concluded that patients treated with CABG have a lower mortality compared with DES. The most comprehensive such study was ASCERT, which linked the American College of Cardiology Foundation National Cardiovascular Data (PCI) Registry and the Society of Thoracic Surgeons Adult Cardiac Surgery (CABG) Database to the Centers for Medicare and Medicaid Services (United States). Outcomes were evaluated in nearly 200,000 patients over the age of 65 years who had two- or three-vessel coronary artery disease and who did not require emergency revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/43\">",
"     43",
"    </a>",
"    ]. DES were used in 78 percent of patients who underwent PCI. At one year, there was no significant difference in adjusted mortality between the CABG and PCI groups (6.24 versus 6.55). However, at four years, there was lower mortality with CABG (16.4 versus 20.8; risk ratio 0.79, 95% CI 0.76-0.82).",
"   </p>",
"   <p>",
"    These observational studies have limitations, the most important of which is their inability to control for unmeasured cofounders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31576/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PCI VERSUS CABG FOR POST-CABG ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data evaluating PCI versus repeat CABG in patients with prior CABG are limited. The factors that influence the choice between these procedures are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link&amp;anchor=H4#H4\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic summarizes the major clinical trials that have compared coronary artery bypass surgery to percutaneous coronary intervention in the management of stable angina pectoris. Recommendations for the choice of revascularization procedure in the different subsets of patients with stable angina, based on these trials, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/1\">",
"      Alderman EL, Kip KE, Whitlow PL, et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2004; 44:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/2\">",
"      Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/3\">",
"      Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/4\">",
"      Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993; 341:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/5\">",
"      Sculpher MJ, Seed P, Henderson RA, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 1994; 344:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/6\">",
"      Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation 1996; 94:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/7\">",
"      Moliterno DJ, Elliott JM. Randomized trials of myocardial revascularization. Curr Probl Cardiol 1995; 20:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/8\">",
"      Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/9\">",
"      King SB 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994; 331:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/10\">",
"      Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. Circulation 1996; 93:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/11\">",
"      First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 1995; 346:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/12\">",
"      Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/13\">",
"      Rodriguez A, Boullon F, Perez-Bali&ntilde;o N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 1993; 22:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/14\">",
"      van Domburg RT, Foley DP, Breeman A, et al. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J 2002; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/15\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/16\">",
"      Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation 1997; 96:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/17\">",
"      Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/18\">",
"      BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/19\">",
"      Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation 2000; 101:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/20\">",
"      Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 1998; 352:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/21\">",
"      King SB 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000; 35:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/22\">",
"      Kurbaan AS, Bowker TJ, Ilsley CD, Rickards AF. Impact of postangioplasty restenosis on comparisons of outcome between angioplasty and bypass grafting. Coronary Angioplasty versus Bypass Revascularisation Investigation (CABRI) Investigators. Am J Cardiol 1998; 82:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/23\">",
"      Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/24\">",
"      Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/25\">",
"      Kim SW, Hong MK, Lee CW, et al. Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up. Am Heart J 2000; 139:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/26\">",
"      SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/27\">",
"      van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/28\">",
"      Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/29\">",
"      Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/30\">",
"      Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005; 293:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/31\">",
"      Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008; 118:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/32\">",
"      Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008; 118:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/33\">",
"      Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/34\">",
"      Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/35\">",
"      Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1:219.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.syntaxscore.com/ (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/37\">",
"      Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med 2011; 364:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/38\">",
"      Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/39\">",
"      Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/40\">",
"      Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010; 55:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/41\">",
"      Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008; 358:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/42\">",
"      Li Y, Zheng Z, Xu B, et al. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution. Circulation 2009; 119:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/43\">",
"      Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/44\">",
"      Park DW, Kim YH, Song HG, et al. Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the Asan Medical Center-Multivessel Revascularization Registry. J Am Coll Cardiol 2011; 57:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31576/abstract/45\">",
"      Mauri L. Why we still need randomized trials to compare effectiveness. N Engl J Med 2012; 366:1538.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1578 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31576=[""].join("\n");
var outline_f30_53_31576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PCI VERSUS CABG FOR SINGLE VESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BALLOON ANGIOPLASTY VERSUS CABG FOR MULTIVESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limitations to the trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BARI trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - BARI registry data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RITA trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GABI trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EAST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CABRI trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      STENTING VERSUS CABG FOR MULTIVESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bare-metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - ARTS I trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - SoS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - SYNTAX trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16727687\">",
"      - Evidence from registries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PCI VERSUS CABG FOR POST-CABG ANGINA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1578|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24013\" title=\"figure 1A\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21229\" title=\"figure 1B\">",
"      Survival advantage of arterial coronary bypass grafts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=related_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31577="Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment";
var content_f30_53_31577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Cecile Tremblay, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Michael T Brady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31577/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/53/31577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) was first isolated and characterized from patients with lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/1\">",
"     1",
"    </a>",
"    ] and was originally named human B-lymphotropic virus. The name was changed to human herpesvirus 6 as its tropism was further characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infection in children will be presented here. The virology, pathogenesis, and epidemiology and the clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infections in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentations of human herpesvirus 6 (HHV-6) infection vary depending upon the age and immune competence of the child. The classic manifestations of HHV-6 infection in immunocompetent children are roseola infantum (also known as exanthem subitum, and sixth disease) and acute febrile illnesses with or without a rash. However, nonspecific symptoms without fever, such as fussiness and rhinorrhea, can occur with acquisition of the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/3\">",
"     3",
"    </a>",
"    ]. Other clinical syndromes (eg, hepatitis, myocarditis, encephalitis) may occur, sometimes in the setting of coinfection with another viral illness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective cohort of 277 children who were followed for the first two years of life, primary infection with HHV-6 was symptomatic in 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/3\">",
"     3",
"    </a>",
"    ]. Fever, fussiness, and rhinorrhea were reported most frequently (in 57, 69, and 65 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/3\">",
"     3",
"    </a>",
"    ]. Fever occurred more frequently when children experienced their infection after six months of age. Cough, diarrhea, and rash occur in a minority of children with primary infection. Primary infection with HHV-6 results in the classic syndrome of roseola infantum in approximately 33 percent of children in the United States, 70 to 80 percent of children in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and 21 percent of children in Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Roseola infantum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1988, HHV-6 was identified as the causative agent of the common childhood disease roseola infantum (exanthem subitum, also called roseola or sixth disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/9\">",
"     9",
"    </a>",
"    ]. Roseola is characterized by three to five days of high fever that resolves abruptly and is followed by development of a rash (",
"    <a class=\"graphic graphic_picture graphicRef81967 \" href=\"UTD.htm?9/7/9329\">",
"     picture 1",
"    </a>",
"    ). It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28982?source=see_link\">",
"     \"Roseola infantum (exanthem subitum)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute febrile illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute HHV-6 can also present as a febrile illness without a rash [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6,10-13\">",
"     6,10-13",
"    </a>",
"    ]. In a prospective study of 1653 children who presented to the hospital for acute febrile illness, 10 percent were found to have primary HHV-6 infection as confirmed by viral isolation from the blood or seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6\">",
"     6",
"    </a>",
"    ]. Fever was most commonly accompanied by irritability, otitis media, upper and lower respiratory symptoms, or diarrhea. Seizures occurred in 13 percent. In another report, outbreaks of HHV-6 infection that presented as a febrile illness with or without a rash were reported in a number of day-care centers in Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Febrile seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 infection has been associated with febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6,14-17\">",
"     6,14-17",
"    </a>",
"    ]. In one study, it was estimated that primary HHV-6 infection carried a risk of seizure of 29 percent among children 12 to 18 months old and 36 percent among children older than 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6\">",
"     6",
"    </a>",
"    ]. In another study of 105 children with febrile seizures (21 with documented primary HHV-6 infection and 84 without), those with HHV-6 infection tended to be younger and to suffer more complicated convulsions (repeated clusters of seizures, focal seizures, and prolonged seizures) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=see_link\">",
"     \"Febrile seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=see_link\">",
"     \"Patient information: Febrile seizures (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meningoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalitis of variable severity can occur as a complication of roseola or as the primary manifestation of HHV-6 infection in otherwise immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. Panencephalitis is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], but a focal necrotic encephalitis mimicking herpes simplex virus (HSV) encephalitis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. The detection of viral antigens in neural cells suggests that the encephalitis is caused by a direct viral effect. Pathologic data suggest an association between HHV-6B and mesial temporal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/27\">",
"     27",
"    </a>",
"    ]. However a study measuring cerebrospinal fluid (CSF) cytokine levels in 13 children with HHV-6 encephalopathy has shown a role of IL-8 in the pathogenesis process suggesting a potential immune-mediated pathogenic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21769?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal transmission has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/29\">",
"     29",
"    </a>",
"    ] and may result from either transplacental transmission or through germ-line transmission of chromosomally integrated HHV-6 (CI-HHV-6) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/29\">",
"     29",
"    </a>",
"    ]. Congenital HHV-6 infection is present in approximately 1 percent of newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Most prenatal transmission was thought to result from transplacental transmission following maternal reactivation or, less commonly, following maternal primary infection (initial infection or with a new strain). However, in a prospective study, a majority of congenital infections (86 percent) occurred as a result of germ-line transmission of CI-HHV-6 from either parent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/29\">",
"     29",
"    </a>",
"    ]. Most congenital infections with HHV-6 are asymptomatic. One report describes five infants with congenital HHV-6 identified in a neonatal intensive care unit. Three of the five experienced respiratory failure of unproven etiology, and two had congenital anomalies (tricuspid atresia and pulmonary valve atresia, and jejunal atresia) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/32\">",
"     32",
"    </a>",
"    ]. The role of HHV-6 in the clinical conditions of these five infants could not be determined.",
"   </p>",
"   <p>",
"    Neonates and young infants with HHV-6 may develop a hepatitis, which is rarely fulminant [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Less common presentations include a mononucleosis-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/35\">",
"     35",
"    </a>",
"    ], pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/36\">",
"     36",
"    </a>",
"    ], myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], immune thrombocytopenia (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], papular-purpuric \"gloves and socks\" syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/41\">",
"     41",
"    </a>",
"    ], and Gianotti-Crosti syndrome (characterized by papular acrodermatitis of the face, extremities, and trunk, accompanied by lymphadenopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/42\">",
"     42",
"    </a>",
"    ], and purpura fulminans [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/43\">",
"     43",
"    </a>",
"    ]. Guillain-Barr&eacute; syndrome, facial nerve palsy, and viral-associated hemophagocytic syndrome and Langerhans cell histiocytosis also have been reported following HHV-6 infection in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. A retrospective study found HHV-6 in explanted hearts from children who underwent cardiac transplantation for idiopathic dilated cardiomyopathy and congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/50\">",
"     50",
"    </a>",
"    ]. Because HHV-6 may be activated by a number of acute illnesses, in many of these clinical syndromes, it may be difficult to establish HHV-6 as the causative agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medication hypersensitivity syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of HHV-6 has been described in association with (at the time of the reaction or shortly after), and possibly as a contributing factor in, the pathogenesis of drug-induced hypersensitivity syndrome (DIHS) or drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. The association was initially noted with anticonvulsant medications (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"     zonisamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Subsequently, however, other medications have been associated with DIHS and HHV-6 reactivation (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/14/21733?source=see_link\">",
"     mexiletine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , teicoplanin, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunocompromised children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with primary or secondary cellular immune deficiencies are more likely than immunocompetent children to have clinically relevant reactivation or new infection with herpesviruses such as HHV-6. However, establishing the pathogenicity of HHV-6 in such children is problematic for several reasons, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with cellular immune deficiencies are frequently co-infected with other herpesviruses, such as cytomegalovirus (CMV), and other opportunistic infections [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/59\">",
"       59",
"      </a>",
"      ]. Rises in antibody titers often occur against several viruses simultaneously. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Serodiagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The high prevalence of viral DNA in peripheral blood mononuclear cells of healthy controls limits the use of qualitative polymerase chain reaction (PCR) to discriminate between latency and active infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Virus detection'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5698667\">",
"    <span class=\"h3\">",
"     Children with cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an observational study, herpes virus DNA (HHV-6 or CMV) was detected by PCR in the plasma or white blood cells of children with Hodgkin or non-Hodgkin lymphoma more often than in controls (46 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/60\">",
"     60",
"    </a>",
"    ]. The presence of both HHV-6 and CMV was associated with more frequent episodes of febrile neutropenia, absolute neutrophil count &lt;800",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    lymphocytes &lt;500",
"    <span class=\"nowrap\">",
"     cell/microL,",
"    </span>",
"    and hemoglobin &lt;9.1",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The presence of HHV-6 DNA was predictive of immunosuppression before the onset of CMV infection.",
"   </p>",
"   <p>",
"    In a cross-sectional study of beta-herpesviruses (HHV-6, HHV7, and CMV) in 30 children with cancer, HHV-6B DNA was detected in the blood of four patients (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/61\">",
"     61",
"    </a>",
"    ]. HHV-6B DNA was associated with hepatitis in one case and mild viral illness in another. Although HHV-6B was detected less frequently in children with cancer than in a control group of children with solid-organ transplants, it should be considered in the differential diagnosis of febrile children with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports of HHV-6 infection in adult transplant recipients have been published. Fewer reports have been published on children. HHV-6 reactivation syndromes occur in approximately 50 percent of hematopoietic stem cell transplant recipients and 20 to 62 percent of solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Reactivation of HHV-6 usually occurs two to four weeks post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/64\">",
"     64",
"    </a>",
"    ]. Rarely, primary infection with HHV-6 can occur through transmission from the donor [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. In addition, HHV-6 may be a co-factor for cytomegalovirus disease in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/63,68\">",
"     63,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in immunocompetent hosts, the majority of HHV-6 infections in transplant recipients are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the following manifestations have been described in immunocompromised children, including those who have undergone hematopoietic stem cell or solid organ transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained fever [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,69,70\">",
"       62,69,70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Viremia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rash [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/67,71\">",
"       67,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,66\">",
"       62,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pneumonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,72,73\">",
"       62,72,73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,74-76\">",
"       62,74-76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mollaret's meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone marrow suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62,79,80\">",
"       62,79,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Macrophage activation syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/81\">",
"       81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Graft failure [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Graft rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Graft-versus-host disease (GVHD) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/59,82\">",
"       59,82",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The correlation between GVHD and HHV-6 is present in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/72,82\">",
"     72,82",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/64,83\">",
"     64,83",
"    </a>",
"    ]. Coinfection with CMV in transplant recipients may worsen post-transplant pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a diagnosis of primary human herpesvirus 6 (HHV-6) infection is made in infancy or childhood, it is usually based upon the clinical presentation. Laboratory investigation is seldom necessary for patients with classic roseola. For atypical presentations, complications, and immunocompromised hosts, several laboratory tools are available. However, the high seroprevalence and frequent presence of HHV-6 in blood (",
"    <a class=\"graphic graphic_figure graphicRef57693 \" href=\"UTD.htm?26/45/27358\">",
"     figure 1",
"    </a>",
"    ) complicate the interpretation of results [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/6\">",
"     6",
"    </a>",
"    ]. HHV-6 DNA persists in most children intermittently following primary infection and is unrelated to illness. Reactivation of HHV-6, as measured by reverse transcription-polymerase chain reaction (PCR), occurs in healthy children without apparent illness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serodiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect immunofluorescence assays, anticomplement immunofluorescence, competitive radioimmune assay, neutralization and enzyme immunoassays detecting HHV-6 IgG antibody responses can be used to diagnose acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/85-87\">",
"     85-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of these assays varies. They do not distinguish between the HHV-6A and HHV-6B variants. There is also cross-reactivity with HHV-7. Because most people older than two years of age are seropositive for HHV-6, a single positive result cannot be interpreted. Paired sera need to be collected, with a &ge;fourfold rise in titers considered diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/88\">",
"     88",
"    </a>",
"    ]. Seroconversion from negative to positive is good evidence of primary infection.",
"   </p>",
"   <p>",
"    Characterization of the IgG isotype immune response in various populations has revealed two different patterns. IgG1 was dominant in the latent phase of HHV-6 infection in healthy children, pregnant women, and transplant patients with stable levels of antibodies, whereas IgG1 and IgG4 were detected in the reactivation of HHV-6 in transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 IgM develops within four to seven days of infection. However, many culture-positive children do not develop detectable IgM responses, and approximately 5 percent of healthy adults are IgM positive at any given time, making this test unreliable for a definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, assays that detect HHV-6 IgM often lack specificity, although new generation capture assays are improving [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Virus detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of virus detection include culture, monoclonal and polyclonal antibodies, and qualitative and quantitative PCR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-6 can be readily cultured from peripheral blood mononuclear cells in a high percentage of young children in the febrile phase of acute infection before the roseola rash develops. However, this test is not always available. Virus recovery is more difficult in older children and adults. In immunocompromised hosts, higher rates of viral replication might make recovery of virus from lymphocytes more difficult to interpret.",
"     </li>",
"     <li>",
"      Monoclonal antibodies against specific HHV-6A and B antigens, as well as a polyclonal antibody against HHV-6 U90 protein, permit HHV-6 variant determination and detection in tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Qualitative and quantitative DNA PCR assays can detect HHV-6 genome from several tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/93-95\">",
"       93-95",
"      </a>",
"      ]. However, because HHV-6 may establish a latent infection, the clinical significance of its qualitative detection is unclear. Quantification of cell-free virus in serum, plasma, and cerebrospinal fluid (CSF) by PCR may be a better means of diagnosing active HHV-6 infections. Multiplex RT-PCR DNA microarray is also being developed for CNS detection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, human herpesvirus 6 (HHV-6) infection is a benign self-limited disease that does not warrant specific therapy. Anecdotal reports support the use of antivirals in selected patients, but antiviral efficacy has not been evaluated in any controlled trials.",
"   </p>",
"   <p>",
"    In vitro, HHV-6 has a susceptibility pattern similar to cytomegalovirus (CMV):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       Acyclovir",
"      </a>",
"      has very little activity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=see_link\">",
"       Foscarnet",
"      </a>",
"      is active against HHV-6A and HHV-6B. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"       \"Foscarnet: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      is active against HHV-6B, but in some reports HHV-6A was relatively resistant to ganciclovir [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/97,98\">",
"       97,98",
"      </a>",
"      ]. In a retrospective study, ganciclovir prophylaxis in children receiving bone marrow transplant was associated with a decrease in HHV-6 reactivation and HHV-6 viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/99\">",
"       99",
"      </a>",
"      ]. In addition, ganciclovir has been used successfully to treat a case of encephalomyelitis associated with HHV-6 reactivation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31577/abstract/100\">",
"       100",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"       \"Ganciclovir and valganciclovir: An overview\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective, controlled trials are needed to evaluate the utility of these agents in HHV-6-associated conditions, such as encephalitis and pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=see_link\">",
"       \"Patient information: Roseola (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentations of human herpesvirus 6 (HHV-6) infection vary depending upon the age and immune competence of the child. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic manifestations of primary HHV-6 infection in immunocompetent children are roseola infantum (also known as exanthem subitum, and sixth disease) and acute febrile illnesses with or without a rash. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28982?source=see_link\">",
"       \"Roseola infantum (exanthem subitum)\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute febrile illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 has been reported in association with a variety of other clinical syndromes (eg, hepatitis, myocarditis). However, HHV-6 may be activated by a number of acute illnesses, and it is difficult to establish HHV-6 as the causative agent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically relevant reactivation of HHV-6 may occur in immunocompromised children, including transplant recipients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Immunocompromised children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of primary HHV-6 infection in immunocompetent infants and children is usually made based upon the history and examination. Laboratory investigation is seldom necessary for patients with classic roseola. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immunocompromised patients and those with atypical presentations or complications, a variety of tests can be used to detect HHV-6 IgG antibody or virus. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Serodiagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Virus detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 infection is usually self-limited and does not warrant specific therapy. However, if treatment is indicated,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=see_link\">",
"       foscarnet",
"      </a>",
"      is active against HHV-6A and HHV-6B.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      is active against HHV-6B, but resistance of HHV-6A to ganciclovir has been reported. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/1\">",
"      Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/2\">",
"      Ablashi DV, Salahuddin SZ, Josephs SF, et al. HBLV (or HHV-6) in human cell lines. Nature 1987; 329:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/3\">",
"      Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005; 352:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/4\">",
"      Irving WL, Chang J, Raymond DR, et al. Roseola infantum and other syndromes associated with acute HHV6 infection. Arch Dis Child 1990; 65:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/5\">",
"      Rohayem J, Dinger J, Fischer R, et al. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol 2001; 39:4585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/6\">",
"      Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/7\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994; 93:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/8\">",
"      Vianna RA, de Oliveira SA, Camacho LA, et al. Role of human herpesvirus 6 infection in young Brazilian children with rash illnesses. Pediatr Infect Dis J 2008; 27:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/9\">",
"      Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/10\">",
"      Pruksananonda P, Hall CB, Insel RA, et al. Primary human herpesvirus 6 infection in young children. N Engl J Med 1992; 326:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/11\">",
"      Suga S, Yoshikawa T, Asano Y, et al. Human herpesvirus-6 infection (exanthem subitum) without rash. Pediatrics 1989; 83:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/12\">",
"      Freitas RB, Monteiro TA, Linhares AC. Outbreaks of human-herpes virus 6 (HHV-6) infection in day-care centers in Bel&eacute;m, Par&aacute;, Brazil. Rev Inst Med Trop Sao Paulo 2000; 42:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/13\">",
"      Zerr DM, Frenkel LM, Huang ML, et al. Polymerase chain reaction diagnosis of primary human herpesvirus-6 infection in the acute care setting. J Pediatr 2006; 149:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/14\">",
"      Ward KN, Andrews NJ, Verity CM, et al. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child 2005; 90:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/15\">",
"      Suga S, Suzuki K, Ihira M, et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child 2000; 82:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/16\">",
"      Juntunen A, Herrg&aring;rd E, Mannonen L, et al. A major role of viruses in convulsive status epilepticus in children: a prospective study of 22 children. Eur J Pediatr 2001; 160:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/17\">",
"      Laina I, Syriopoulou VP, Daikos GL, et al. Febrile seizures and primary human herpesvirus 6 infection. Pediatr Neurol 2010; 42:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/18\">",
"      Ahtiluoto S, Mannonen L, Paetau A, et al. In situ hybridization detection of human herpesvirus 6 in brain tissue from fatal encephalitis. Pediatrics 2000; 105:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/19\">",
"      McCullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 1995; 21:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/20\">",
"      Ohsaka M, Houkin K, Takigami M, Koyanagi I. Acute necrotizing encephalopathy associated with human herpesvirus-6 infection. Pediatr Neurol 2006; 34:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/21\">",
"      Mannonen L, Herrg&aring;rd E, Valmari P, et al. Primary human herpesvirus-6 infection in the central nervous system can cause severe disease. Pediatr Neurol 2007; 37:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/22\">",
"      Crawford JR, Kadom N, Santi MR, et al. Human herpesvirus 6 rhombencephalitis in immunocompetent children. J Child Neurol 2007; 22:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/23\">",
"      Provenzale JM, van Landingham K, White LE. Clinical and imaging findings suggesting human herpesvirus 6 encephalitis. Pediatr Neurol 2010; 42:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/24\">",
"      Wilborn F, Schmidt CA, Brinkmann V, et al. A potential role for human herpesvirus type 6 in nervous system disease. J Neuroimmunol 1994; 49:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/25\">",
"      Asano Y, Yoshikawa T, Kajita Y, et al. Fatal encephalitis/encephalopathy in primary human herpesvirus-6 infection. Arch Dis Child 1992; 67:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/26\">",
"      Matsumoto K, Kato A, Inagi R, et al. Herpesvirus-6 (HHV-6) encephalitis in a child presenting as a focal necrotic lesion. Acta Neurochir (Wien) 1999; 141:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/27\">",
"      Fotheringham J, Donati D, Akhyani N, et al. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med 2007; 4:e180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/28\">",
"      Kawabe S, Ito Y, Ohta R, et al. Comparison of the levels of human herpesvirus 6 (HHV-6) DNA and cytokines in the cerebrospinal fluid and serum of children with HHV-6 encephalopathy. J Med Virol 2010; 82:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/29\">",
"      Hall CB, Caserta MT, Schnabel K, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 2008; 122:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/30\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr 2004; 145:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/31\">",
"      Adams O, Krempe C, K&ouml;gler G, et al. Congenital infections with human herpesvirus 6. J Infect Dis 1998; 178:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/32\">",
"      Rentz AC, Stevenson J, Hymas W, et al. Human herpesvirus 6 in the newborn intensive care unit. Eur J Clin Microbiol Infect Dis 2007; 26:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/33\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Fatal fulminant hepatitis in an infant with human herpesvirus-6 infection. Lancet 1990; 335:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/34\">",
"      Mendel I, de Matteis M, Bertin C, et al. Fulminant hepatitis in neonates with human herpesvirus 6 infection. Pediatr Infect Dis J 1995; 14:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/35\">",
"      Kanegane C, Katayama K, Kyoutani S, et al. Mononucleosis-like illness in an infant associated with human herpesvirus 6 infection. Acta Paediatr Jpn 1995; 37:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/36\">",
"      Hammerling JA, Lambrecht RS, Kehl KS, Carrigan DR. Prevalence of human herpesvirus 6 in lung tissue from children with pneumonitis. J Clin Pathol 1996; 49:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/37\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J Clin Pathol 2001; 54:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/38\">",
"      Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/39\">",
"      Saijo M, Saijo H, Yamamoto M, et al. Thrombocytopenic purpura associated with primary human herpesvirus 6 infection. Pediatr Infect Dis J 1995; 14:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/40\">",
"      Nishimura K, Igarashi M. Thrombocytopenic purpura associated with exanthema subitum. Pediatrics 1977; 60:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/41\">",
"      Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J 2009; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/42\">",
"      Chuh AA, Chan HH, Chiu SS, et al. A prospective case control study of the association of Gianotti-Crosti syndrome with human herpesvirus 6 and human herpesvirus 7 infections. Pediatr Dermatol 2002; 19:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/43\">",
"      Boccara O, Lesage F, Regnault V, et al. Nonbacterial purpura fulminans and severe autoimmune acquired protein S deficiency associated with human herpesvirus-6 active replication. Br J Dermatol 2009; 161:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/44\">",
"      Miyake F, Yoshikawa T, Suzuki K, et al. Guillain-Barr&eacute; syndrome after exanthem subitum. Pediatr Infect Dis J 2002; 21:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/45\">",
"      Pitk&auml;ranta A, Lahdenne P, Piiparinen H. Facial nerve palsy after human herpesvirus 6 infection. Pediatr Infect Dis J 2004; 23:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/46\">",
"      Portolani M, Cermelli C, Meacci M, et al. Primary infection by HHV-6 variant B associated with a fatal case of hemophagocytic syndrome. New Microbiol 1997; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/47\">",
"      Huang LM, Lee CY, Lin KH, et al. Human herpesvirus-6 associated with fatal haemophagocytic syndrome. Lancet 1990; 336:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/48\">",
"      Takagi M, Unno A, Maruyama T, et al. Human herpesvirus-6 (HHV-6)-associated hemophagocytic syndrome. Pediatr Hematol Oncol 1996; 13:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/49\">",
"      Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children. J Pediatr Orthop 2004; 24:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/50\">",
"      Comar M, D'Agaro P, Campello C, et al. Human herpes virus 6 in archival cardiac tissues from children with idiopathic dilated cardiomyopathy or congenital heart disease. J Clin Pathol 2009; 62:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/51\">",
"      Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/52\">",
"      Aihara Y, Ito SI, Kobayashi Y, et al. Carbamazepine-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction. Br J Dermatol 2003; 149:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/53\">",
"      Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/54\">",
"      Conilleau V, Dompmartin A, Verneuil L, et al. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999; 41:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/55\">",
"      Oskay T, Karademir A, Ert&uuml;rk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. Epilepsy Res 2006; 70:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/56\">",
"      Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/57\">",
"      Tamagawa-Mineoka R, Katoh N, Nara T, et al. DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6. Int J Dermatol 2007; 46:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/58\">",
"      Morimoto T, Sato T, Matsuoka A, et al. Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6. Intern Med 2006; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/59\">",
"      Vuorinen T, Kotilainen P, Lautenschlager I, et al. Interstitial pneumonitis and coinfection of human herpesvirus 6 and Pneumocystis carinii in a patient with hypogammaglobulinemia. J Clin Microbiol 2004; 42:5415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/60\">",
"      Loutfy SA, Fawzy M, El-Wakil M, Moneer MM. Presence of human herpes virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection. Virol J 2010; 7:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/61\">",
"      Yee-Guardino S, Gowans K, Yen-Lieberman B, et al. Beta-herpesviruses in febrile children with cancer. Emerg Infect Dis 2008; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/62\">",
"      Dockrell DH, Paya CV. Human herpesvirus-6 and -7 in transplantation. Rev Med Virol 2001; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/63\">",
"      Yoshikawa T. Human herpesvirus-6 and -7 infections in transplantation. Pediatr Transplant 2003; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/64\">",
"      Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis 2002; 185:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/65\">",
"      Lau YL, Peiris M, Chan GC, et al. Primary human herpes virus 6 infection transmitted from donor to recipient through bone marrow infusion. Bone Marrow Transplant 1998; 21:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/66\">",
"      Ward KN, Gray JJ, Efstathiou S. Brief report: primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor. J Med Virol 1989; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/67\">",
"      Muramatsu H, Watanabe N, Matsumoto K, et al. Primary infection of human herpesvirus-6 in an infant who received cord blood SCT. Bone Marrow Transplant 2009; 43:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/68\">",
"      Buchbinder S, Elmaagacli AH, Schaefer UW, Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/69\">",
"      Yoshikawa T, Ihira M, Furukawa H, et al. Four cases of human herpesvirus 6 variant B infection after pediatric liver transplantation. Transplantation 1998; 65:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/70\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Human herpesvirus 6 infection after living related liver transplantation. J Med Virol 2000; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/71\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Reactivation of herpesvirus type 6 in children receiving bone marrow transplants for leukemia. N Engl J Med 1991; 324:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/72\">",
"      Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/73\">",
"      Knox KK, Pietryga D, Harrington DJ, et al. Progressive immunodeficiency and fatal pneumonitis associated with human herpesvirus 6 infection in an infant. Clin Infect Dis 1995; 20:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/74\">",
"      Allen UD, Tellier R, Doyle J, et al. The utility of plasma polymerase chain reaction for human herpes virus-6 among pediatric bone marrow transplant recipients: results of a pilot study. Bone Marrow Transplant 2001; 28:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/75\">",
"      Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000; 69:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/76\">",
"      Nash PJ, Avery RK, Tang WH, et al. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/77\">",
"      Capouya JD, Berman DM, Dumois JA. Mollaret's meningitis due to human herpesvirus 6 in an adolescent. Clin Pediatr (Phila) 2006; 45:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/78\">",
"      Delbridge MS, Karim MS, Shrestha BM, McKane W. Colitis in a renal transplant patient with human herpesvirus-6 infection. Transpl Infect Dis 2006; 8:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/79\">",
"      Drobyski WR, Dunne WM, Burd EM, et al. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. J Infect Dis 1993; 167:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/80\">",
"      Wang FZ, Linde A, Dahl H, Ljungman P. Human herpesvirus 6 infection inhibits specific lymphocyte proliferation responses and is related to lymphocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/81\">",
"      Lecointe D, Fabre M, Habes D, et al. [Macrophage activation syndrome in primary human herpes virus-6 infection: a rare condition after liver transplantation in infants]. Gastroenterol Clin Biol 2000; 24:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/82\">",
"      Volin L, Lautenschlager I, Juvonen E, et al. Human herpesvirus 6 antigenaemia in allogeneic stem cell transplant recipients: impact on clinical course and association with other beta-herpesviruses. Br J Haematol 2004; 126:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/83\">",
"      Wang FZ, Dahl H, Linde A, et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/84\">",
"      Caserta MT, McDermott MP, Dewhurst S, et al. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr 2004; 145:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/85\">",
"      Couillard M, Joly JR, Desch&ecirc;nes L, Richer G. Evaluation of variables in immunofluorescence procedures for the detection of antibodies against human herpesvirus 6 (HHV-6). Diagn Microbiol Infect Dis 1992; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/86\">",
"      Robert C, Agut H, Aubin JT, et al. Detection of antibodies to human herpesvirus-6 using immunofluorescence assay. Res Virol 1990; 141:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/87\">",
"      Chou SW, Scott KM. Rises in antibody to human herpesvirus 6 detected by enzyme immunoassay in transplant recipients with primary cytomegalovirus infection. J Clin Microbiol 1990; 28:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/88\">",
"      Linnavuori K, Peltola H, Hovi T. Serology versus clinical signs or symptoms and main laboratory findings in the diagnosis of exanthema subitum (roseola infantum). Pediatrics 1992; 89:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/89\">",
"      Carricart SE, Ethel CS, Bustos D, et al. Isotype immune response of IgG antibodies at the persistence and reactivation stages of human herpes virus 6 infection. J Clin Virol 2004; 31:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/90\">",
"      Suga S, Yoshikawa T, Asano Y, et al. IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation. Microbiol Immunol 1992; 36:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/91\">",
"      Nielsen L, Vestergaard BF. A mu-capture immunoassay for detection of human herpes virus-6 (HHV-6) IgM antibodies in human serum. J Clin Virol 2002; 25:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/92\">",
"      Nishimura N, Yoshikawa T, Ozaki T, et al. In vitro and in vivo analysis of human herpesvirus-6 U90 protein expression. J Med Virol 2005; 75:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/93\">",
"      Norton RA, Caserta MT, Hall CB, et al. Detection of human herpesvirus 6 by reverse transcription-PCR. J Clin Microbiol 1999; 37:3672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/94\">",
"      Fujiwara N, Namba H, Ohuchi R, et al. Monitoring of human herpesvirus-6 and -7 genomes in saliva samples of healthy adults by competitive quantitative PCR. J Med Virol 2000; 61:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/95\">",
"      Blumberg BM, Mock DJ, Powers JM, et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol 2000; 16:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/96\">",
"      Leveque N, Van Haecke A, Renois F, et al. Rapid virological diagnosis of central nervous system infections by use of a multiplex reverse transcription-PCR DNA microarray. J Clin Microbiol 2011; 49:3874.",
"     </a>",
"    </li>",
"    <li>",
"     Williams MV. HHV-6: response to antiviral agents. In: Human Herpesvirus-6: Epidemiology, Molecular Biology, and Clinical Pathology, Ablashi DV, Krueger RF, Salahuddin SZ (Eds), Elsevier Biomedical Press, Amsterdam 1992. p.317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/98\">",
"      Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001; 82:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/99\">",
"      Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31577/abstract/100\">",
"      Denes E, Magy L, Pradeau K, et al. Successful treatment of human herpesvirus 6 encephalomyelitis in immunocompetent patient. Emerg Infect Dis 2004; 10:729.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5969 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31577=[""].join("\n");
var outline_f30_53_31577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Roseola infantum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute febrile illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medication hypersensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunocompromised children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5698667\">",
"      - Children with cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serodiagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Virus detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5969|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/45/27358\" title=\"figure 1\">",
"      HHV 6 infants young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5969|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/7/9329\" title=\"picture 1\">",
"      Roseola rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21769?source=related_link\">",
"      Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=related_link\">",
"      Patient information: Roseola (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28982?source=related_link\">",
"      Roseola infantum (exanthem subitum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31578="Prevention of intravascular catheter-related infections";
var content_f30_53_31578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of intravascular catheter-related infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Jeffrey D Band, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Robert Gaynes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/53/31578/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/53/31578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection, phlebitis, and less often bacteremia remain a major problem with intravascular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of serious catheter-related bloodstream infections are associated with central venous catheters (CVCs), particularly those placed in an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ]. CVC-related bloodstream infection is likely if a primary bloodstream infection develops in a patient who had a CVC within the 48-hour period before the development of the bloodstream infection. If the time interval is longer than 48 hours, there must be compelling evidence that the infection was related to the vascular access device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strict adherence to hand hygiene recommendations and the use of aseptic techniques during insertion and dressing changes remain the most important measures for the prevention of catheter-associated infections. These measures are emphasized in guidelines from the Healthcare Infection Control Practices Advisory Committee (HICPAC), the Centers for Disease Control and Prevention (CDC), and a working group composed of members from professional organizations representing a variety of medical disciplines [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other preventive measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choosing appropriate sites for catheter insertion",
"     </li>",
"     <li>",
"      Using the appropriate type of catheter material",
"     </li>",
"     <li>",
"      Using barrier precautions during insertion",
"     </li>",
"     <li>",
"      Changing catheter administration sets at appropriate intervals",
"     </li>",
"     <li>",
"      Ensuring proper catheter-site care",
"     </li>",
"     <li>",
"      Ensuring removal of catheters when no longer essential",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of the location, duration, catheter material, and catheter care will be reviewed here, and recommendations presented for the prevention of infections associated with different types of intravascular catheters (",
"    <a class=\"graphic graphic_table graphicRef75251 \" href=\"UTD.htm?32/35/33340\">",
"     table 1",
"    </a>",
"    ). Issues related to the definitions, epidemiology (including bacteriology), diagnosis, and treatment of intravascular catheter-associated infections, both local and systemic, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF INFECTION RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major determinants of infection risk with intravascular catheters: the type of catheter, the location of catheter placement, and the duration of catheter placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type of catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;All types of intravascular catheters are associated with a risk of both local infection and catheter-related bloodstream infection (CR-BSI). The risk of CR-BSI with the different types of intravascular catheters was evaluated in a systematic review of 200 prospective studies that used appropriate criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/6\">",
"     6",
"    </a>",
"    ]. The following rates of CR-BSI, from lowest to highest, were noted per 1000 catheter-days (",
"    <a class=\"graphic graphic_table graphicRef75247 \" href=\"UTD.htm?1/22/1389\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripherally inserted midline catheters &ndash; 0.2 (95% CI 0.0-0.5)",
"     </li>",
"     <li>",
"      Peripheral intravenous catheters &ndash; 0.5 (95% CI 0.2-0.7)",
"     </li>",
"     <li>",
"      Peripherally inserted central catheters &ndash; 1.1 (95% CI 0.9-1.3)",
"     </li>",
"     <li>",
"      Cuffed and tunneled central venous catheters &ndash; 1.6 (95% CI 1.5-1.7)",
"     </li>",
"     <li>",
"      Arterial catheters for hemodynamic monitoring &ndash; 1.7 (95% CI 1.2-2.3)",
"     </li>",
"     <li>",
"      Noncuffed central venous catheters",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nonmedicated and tunneled &ndash; 1.7 (95% CI 1.2-2.3)",
"     </li>",
"     <li>",
"      Nonmedicated and nontunneled &ndash; 2.7 (95% CI 2.6-2.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary artery catheters &ndash; 3.7 (95% CI 2.4-5.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, all types of intravascular catheters pose significant but often widely differing risks of BSI. Because the study was unable to adjust for different degrees of severity of illness, a particular type of catheter could be associated with an increased risk of infection if it were preferentially used in more severely ill or vulnerable patients.",
"   </p>",
"   <p>",
"    Peripherally inserted central catheters (PICCs) have been associated with a lower rate of bloodstream infection than centrally inserted catheters in studies conducted largely among outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]; studies among inpatients have demonstrated infection rates comparable to those of other central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/8\">",
"     8",
"    </a>",
"    ]. A higher rate of PICC-related bloodstream infections may occur in the more severely ill, including oncology and hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a study of 251 PICCs placed in 115 hospitalized patients, of whom 42 percent had an ICU stay during the study period, the rate of CR-BSI was 2.1 per 1000 catheter-days, similar to rates seen with conventional CVCs placed in the internal jugular or subclavian veins (2 to 5 per 1000 catheter-days) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their low rate of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/6,11\">",
"     6,11",
"    </a>",
"    ], midline catheters, which are peripherally inserted and terminate three to eight inches from the insertion site, are now infrequently used, in part because the rate of complications. The rate of catheter dysfunction may be more than twice as high with midline catheters compared with PICCs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among central venous catheters, higher rates of catheter-related infection have been described with triple lumen compared with single lumen catheters when used for administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, this increase in infection risk compared with single lumen catheters was not seen in a randomized trial of critically ill patients in an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1532435\">",
"    <span class=\"h3\">",
"     Surgically-implanted central catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgically-implanted tunneled catheters are generally associated with significantly lower rates of bloodstream infection (0.1 to 0.2 per 100 catheter-days) than percutaneously inserted catheters. In addition, subcutaneous infusion ports may be associated with a 10- to 12-fold lower rate of infection than tunneled catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1531907\">",
"    <span class=\"h3\">",
"     Needleless devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have shown an association between the use of needleless intravascular access devices and an increased risk for CR-BSI under certain circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. These specifically include receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN), having a tunneled CVC or one with multiple ports, showering (as opposed to bathing), and changing the needleless device end cap infrequently (eg, once weekly versus every two days).",
"   </p>",
"   <p>",
"    Newer mechanical valve needleless connectors have also been temporally associated with increased rates of healthcare-associated BSI that have not been clearly associated with lack of compliance with recommended catheter care (relative risk 1.54; 95% CI, 1.37-1.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These devices generate positive or negative pressure and are accessed using luer lock connectors, eliminating needle use for device access. In one study, the rate of CR-BSI in five hospitals increased from 6.2 to 9.5 infections per 1000 catheter-days after the introduction of a mechanical valve connector into routine use, despite similar surveillance and prevention strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, positive-pressure needleless connectors with mechanical valves should not be used routinely without a thorough assessment of risks, benefits, and education regarding proper use [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site chosen for catheter placement influences the subsequent risk for catheter-associated infection. As an example, the risk of infection with peripheral venous catheters is higher in the lower compared to the upper extremity and higher in the wrist or upper arm compared to the hand [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2,25\">",
"     2,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of central venous catheters (CVCs) is also important. Catheter-related infection is generally more common with catheters in the femoral [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/26-29\">",
"     26-29",
"    </a>",
"    ] and, probably to a lesser degree, internal jugular veins [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/28,30\">",
"     28,30",
"    </a>",
"    ] compared to the subclavian vein. An increase in risk with internal jugular compared to subclavian sites of insertion has also been noted with pulmonary artery catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this difference according to the site of insertion was illustrated by meta-analysis of nine observational studies and one randomized controlled trial, which included ICU patients with short-term CVC placement. The pooled catheter-associated infection rate was lower with non-tunnelled subclavian catheters (1.3 events per 1000 catheter-days) than either internal jugular or femoral catheters (2.6 and 3.6 events per 1000 catheter-days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this meta-analysis was limited by the lack of randomization by site in most studies, significant clinical heterogeneity in the studies (eg, with regards to insertion techniques, and other prevention strategies) and lack of standard definitions of catheter related infections.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis included a different subset of studies evaluating CVC location and infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/33\">",
"     33",
"    </a>",
"    ]. Many of the included studies were performed at a time when overall rates of CVC infections had fallen dramatically. This meta-analysis had similar limitations to the above meta-analysis and additionally excluded two outlier studies from the analysis. It did not demonstrate any difference in the rate of infections between femoral versus subclavian or internal jugular catheters.",
"   </p>",
"   <p>",
"    However, in the one trial included in both meta-analyses, in which 289 patients were randomly assigned to either the femoral or subclavian sites for central venous catheter placement, femoral catheterization was associated with a significant increase in overall infection (20 versus 3.7 per 1000 catheter-days), clinical sepsis with or without documented bloodstream infection (4.5 versus 1.2 per 1000 catheter-days), and thrombotic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in infection risk among sites of catheterization may be minimized when experienced physicians insert the catheters, strict sterile technique is used, and trained intensive care unit nursing staff performs catheter care [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We continue to recommend avoiding the femoral site for insertion of central venous or pulmonary artery catheters, if possible. The subclavian site may be associated with the lowest risk of infection and is particularly preferred in patients with advanced kidney disease who may need the internal jugular site for vascular access. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Non-tunneled catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of catheterization has been considered an important risk factor for infection with both peripheral venous and arterial catheters. The risk of infection has been reported to increase after the following intervals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral venous catheter &ndash; greater than three to four days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25,35-37\">",
"       25,35-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Central venous catheter &ndash; greater than six days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary artery (Swan-Ganz) catheter &ndash; greater than three to four days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/31,39,40\">",
"       31,39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arterial catheter &ndash; greater than four to six days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Peripheral venous catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies have shown an increased rate of phlebitis over time with peripheral venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25,35-37\">",
"     25,35-37",
"    </a>",
"    ]. The incidence of phlebitis was evaluated in a prospective study of 1054 small peripheral venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of phlebitis exceeded 50 percent by day four. The rate of catheter-related infection was much lower (5.4 percent) and there were no cases of bacteremia.",
"   </p>",
"   <p>",
"    In contrast to these findings, another large observational study failed to demonstrate a difference in the risk of complications for peripheral venous catheters after three days of cannulation, and suggested that routine replacement of peripheral catheters may not be required [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the ease of changing peripheral sites and the probable increase in infection risk over time, it is our practice to replace or remove peripheral venous catheters at four days, or earlier if there are signs of phlebitis or malfunction (",
"    <a class=\"graphic graphic_table graphicRef77380 \" href=\"UTD.htm?18/52/19276\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ]. If no alternate sites are available, we leave the catheter in place if there are no signs of phlebitis or other complication. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An exception to this time interval is when adherence to aseptic technique cannot be assured, which primarily occurs when catheters are placed during a medical emergency. In this setting, the catheter should be replaced as soon as possible and no longer than 48 hours after insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Central venous or pulmonary artery catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection with central venous and pulmonary artery catheters increases with the duration of use [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/31,38,39\">",
"     31,38,39",
"    </a>",
"    ]. However, a defined time period to routinely change these catheters has not been conclusively established [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] and changing such catheters is not as simple as changing peripheral venous catheters. As a result, routine replacement of these catheters is not recommended (",
"    <a class=\"graphic graphic_table graphicRef76738 \" href=\"UTD.htm?17/60/18380\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75277 \" href=\"UTD.htm?5/21/5468\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Vigilant clinical evaluation and assessment of the catheter site should be performed at least every other day. Indications for catheter replacement include purulence at the insertion site with short-term central venous catheters and hemodynamic stability that is suspected to be due to catheter-related bloodstream infection with all central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ]. Guidewire techniques should not be used to exchange catheters, since this approach increases the risk of bloodstream infection (eg, 6 versus 0 percent with replacement of the catheter at a new site in a randomized trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Arterial catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral arterial catheters are primarily used for hemodynamic monitoring. The risk of infection increases after more than four to six days. This was illustrated in two reports with a total 201 peripheral arterial catheters, in which there were 34 local infections and nine episodes of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Twenty-six of the local infections and all of the episodes of bacteremia occurred more than four days after catheter placement. However, given the limited number of access sites, routine replacement of these catheters is not recommended (",
"    <a class=\"graphic graphic_table graphicRef65076 \" href=\"UTD.htm?30/48/31499\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Peripherally inserted catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripherally inserted catheters are commonly used for the administration of home intravenous antibiotics. These flexible catheters are usually inserted into the veins of the arm and threaded into the superior vena cava.",
"   </p>",
"   <p>",
"    Two types of peripheral catheters may be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripherally inserted central catheters (PICCs)",
"     </li>",
"     <li>",
"      Peripherally inserted midline catheters in which the tip of the catheter terminates 3 to 8 inches above the insertion site in the proximal portion of the upper extremity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These catheters can be left in place for months (",
"    <a class=\"graphic graphic_table graphicRef57970 \" href=\"UTD.htm?8/22/8556\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63491 \" href=\"UTD.htm?7/33/7708\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CATHETER MATERIAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peripheral catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between catheter material and the risk for bloodstream infection has been examined most comprehensively with peripheral venous catheters. Data from several studies suggest that peripheral venous catheters composed of Teflon or polyurethane result in fewer complications and bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25,45\">",
"     25,45",
"    </a>",
"    ]. One report, for example, concluded that the risk of bacteremia with peripheral venous catheters made of Teflon was so low that the use of small steel needles, which are associated with an appreciable risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/37\">",
"     37",
"    </a>",
"    ], no longer seemed justifiable in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Central catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential confounders have made it difficult to draw conclusions about the infection risk with different types of central venous catheters (CVCs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923683666\">",
"    <span class=\"h3\">",
"     Antimicrobial impregnated catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiseptic- or antimicrobial-impregnated CVCs may reduce the incidence of catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/46-53\">",
"     46-53",
"    </a>",
"    ]. A meta-analysis of 11 randomized trials demonstrated a benefit of antiseptic-impregnated catheters over nonimpregnated catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/47\">",
"     47",
"    </a>",
"    ]. Types of catheters include",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"      chlorhexidine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"      silver sulfadiazine",
"     </a>",
"    </span>",
"    coated catheters and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"      minocycline",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"      rifampin",
"     </a>",
"    </span>",
"    coated catheters.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"      Chlorhexidine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"      silver sulfadiazine",
"     </a>",
"     -impregnated",
"    </span>",
"    catheters have been associated with significant reductions in catheter-related bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/47,53\">",
"     47,53",
"    </a>",
"    ]. In a meta-analysis of",
"    <span class=\"nowrap\">",
"     chlorhexidine/silver",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    including more than 2600 catheters, the summary odds ratio for catheter colonization was 0.44 (95% confidence interval [CI], 0.36-0.54; P&lt;.001), indicating a significant decrease in catheter colonization associated with impregnated catheters.",
"   </p>",
"   <p>",
"    Reductions in catheter-related infection have also been observed with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"      minocycline",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"      rifampin",
"     </a>",
"    </span>",
"    bonded catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. In a trial of 736 catheter insertions comparing",
"    <span class=\"nowrap\">",
"     minocycline/rifampin-impregnated",
"    </span>",
"    catheters with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"      chlorhexidine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"      silver sulfadiazine",
"     </a>",
"     -impregnated",
"    </span>",
"    catheters, patients who received a",
"    <span class=\"nowrap\">",
"     minocycline/rifampin-impregnated",
"    </span>",
"    catheter had a lower rate of bloodstream infection than patients who received a",
"    <span class=\"nowrap\">",
"     chlorhexidine/silver",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    -impregnated catheter (0.3 versus 3.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/52\">",
"     52",
"    </a>",
"    ]. No adverse effect related to the",
"    <span class=\"nowrap\">",
"     minocycline/rifampin-impregnated",
"    </span>",
"    catheters or change in antimicrobial resistance was noted. The better outcome observed with the",
"    <span class=\"nowrap\">",
"     minocycline/rifampin-impregnated",
"    </span>",
"    catheter might have been related in part to differences in catheter design; the",
"    <span class=\"nowrap\">",
"     chlorhexidine/silver",
"    </span>",
"    sulfadiazine catheter was coated only on the external surface of the catheter whereas the",
"    <span class=\"nowrap\">",
"     minocycline/rifampin",
"    </span>",
"    catheter was coated on both the internal and external surface.",
"   </p>",
"   <p>",
"    A second generation catheter has a threefold increase in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    concentration on the external surface of the catheter as well as incorporation of chlorhexidine in the lumen, hub, and extension lines. This catheter was compared with an uncoated catheter in a randomized, double-blind, controlled trial of 780 patients in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/55\">",
"     55",
"    </a>",
"    ]. The antiseptic-coated catheter led to a significant decrease in bacterial colonization and a nonsignificant reduction in the rate of bloodstream infections. Because of the small number of events, no conclusion could be made regarding the effect of the coated catheter on bloodstream infection.",
"   </p>",
"   <p>",
"    Despite the aggregate benefit with the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"      minocycline",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"      rifampin",
"     </a>",
"     -impregnated",
"    </span>",
"    catheter noted in the above studies, the efficacy of these devices remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/53,56\">",
"     53,56",
"    </a>",
"    ]. Meta-analyses have cited methodological flaws including improper definitions, failure to determine clinically important end points, and failure to report key confounding variables. Antimicrobial-impregnated catheters have potential limitations including risk of anaphylaxis reactions and emergence of resistant organisms.",
"   </p>",
"   <p>",
"    Some favor reserving use of an antimicrobial- or antiseptic-bonded for circumstances in which the rate of catheter-related bloodstream infections is higher than national surveillance data rates (eg, &ge;2.5 per 1000 catheter-days), despite adherence to maximal antisepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/57\">",
"     57",
"    </a>",
"    ]. However, many centers in the United States use these catheters routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Silver impregnation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of infection may be reduced by the use of silver-impregnated collagen cuff catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In a randomized trial of 234 catheters, those with a silver-impregnated collagen cuff were less likely than cuffless catheters to be colonized at removal (9 versus 29 percent) and to be associated with bacteremia (1.0 versus 3.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/58\">",
"     58",
"    </a>",
"    ]. However, later trials in tunneled catheters and double or triple lumen catheters did not confirm such benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Heparin bonding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of central venous catheters (CVCs) are manufactured with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded components in an attempt to reduce catheter-associated thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Several studies suggest that their use may diminish the frequency of catheter-related infections. As an example, a prospective double-blind trial randomly assigned 55 adults to heparinized or standard CVCs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/63\">",
"     63",
"    </a>",
"    ]. Among the 32 patients who completed the trial, bacteremia or fungemia occurred significantly more frequently in the standard catheter group (5 of 19 versus 0 of 13 with heparinized catheters). In addition, when the catheters were removed, microbial colonization was more common in the standard catheter group (14 of 19 versus 4 of 13). However, standard catheters remained in place longer and more catheters were used to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , which is a risk factor for bloodstream infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in children have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded catheters reduce catheter thrombosis and that this might be associated with fewer catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In a prospective masked study comparing heparin-bonded and standard femoral venous catheters in 50 critically ill children, the heparin-bonded catheter was associated with a significantly lower rate of thrombotic complications (8 versus 44 percent) as determined by ultrasonography performed within three days after catheter insertion and then weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, positive catheter blood culture results were significantly more common with catheter thrombosis (38 versus 3 percent without catheter thrombosis).",
"   </p>",
"   <p>",
"    At present, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded catheters should be part of a thrombosis-prevention strategy rather than for prevention of infection. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Preventing thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antibiotic locks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibiotic lock technique for prevention of CVC-related infection involves filling the catheter lumen with high concentrations of antibiotics for several hours in an attempt to prevent colonization of the intraluminal surface of the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. We do not favor routine use of antibiotic locks for prevention of infection given the difficulty in preparing the solutions and limited efficacy data.",
"   </p>",
"   <p>",
"    A 2006 meta-analysis evaluated seven randomized trials that compared vancomycin-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock or flush solutions with heparin alone for prevention of bloodstream infection associated with long-term use of CVCs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/67\">",
"     67",
"    </a>",
"    ]. The vancomycin-heparin solution was associated with a significant reduction in catheter-related bloodstream infection (summary risk ratio 0.49, 95% CI 0.26-0.95). The benefit was much greater when used as a lock solution rather than simple flushing through the device. Two of the seven trials performed surveillance cultures to identify vancomycin-resistant organisms; there was no evidence of an increase in resistant organisms.",
"   </p>",
"   <p>",
"    Use of antibiotic lock techniques for treatment of catheter related infection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SITE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chlorhexidine bathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    bathing for ICU patients may reduce catheter-related bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. In a meta-analysis of two controlled trials and 10 observational studies of ICU patients, daily chlorhexidine bathing was associated with a decrease in healthcare-associated bloodstream infections compared with soap and water or no bath (OR 0.44, 95% CI 0.33-0.59) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/74\">",
"     74",
"    </a>",
"    ]. There was significant clinical heterogeneity between the studies, including the concentration and type of chlorhexidine wash used as well as in the utilization of adjunctive infection control measures (nasal antibiotics, active surveillance, enhanced hand washing). However, the reported adverse effects were rare and predominantly mild skin reactions, and the four studies that evaluated cost of the interventions suggested that chlorhexidine was relatively inexpensive. Cost can vary widely depending on the type of chlorhexidine wash used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    bathing may also decrease rates of MRSA and VRE colonization. The largest study included in the meta-analysis above was a before-after intervention study involving six ICUs and over 5,000 admissions, in which all ICU patients were bathed with routine soap for 6 months followed by a 6 month intervention period using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    (4 ounces of 4 percent solution mixed in warm water) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/71\">",
"     71",
"    </a>",
"    ]. Acquisition of MRSA and VRE decreased significantly (32 and 50 percent, respectively). The VRE bacteremia rate decreased by 73 percent (from 2.1 to 0.6",
"    <span class=\"nowrap\">",
"     cases/1000",
"    </span>",
"    patient days), while the MRSA bacteremia rate remained low and unchanged throughout the study period (&lt;0.5",
"    <span class=\"nowrap\">",
"     cases/1000",
"    </span>",
"    patient days). Emergence of potential resistance to chlorhexidine was not studied.",
"   </p>",
"   <p>",
"    Thus, for ICU patients, we suggest daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    bathing, given the apparent efficacy in reduction of catheter-related bloodstream infections and colonization with resistant organisms as well as the minimal adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sterile technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to sterile technique is important for minimizing catheter-associated infection. This includes strict adherence to hand washing and aseptic technique and, with central venous catheter (CVC) insertion, sterile gloves, long-sleeved surgical gown, a surgical mask, and a large sterile sheet drape [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/3,31,75,76\">",
"     3,31,75,76",
"    </a>",
"    ]. However, a 2006 report of intensive care units in 10 academic tertiary-care hospitals found that less than 30 percent had adopted maximal barrier precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the importance of different components of this regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of educating physicians in-training on infection control practices and procedures was evaluated in a nonrandomized pre-post observational trial of insertion of CVCs [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/78\">",
"       78",
"      </a>",
"      ]. Six months after a one-day course, the perceived need for and documented use of full-size sterile drapes increased from 22 to 73 percent and from 44 to 65 percent respectively, while the rate of catheter-associated bloodstream infections decreased from 3.3 to 2.4 per 1000 central line days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Insertion site preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiseptic solution for skin disinfection at the catheter insertion site helps prevent catheter-related infection.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    -based solutions (&gt;0.5 percent chlorhexidine preparation with alcohol) appear to be superior to both aqueous and alcohol-based povidone-iodine in reducing the risk for catheter colonization and catheter-related bloodstream infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. This was illustrated in a meta-analysis of eight randomized trials including 4143 catheter insertions; disinfection with chlorhexidine rather than aqueous povidone-iodine resulted in a 50 percent reduction in catheter-associated bloodstream infections. If there is a contraindication to chlorhexidine, tincture of iodine, an iodophor or 70 percent alcohol can be used as alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    for routine ICU bathing (rather than soap and water) may also be an effective strategy to decrease the rate of bloodstream infection. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Chlorhexidine bathing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of dressing at the insertion site may affect the rate of catheter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Transparent polyurethane versus gauze",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have demonstrated a higher rate of colonization and infection with transparent polyurethane dressings compared to gauze dressings for CVCs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/30,84-87\">",
"     30,84-87",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a meta-analysis of seven trials comparing these two types of dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/84\">",
"     84",
"    </a>",
"    ]. Among patients with CVCs, transparent dressings were associated with a significant increase in the relative risk (RR) of catheter tip infection (RR 1.78, 95% CI 1.30-2.30) and a nonsignificant increase in catheter-related bacteremia (RR 1.63, 95% CI 0.76-3.47).",
"   </p>",
"   <p>",
"    Dressings on short term CVC sites should be replaced every two days (gauze dressings) or every seven days (transparent dressings). Transparent dressings on tunneled sites should be replaced no more than once per week (unless the dressing is soiled or loose), until the insertion site has healed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/4\">",
"     4",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Among patients with peripheral venous catheters in the same meta-analysis, there was a significant increase in catheter tip infection but no change in phlebitis (RR 1.02, 95% CI 0.86-1.20) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/84\">",
"     84",
"    </a>",
"    ]. It has been suggested that the higher colonization rate with transparent dressings may be partly offset by earlier detection of local signs of inflammation. It is possible that \"breathable\" transparent dressings could reduce the growth of microorganisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chlorhexidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    -impregnated sponge (CHGIS) in intravenous catheter dressings may reduce catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/88\">",
"     88",
"    </a>",
"    ]. Among 1636 patients with central venous or arterial catheters, use of a dressing incorporating a CHGIS compared with standard dressings was associated with a significant decrease in catheter-related bloodstream infection; the rates decreased from 1.3 to 0.4 per 1000 catheter-days [hazard ratio 0.39]. Catheter colonization rates were similar at the 3-day and the 7-day dressing change.",
"   </p>",
"   <p>",
"    It is important to note that the observed incidence of infection may have been influenced by several factors, including the inclusion of arterial catheters (46 percent), and the exclusion of antimicrobial-impregnated catheters.",
"   </p>",
"   <p>",
"    In a smaller randomized controlled trial of ICU patients requiring a central venous catheter for more than three days, use of CHGIS had no effect on catheter colonization rates, nonbacteremic catheter-related infections, or catheter-related bloodstream infections, although the low number of events limited the power of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Topical antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antimicrobial ointments have not been consistently demonstrated to reduce the rate of infection, but have been associated with increased rates of antimicrobial resistance and Candida colonization and only modest protection against catheter-related infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/59,89,90\">",
"     59,89,90",
"    </a>",
"    ]. Furthermore, protection against infection has primarily been seen with peripheral venous catheters left in place for more than four days, which is longer than the recommended duration [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/90\">",
"     90",
"    </a>",
"    ]. An important exception to these observations is central venous catheters used for hemodialysis in which topical antimicrobial ointments significantly reduce both catheter-related infection and bacteremia. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Duration'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link&amp;anchor=H25#H25\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Topical antimicrobial exit site application'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CATHETER CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Access point management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contaminated needleless connectors, catheter hubs, or injection ports are recognized sources for central venous catheter (CVC)-associated infections, including BSI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/17,21,22,91\">",
"     17,21,22,91",
"    </a>",
"    ]. Such infections can occur both in hospitalized patients and in those treated with home infusion therapy and, in many cases, have been associated with failure to follow the manufacturers' recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, alcohol swabbing may fail to disinfect the connector [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1531907\">",
"     'Needleless devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of preventive measures were recommended or suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two measures were strongly recommended: minimizing contamination risk by wiping the access port with an appropriate antiseptic; and accessing the port only with sterile devices. No specific protocol for decontamination was provided. The most common practice involves swabbing the membranous septum with 70 percent alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of other measures were suggested, as the supporting data were less strong:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Change the needleless components as least as frequently as the administration set.",
"     </li>",
"     <li>",
"      Change caps no more frequently than every 72 hours or according to manufacturers' recommendations.",
"     </li>",
"     <li>",
"      Ensure that all components of the system are compatible to minimize leaks and breaks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to injection ports, two measures were strongly recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clean access ports with 70 percent alcohol or an iodophor before accessing the system.",
"     </li>",
"     <li>",
"      Cap all stopcocks when not in use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of infection increases with the duration that a catheter remains in place, data from clinical trials suggest that routine replacement of catheters does not decrease that risk.",
"   </p>",
"   <p>",
"    Several observational studies have suggested that the risk of local infection with peripheral venous catheters increases over time (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Duration'",
"    </a>",
"    above). However, in a large trial of 3379 patients with peripheral catheters who were randomly assigned to routine catheter replacement every three days or replacement only when clinically indicated, there was no difference in the rate of phlebitis (tenderness, erythema, swelling, discharge, or a palpable cord at the insertion site) between the two groups (7 percent in both) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/93\">",
"     93",
"    </a>",
"    ]. Rates of infiltration (27 versus 32 percent), occlusion (40 versus 40 percent), and catheter-related bloodstream infections (0.1 versus 0 percent) were also similar with routine versus clinically indicated replacement. Of note, less than 25 percent of devices remained in place for periods longer than four days.",
"   </p>",
"   <p>",
"    Until further data clearly demonstrate no increased complication risk of extending peripheral venous catheter use beyond four days, we recommend replacing or removing peripheral venous catheters every four days, or earlier if there are signs of phlebitis or malfunction (",
"    <a class=\"graphic graphic_table graphicRef77380 \" href=\"UTD.htm?18/52/19276\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The risk of infection with central venous and pulmonary artery catheters also increases with the duration of use [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/31,38,39\">",
"     31,38,39",
"    </a>",
"    ]. However, a defined time period to routinely changes these catheters has not been defined and access sites may be limited; as a result, routine replacement of these catheters is not recommended (",
"    <a class=\"graphic graphic_table graphicRef76738 \" href=\"UTD.htm?17/60/18380\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of efficacy of routine replacement of such catheters was best demonstrated in a randomized controlled trial in intensive care units in which 160 adults were assigned one of four methods of central venous or pulmonary artery catheter exchange: replacement every three days, either by insertion at a new site (group 1) or by exchange over a guidewire (group 2); or replacement when clinically indicated either by insertion at a new site (group 3) or by exchange over a guidewire (group 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/43\">",
"     43",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rates (per 1000 days of catheter use) of bloodstream infection were: 3 in group 1; 6 in group 2; 2 in group 3; and 3 in group 4.",
"     </li>",
"     <li>",
"      Exchanging catheters over a guidewire after the first three days of catheterization significantly increased the bloodstream infection risk (6 versus 0 percent). On the other hand, the scheduled replacement of catheters at new sites was associated with a higher risk of mechanical complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, vigilant clinical evaluation and assessment of the catheter site at least every other day are recommended instead of scheduled changes of the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is the timing of replacement of catheter administration sets to minimize bacterial contamination. In a review of 487 patients, the prevalence of contamination of the intravenous fluid was not significantly different when the administration sets were replaced at 72 compared to 48 hour intervals (1.5 versus 0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/94\">",
"     94",
"    </a>",
"    ]. Contamination was almost always with small number of coagulase-negative staphylococci and no contaminated infusion was associated with clinical signs of sepsis or with bacteremia. In a randomized trial, there was no significant difference in contamination between no tubing change at 96 hours and tubing change at 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following conclusions were reached in a meta-analysis that included 15 randomized or quasi-randomized controlled trials of central and peripheral venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence that changing administration sets more often than every 96 hours reduces the incidence of bloodstream infection when the fluids administered do not contain lipids, blood, or blood products.",
"     </li>",
"     <li>",
"      There are not sufficient data to know whether changing administration sets less often than every 96 hours affects the incidence of infection.",
"     </li>",
"     <li>",
"      There is no evidence to contradict current recommendations that administration sets that contain lipids or blood products should be changed every 24 hours. The more rapid rate of administration set replacement is based upon studies suggesting that these solutions promote bacterial and fungal growth [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/97,98\">",
"       97,98",
"      </a>",
"      ], and possibly bloodstream infection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/99-101\">",
"       99-101",
"      </a>",
"      ]. However, some consider the evidence inconclusive [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended intervals for changing catheters and related equipment are presented in the accompanying tables for the specific types of catheters. The recommendations in these tables are based upon data in the literature. When the data are insufficient to make a determination, no recommendation is made.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral venous catheters (",
"      <a class=\"graphic graphic_table graphicRef77380 \" href=\"UTD.htm?18/52/19276\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central venous catheters (",
"      <a class=\"graphic graphic_table graphicRef76738 \" href=\"UTD.htm?17/60/18380\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary arterial catheters (",
"      <a class=\"graphic graphic_table graphicRef75277 \" href=\"UTD.htm?5/21/5468\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral arterial catheters (",
"      <a class=\"graphic graphic_table graphicRef65076 \" href=\"UTD.htm?30/48/31499\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripherally inserted central venous catheters (",
"      <a class=\"graphic graphic_table graphicRef57970 \" href=\"UTD.htm?8/22/8556\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripherally inserted midline catheters (",
"      <a class=\"graphic graphic_table graphicRef63491 \" href=\"UTD.htm?7/33/7708\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central hemodialysis catheters (",
"      <a class=\"graphic graphic_table graphicRef51737 \" href=\"UTD.htm?25/55/26491\">",
"       table 9",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"       \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Umbilical vein or artery catheters (",
"      <a class=\"graphic graphic_table graphicRef69746 \" href=\"UTD.htm?11/63/12284\">",
"       table 10",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An exception to these general recommendations is that we remove and, if necessary, replace all catheters placed under emergency conditions (ie, catheters placed without the usual sterile precautions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Preventing thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded central venous catheters (CVCs) in critically ill children reduce the rate of catheter thrombosis, which may be associated with fewer catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In a prospective masked study in 50 children, the heparin-bonded catheter was associated with a significantly lower rate of thrombotic complications (8 versus 44 percent with a non-bonded catheter) and positive catheter blood culture results were significantly more common with catheter thrombosis (38 versus 3 percent without catheter thrombosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Heparin bonding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A similar association between thrombosis and infection has been suggested in other studies and routine infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. The potential efficacy of this approach was illustrated in a randomized controlled trial in 204 hospitalized adults with hematologic or oncologic malignancy and a nontunneled CVC; the patients were assigned to treatment with an infusion of low dose heparin or normal saline (control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/103\">",
"     103",
"    </a>",
"    ]. Catheter-related bloodstream infection was significantly less common in the heparin group (6.8 versus 16.6 percent in the control group). In a trial of 341 ICU patients who required CVC placement, there was a trend towards fewer episodes of lumen non-patency (3.8 versus 6.3 percent) and catheter-related bloodstream infections (0 versus 3.1 per 1000 catheter-days) in patients who were randomly assigned to have their catheters flushed with heparin compared with normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/105\">",
"     105",
"    </a>",
"    ]. However, these differences were not statistically significant.",
"   </p>",
"   <p>",
"    These observations support the use of clot prevention strategies to reduce the rate of CVC-related infection, at least in patients with hematologic or oncologic malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with measures to prevent intravascular catheter infections is a challenging problem [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Compliance with infection control practices for prevention of central venous catheter-related bloodstream infection was evaluated in a survey of infection control coordinators at 516 Veterans Administration (VA) and non-VA hospitals United States for the period March 16 through August 1, 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/106\">",
"     106",
"    </a>",
"    ]. There were two main findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of compliance was significantly higher at VA hospitals for maximal sterile barrier precautions (84 versus 71 percent), the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      at the insertion site (91 versus 69 percent), and the composite of these two approaches plus avoidance of routine central venous catheter replacement (62 versus 44 percent).",
"     </li>",
"     <li>",
"      Use of these preventive measures was higher in hospitals with a certified infection control professional, a higher safety culture score, and participation in an in infection prevention collaborative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively low rate of compliance is important since the rate of CVC-related bloodstream infections can be significantly reduced by implementation of such infection prevention measures. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Catheter teams and use of checklist'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Catheter teams and use of checklist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from several studies suggest that catheters placed under emergency conditions are associated with higher rates of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/25,108\">",
"     25,108",
"    </a>",
"    ]. In contrast, catheters placed by health care workers skilled in intravenous catheter placement have lower rates of infection. This has been demonstrated with insertion of both central venous catheters (CVCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/107,109-112\">",
"     107,109-112",
"    </a>",
"    ] and peripheral intravenous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study involved 103 intensive care units in Michigan and over 375,000 catheter-days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/107\">",
"     107",
"    </a>",
"    ]. The intervention (sometimes called the Pronovost checklist) consisted of five evidence-based procedures that are strongly recommended by the Centers for Disease Control and Prevention guidelines for the prevention of intravascular catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hand washing",
"     </li>",
"     <li>",
"      Full barrier precautions during insertion of CVCs",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       Chlorhexidine",
"      </a>",
"      for skin disinfection",
"     </li>",
"     <li>",
"      Avoidance of the femoral insertion site",
"     </li>",
"     <li>",
"      Removal of catheters when no longer indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following implementation of the evidence-based intervention, the mean rate of catheter-related bloodstream infections per 1000 catheter-days decreased from 7.7 at baseline to 1.4 at 16 to 18 months. The rate of infection fell continuously during this period (incidence-rate ratio 0.62 in the first three months and 0.34 at 16 to 18 months). The use of antibiotic-impregnated catheters was not reported.",
"   </p>",
"   <p>",
"    The importance of a specialized team for peripheral venous catheters was illustrated in a controlled trial in a university hospital in which patients were randomly assigned to insertion by a house officer and maintenance by the ward nursing staff or insertion and maintenance by an intravenous therapy team [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/113\">",
"     113",
"    </a>",
"    ]. The team approach was associated with a significantly lower frequency of signs or symptoms of inflammation (7.9 versus 21.7 percent with the house staff-nursing approach), no episodes of bacteremia versus three (2.2 percent), and a higher number of catheters placed per patient (2.1 versus 1.6). The last observation suggests that timely replacement of the catheter may be the most important factor in reducing infectious complications (",
"    <a class=\"graphic graphic_table graphicRef77380 \" href=\"UTD.htm?18/52/19276\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Even in the absence of a specialized catheter team, the rate of catheter-related infections can be reduced by a comprehensive prevention strategy (eg, guidelines for insertion and care of the catheter, gauze dressings, and hand disinfection before and after any care of the line) that includes slide shows, practical demonstrations, and in-service training [",
"    <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/33/35345?source=see_link\">",
"       \"Patient information: Central line infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Catheter type",
"    </span>",
"    &nbsp;&mdash;&nbsp;All types of intravascular catheters are associated with a risk of both local infection and catheter-related bloodstream infection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Type of catheter'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Catheter location and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site chosen for catheter placement can influence the infection risk. For peripheral venous catheters, the risk is higher in the lower compared to the upper extremity and higher in the wrist or upper arm compared to the hand. For central venous or pulmonary catheters, infection is generally more common with catheters in the femoral and, probably to a lesser degree, internal jugular veins compared to the subclavian vein. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Location'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend placement of a peripheral venous catheter in the upper extremity rather than the lower extremity (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend avoiding the femoral site for insertion of central venous or pulmonary artery catheters, if possible (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of infection increases with the duration of infection, increasing after more than three to six days at all catheter sites. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Duration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H27\">",
"     'Replacement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At this time, we recommend replacing or removing peripheral venous catheters every four days, or earlier if there are signs of phlebitis or malfunction (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If no alternative sites are available, the catheter can be left in place if there are no signs of phlebitis or other complication. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Duration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      An exception to this time interval is when adherence to aseptic technique cannot be assured, which primarily occurs when catheters are placed during a medical emergency. In this setting, we suggest that the catheter be replaced as soon as possible and no longer than 48 hours after insertion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A defined time period to routinely change central venous, pulmonary artery, or peripheral arterial catheters has not been conclusively established and access sites are more limited. We recommend AGAINST routine replacement of these catheters (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Central venous or pulmonary artery catheters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Arterial catheters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vigilant clinical evaluation and assessment of the catheter site should be performed at least every other day. Indications for catheter replacement include purulence at the insertion site with short-term central venous catheters and hemodynamic stability that is suspected to be due to catheter-related bloodstream infection with all central venous catheters. When central venous catheters are replaced, we recommend against the use of guidewire techniques to exchange catheters (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), since this approach increases the risk of bloodstream infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Central venous or pulmonary artery catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend AGAINST routine replacement of peripherally inserted central catheters, which can be left in place for months (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Peripherally inserted catheters'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Catheter materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different types of catheter materials have been tested in patients with central venous catheters in an attempt to minimize the risk of infection. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Central catheters'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of antimicrobial-impregnated catheters (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1923683666\">",
"       'Antimicrobial impregnated catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -bonded catheters purely for prevention of infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Heparin bonding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Preventing thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the antibiotic lock technique reduces the incidence of infection, we do not currently recommend use of this technique for prevention of catheter-related infections. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antibiotic locks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Catheter and site care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter and site care measures can minimize the incidence of catheter-related infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the following evidence-based procedures from the Centers for Disease Control and Prevention (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Catheter teams and use of checklist'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Insertion site preparation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hand washing with antiseptic-containing soap or alcohol-based gels or foams; the use of gloves does not obviate the need for hand hygiene.",
"     </li>",
"     <li>",
"      Full barrier precautions during insertion of central venous catheters, including sterile gloves, long-sleeved surgical gown, a surgical mask, and a large sterile sheet drape.",
"     </li>",
"     <li>",
"      2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      for skin disinfection. The antiseptic should air dry before catheter insertion.",
"     </li>",
"     <li>",
"      Avoidance of the femoral insertion site",
"     </li>",
"     <li>",
"      Prompt removal of catheters when no longer indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For intensive care unit patients, we suggest daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      bathing to reduce catheter-associated bloodstream infections (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Chlorhexidine bathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest gauze rather than transparent dressings with central venous catheters (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A gauze dressing is particularly preferred if the patient is diaphoretic or the site is bleeding or oozing. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Insertion site preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Except for central venous catheters used for hemodialysis, we suggest NOT using topical antibiotic ointment or cream on the insertion site because of lack of proven benefit and the potential to promote antimicrobial resistance and fungal colonization (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Insertion site preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link&amp;anchor=H25#H25\">",
"       \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Topical antimicrobial exit site application'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With respect to the care of CVC points of access (eg, needleless intravascular devices and injection ports), the Centers for Disease Control recommendations cited above should be followed [",
"      <a class=\"abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"       2",
"      </a>",
"      ]. The evidence was strongest for cleaning the points of access before accessing the system (70 percent alcohol is preferred). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Access point management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend exchanging administration sets every 72 hours unless catheter-related infection is suspected and every 24 hours if lipid emulsions or blood or blood products are given since these fluids enhance microbial growth (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/1\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/2\">",
"      O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/3\">",
"      O'Grady NP, Gerberding JL, Weinstein RA, Masur H. Patient safety and the science of prevention: the time for implementing the Guidelines for the prevention of intravascular catheter-related infections is now. Crit Care Med 2003; 31:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/4\">",
"      O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:e162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/5\">",
"      Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol 2013; 31:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/6\">",
"      Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/7\">",
"      Ng PK, Ault MJ, Ellrodt AG, Maldonado L. Peripherally inserted central catheters in general medicine. Mayo Clin Proc 1997; 72:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/8\">",
"      Pongruangporn M, Ajenjo MC, Russo AJ, et al. Patient- and device-specific risk factors for peripherally inserted central venous catheter-related bloodstream infections. Infect Control Hosp Epidemiol 2013; 34:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/9\">",
"      Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/10\">",
"      Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest 2005; 128:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/11\">",
"      Mermel LA, Parenteau S, Tow SM. The risk of midline catheterization in hospitalized patients. A prospective study. Ann Intern Med 1995; 123:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/12\">",
"      Moureau N, Poole S, Murdock MA, et al. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol 2002; 13:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/13\">",
"      Clark-Christoff N, Watters VA, Sparks W, et al. Use of triple-lumen subclavian catheters for administration of total parenteral nutrition. JPEN J Parenter Enteral Nutr 1992; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/14\">",
"      McCarthy MC, Shives JK, Robison RJ, Broadie TA. Prospective evaluation of single and triple lumen catheters in total parenteral nutrition. JPEN J Parenter Enteral Nutr 1987; 11:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/15\">",
"      Farkas JC, Liu N, Bleriot JP, et al. Single- versus triple-lumen central catheter-related sepsis: a prospective randomized study in a critically ill population. Am J Med 1992; 93:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/16\">",
"      Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/17\">",
"      Cookson ST, Ihrig M, O'Mara EM, et al. Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device. Infect Control Hosp Epidemiol 1998; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/18\">",
"      Do AN, Ray BJ, Banerjee SN, et al. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis 1999; 179:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/19\">",
"      Danzig LE, Short LJ, Collins K, et al. Bloodstream infections associated with a needleless intravenous infusion system in patients receiving home infusion therapy. JAMA 1995; 273:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/20\">",
"      Kellerman S, Shay DK, Howard J, et al. Bloodstream infections in home infusion patients: the influence of race and needleless intravascular access devices. J Pediatr 1996; 129:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/21\">",
"      Rupp ME, Sholtz LA, Jourdan DR, et al. Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve. Clin Infect Dis 2007; 44:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/22\">",
"      Maragakis LL, Bradley KL, Song X, et al. Increased catheter-related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol 2006; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/23\">",
"      Jarvis WR, Murphy C, Hall KK, et al. Health care-associated bloodstream infections associated with negative- or positive-pressure or displacement mechanical valve needleless connectors. Clin Infect Dis 2009; 49:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/24\">",
"      Marschall J, Mermel LA, Classen D, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/25\">",
"      Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med 1991; 114:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/26\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/27\">",
"      Collignon P, Soni N, Pearson I, et al. Sepsis associated with central vein catheters in critically ill patients. Intensive Care Med 1988; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/28\">",
"      Lorente L, Henry C, Mart&iacute;n MM, et al. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care 2005; 9:R631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/29\">",
"      Ge X, Cavallazzi R, Li C, et al. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev 2012; 3:CD004084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/30\">",
"      Richet H, Hubert B, Nitemberg G, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol 1990; 28:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/31\">",
"      Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med 1991; 91:197S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/32\">",
"      Parienti JJ, du Cheyron D, Timsit JF, et al. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. Crit Care Med 2012; 40:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/33\">",
"      Marik PE, Flemmer M, Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis. Crit Care Med 2012; 40:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/34\">",
"      Deshpande KS, Hatem C, Ulrich HL, et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit Care Med 2005; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/35\">",
"      Lai KK. Safety of prolonging peripheral cannula and i.v. tubing use from 72 hours to 96 hours. Am J Infect Control 1998; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/36\">",
"      Collin J, Collin C, Constable FL, Johnston ID. Infusion thrombophlebitis and infection with various cannulas. Lancet 1975; 2:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/37\">",
"      Band JD, Maki DG. Steel needles used for intravenous therapy. Morbidity in patients with hematologic malignancy. Arch Intern Med 1980; 140:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/38\">",
"      Gil RT, Kruse JA, Thill-Baharozian MC, Carlson RW. Triple- vs single-lumen central venous catheters. A prospective study in a critically ill population. Arch Intern Med 1989; 149:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/39\">",
"      Maki DG, Stolz SS, Wheeler S, Mermel LA. A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. Crit Care Med 1994; 22:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/40\">",
"      Raad I, Umphrey J, Khan A, et al. The duration of placement as a predictor of peripheral and pulmonary arterial catheter infections. J Hosp Infect 1993; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/41\">",
"      Band JD, Maki DG. Infections caused by aterial catheters used for hemodynamic monitoring. Am J Med 1979; 67:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/42\">",
"      Bregenzer T, Conen D, Sakmann P, Widmer AF. Is routine replacement of peripheral intravenous catheters necessary? Arch Intern Med 1998; 158:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/43\">",
"      Cobb DK, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med 1992; 327:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/44\">",
"      Eyer S, Brummitt C, Crossley K, et al. Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med 1990; 18:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/45\">",
"      Sheth NK, Franson TR, Rose HD, et al. Colonization of bacteria on polyvinyl chloride and Teflon intravascular catheters in hospitalized patients. J Clin Microbiol 1983; 18:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/46\">",
"      Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997; 127:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/47\">",
"      Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/48\">",
"      Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA 1991; 265:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/49\">",
"      Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/50\">",
"      Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004; 22:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/51\">",
"      Fraenkel D, Rickard C, Thomas P, et al. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med 2006; 34:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/52\">",
"      Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999; 340:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/53\">",
"      Casey AL, Mermel LA, Nightingale P, Elliott TS. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/54\">",
"      Ramos ER, Reitzel R, Jiang Y, et al. Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience. Crit Care Med 2011; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/55\">",
"      Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005; 143:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/56\">",
"      McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis 2003; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/57\">",
"      National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/58\">",
"      Maki DG, Cobb L, Garman JK, et al. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med 1988; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/59\">",
"      Bentivegna PE. The Vitacuff and intravascular catheter-related infection. JAMA 1989; 262:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/60\">",
"      Kalfon P, de Vaumas C, Samba D, et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med 2007; 35:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/61\">",
"      Groeger JS, Lucas AB, Coit D, et al. A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. Ann Surg 1993; 218:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/62\">",
"      Arvaniti K, Lathyris D, Clouva-Molyvdas P, et al. Comparison of Oligon catheters and chlorhexidine-impregnated sponges with standard multilumen central venous catheters for prevention of associated colonization and infections in intensive care unit patients: a multicenter, randomized, controlled study. Crit Care Med 2012; 40:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/63\">",
"      Appelgren P, Ransj&ouml; U, Bindslev L, et al. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit Care Med 1996; 24:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/64\">",
"      Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr 1995; 126:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/65\">",
"      Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/66\">",
"      Alonso-Echanove J, Edwards JR, Richards MJ, et al. Effect of nurse staffing and antimicrobial-impregnated central venous catheters on the risk for bloodstream infections in intensive care units. Infect Control Hosp Epidemiol 2003; 24:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/67\">",
"      Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/68\">",
"      Carratal&agrave; J, Niub&oacute; J, Fern&aacute;ndez-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999; 43:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/69\">",
"      Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006; 166:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/70\">",
"      Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/71\">",
"      Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/72\">",
"      Montecalvo MA, McKenna D, Yarrish R, et al. Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability. Am J Med 2012; 125:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/73\">",
"      Munoz-Price LS, Dezfulian C, Wyckoff M, et al. Effectiveness of stepwise interventions targeted to decrease central catheter-associated bloodstream infections. Crit Care Med 2012; 40:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/74\">",
"      O'Horo JC, Silva GL, Munoz-Price LS, Safdar N. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis. Infect Control Hosp Epidemiol 2012; 33:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/75\">",
"      Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/76\">",
"      Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/77\">",
"      Warren DK, Yokoe DS, Climo MW, et al. Preventing catheter-associated bloodstream infections: a survey of policies for insertion and care of central venous catheters from hospitals in the prevention epicenter program. Infect Control Hosp Epidemiol 2006; 27:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/78\">",
"      Sherertz RJ, Ely EW, Westbrook DM, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/79\">",
"      Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/80\">",
"      Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002; 136:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/81\">",
"      Mimoz O, Villeminey S, Ragot S, et al. Chlorhexidine-based antiseptic solution vs alcohol-based povidone-iodine for central venous catheter care. Arch Intern Med 2007; 167:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/82\">",
"      Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med 1996; 24:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/83\">",
"      Shapey IM, Foster MA, Whitehouse T, et al. Central venous catheter-related bloodstream infections: improving post-insertion catheter care. J Hosp Infect 2009; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/84\">",
"      Hoffmann KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. JAMA 1992; 267:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/85\">",
"      Conly JM, Grieves K, Peters B. A prospective, randomized study comparing transparent and dry gauze dressings for central venous catheters. J Infect Dis 1989; 159:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/86\">",
"      Dickerson N, Horton P, Smith S, Rose RC 3rd. Clinically significant central venous catheter infections in a community hospital: association with type of dressing. J Infect Dis 1989; 160:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/87\">",
"      Webster J, Gillies D, O'Riordan E, et al. Gauze and tape and transparent polyurethane dressings for central venous catheters. Cochrane Database Syst Rev 2011; :CD003827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/88\">",
"      Timsit JF, Schwebel C, Bouadma L, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009; 301:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/89\">",
"      Zakrzewska-Bode A, Muytjens HL, Liem KD, Hoogkamp-Korstanje JA. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J Hosp Infect 1995; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/90\">",
"      Maki DG, Band JD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am J Med 1981; 70:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/91\">",
"      Menyhay SZ, Maki DG. Disinfection of needleless catheter connectors and access ports with alcohol may not prevent microbial entry: the promise of a novel antiseptic-barrier cap. Infect Control Hosp Epidemiol 2006; 27:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/92\">",
"      Salzman MB, Isenberg HD, Rubin LG. Use of disinfectants to reduce microbial contamination of hubs of vascular catheters. J Clin Microbiol 1993; 31:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/93\">",
"      Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet 2012; 380:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/94\">",
"      Maki DG, Botticelli JT, LeRoy ML, Thielke TS. Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective. JAMA 1987; 258:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/95\">",
"      Josephson A, Gombert ME, Sierra MF, et al. The relationship between intravenous fluid contamination and the frequency of tubing replacement. Infect Control 1985; 6:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/96\">",
"      Gillies D, O'Riordan L, Wallen M, et al. Optimal timing for intravenous administration set replacement. Cochrane Database Syst Rev 2005; :CD003588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/97\">",
"      Crocker KS, Noga R, Filibeck DJ, et al. Microbial growth comparisons of five commercial parenteral lipid emulsions. JPEN J Parenter Enteral Nutr 1984; 8:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/98\">",
"      Gilbert M, Gallagher SC, Eads M, Elmore MF. Microbial growth patterns in a total parenteral nutrition formulation containing lipid emulsion. JPEN J Parenter Enteral Nutr 1986; 10:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/99\">",
"      Raad I, Hanna HA, Awad A, et al. Optimal frequency of changing intravenous administration sets: is it safe to prolong use beyond 72 hours? Infect Control Hosp Epidemiol 2001; 22:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/100\">",
"      Hanna HA, Raad I. Blood products: a significant risk factor for long-term catheter-related bloodstream infections in cancer patients. Infect Control Hosp Epidemiol 2001; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/101\">",
"      Avila-Figueroa C, Goldmann DA, Richardson DK, et al. Intravenous lipid emulsions are the major determinant of coagulase-negative staphylococcal bacteremia in very low birth weight newborns. Pediatr Infect Dis J 1998; 17:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/102\">",
"      Didier ME, Fischer S, Maki DG. Total nutrient admixtures appear safer than lipid emulsion alone as regards microbial contamination: growth properties of microbial pathogens at room temperature. JPEN J Parenter Enteral Nutr 1998; 22:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/103\">",
"      Abdelkefi A, Torjman L, Ladeb S, et al. Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease. J Clin Oncol 2005; 23:7864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/104\">",
"      Barzaghi A, Dell'Orto M, Rovelli A, et al. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr Hematol Oncol 1995; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/105\">",
"      Schallom ME, Prentice D, Sona C, et al. Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial. Crit Care Med 2012; 40:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/106\">",
"      Krein SL, Hofer TP, Kowalski CP, et al. Use of central venous catheter-related bloodstream infection prevention practices by US hospitals. Mayo Clin Proc 2007; 82:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/107\">",
"      Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/108\">",
"      Larson E, Hargiss C. A decentralized approach to maintenance of intravenous therapy. Am J Infect Control 1984; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/109\">",
"      Centers for Disease Control and Prevention (CDC). Reduction in central line-associated bloodstream infections among patients in intensive care units--Pennsylvania, April 2001-March 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/110\">",
"      Warren DK, Zack JE, Cox MJ, et al. An educational intervention to prevent catheter-associated bloodstream infections in a nonteaching, community medical center. Crit Care Med 2003; 31:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/111\">",
"      Lobo RD, Levin AS, Gomes LM, et al. Impact of an educational program and policy changes on decreasing catheter-associated bloodstream infections in a medical intensive care unit in Brazil. Am J Infect Control 2005; 33:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/112\">",
"      Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med 2004; 32:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/113\">",
"      Soifer NE, Borzak S, Edlin BR, Weinstein RA. Prevention of peripheral venous catheter complications with an intravenous therapy team: a randomized controlled trial. Arch Intern Med 1998; 158:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/114\">",
"      Tomford JW, Hershey CO, McLaren CE, et al. Intravenous therapy team and peripheral venous catheter-associated complications. A prospective controlled study. Arch Intern Med 1984; 144:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/53/31578/abstract/115\">",
"      Eggimann P, Harbarth S, Constantin MN, et al. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 2000; 355:1864.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3811 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31578=[""].join("\n");
var outline_f30_53_31578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF INFECTION RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type of catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1532435\">",
"      - Surgically-implanted central catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1531907\">",
"      - Needleless devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Peripheral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Central venous or pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Arterial catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Peripherally inserted catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CATHETER MATERIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peripheral catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Central catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1923683666\">",
"      - Antimicrobial impregnated catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Silver impregnation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Heparin bonding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antibiotic locks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SITE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chlorhexidine bathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sterile technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Insertion site preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dressing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Transparent polyurethane versus gauze",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chlorhexidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Topical antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CATHETER CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Access point management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Preventing thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Catheter teams and use of checklist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Catheter type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Catheter location and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Catheter materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Catheter and site care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/35/33340\" title=\"table 1\">",
"      Line infection prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/22/1389\" title=\"table 2\">",
"      Catheters used for venous and arterial access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/52/19276\" title=\"table 3\">",
"      Prev venous cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/60/18380\" title=\"table 4\">",
"      Prev CVP cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/21/5468\" title=\"table 5\">",
"      Prev PA cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/48/31499\" title=\"table 6\">",
"      Prevention of infection with arterial catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/22/8556\" title=\"table 7\">",
"      Prev PICC cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/33/7708\" title=\"table 8\">",
"      Prev midline cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/55/26491\" title=\"table 9\">",
"      Prev HD cath infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/63/12284\" title=\"table 10\">",
"      Prev umbilical cath infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/33/35345?source=related_link\">",
"      Patient information: Central line infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_53_31579="Standard days method";
var content_f30_53_31579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for starting the standard days method",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"       Women whose menstrual cycles are usually between 26 and 32 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Date of last period known",
"      </td>",
"      <td>",
"       Start immediately",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Date of last period unknown",
"      </td>",
"      <td>",
"       Start on first day of next period",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"       Special circumstances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Postpartum/breastfeeding",
"      </td>",
"      <td>",
"       <strong>",
"        Wait for at least 4 periods",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Start after two most recent periods are about a month apart",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Three-month DMPA injection used for contraception",
"      </td>",
"      <td>",
"       <strong>",
"        Wait for at least 90 days after last injection",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Start after two most recent periods are about a month apart",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Pill, patch, implant, emergency contraception, intrauterine contraception, miscarriage or abortion",
"      </td>",
"      <td>",
"       <strong>",
"        Cycles before using method or pregnancy were 26 to 32 days long",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Start on first day of next period",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DMPA: depot-medroxyprogesterone acetate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31579=[""].join("\n");
var outline_f30_53_31579=null;
var title_f30_53_31580="Differential diagnosis myositis and fasciitis";
var content_f30_53_31580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of necrotizing myositis and fasciitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical finding",
"      </td>",
"      <td class=\"subtitle1\">",
"       Type I*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Type II*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gas gangrene",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pyomyositis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Myositis viral/parasitic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fever",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diffuse pain",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       ++++(1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Local pain",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++++(2)",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic toxicity",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gas in tissue",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obvious portal of entry",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       &plusmn;(3)",
"      </td>",
"      <td>",
"       ++++(4)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Type I and type II refer to the forms of necrotizing fasciitis; spontaneous gangrenous myositis is type II.",
"     <br>",
"      1. Pain with influenza consists of diffuse myalgia; pleurodynia may be associated with severe, localized pain (eg, devil's grip); pain with trichinosis may be severe and localized.",
"      <br>",
"       2. Severe pain is associated with necrotizing fasciitis due to group A streptococcal infection; the pain may not be severe in type I necrotizing fasciitis because is commonly associated with diabetes with neuropathy.",
"       <br>",
"        3. 50 percent of patients with necrotizing fasciitis due to group A streptococcal infection do not have an obvious portal of entry.",
"        <br>",
"         4. Gas gangrene associated with trauma may be caused by Clostridium perfringens, C. septicum, or C. histolyticum which always have an obvious portal of entry; in comparison, spontaneous gas gangrene caused by C. septicum usually does not have an obvious portal of entry - organisms lodge in tissue as a result of bacteremia originating from a bowel portal of entry.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31580=[""].join("\n");
var outline_f30_53_31580=null;
var title_f30_53_31581="Carvedilol HF subgroup analysis";
var content_f30_53_31581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Carvedilol improves outcome in patients with class IV heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the COPERNICUS trial of 2289 patients with class IV heart failure and a left ventricular ejection fraction carvedilol reduced the risk of death or hospitalization by 24 percent. This favorable effect was seen in all subgroups. Shown are hazard ratios and 95 percent confidence intervals. Recent hospitalization refers to hospitalization for heart failure within the year before enrollment.",
"    <div class=\"footnotes\">",
"     LVEF: left ventricular ejection fraction.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Packer M, Coats AJ, Fowler MB. N Engl J Med 2001; 344:1651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31581=[""].join("\n");
var outline_f30_53_31581=null;
var title_f30_53_31582="Contents: Reproductive endocrine male";
var content_f30_53_31582=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Reproductive endocrine male",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Reproductive endocrine male",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Fertility and sexual function",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/54/11114\">",
"           Causes of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22616\">",
"           Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2170\">",
"           Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17096\">",
"           Diagnosis and treatment of disorders of the androgen receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13706\">",
"           Effects of cytotoxic agents on gonadal function in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38341\">",
"           Erectile dysfunction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33481\">",
"           Evaluation of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/49/32533\">",
"           Evaluation of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31800\">",
"           Male reproductive physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41220\">",
"           Normal sexual differentiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17287\">",
"           Overview of infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/44/42696\">",
"           Overview of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/13/4314\">",
"           Overview of testosterone deficiency in elderly men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39893\">",
"           Overview of vasectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8442\">",
"           Sexual activity in patients with heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20951\">",
"           Sexual dysfunction in uremic men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/17/16664\">",
"           Surgical treatment of erectile dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42904\">",
"           The sexual history and approach to the patient with sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2630\">",
"           Transsexualism: Epidemiology, pathophysiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3610\">",
"           Treatment of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/36/30282\">",
"           Treatment of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/25/8602\">",
"           Treatment of transsexualism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21050\">",
"           Use of androgens and other hormones to enhance athletic performance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypogonadism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30536\">",
"           Causes of primary hypogonadism in males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/18/8488\">",
"           Causes of secondary hypogonadism in males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12824\">",
"           Clinical features and diagnosis of male hypogonadism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30120\">",
"           Hypogonadism in HIV-infected males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/61/23510\">",
"           Induction of fertility in men with secondary hypogonadism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1545\">",
"           Testosterone treatment of male hypogonadism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27384\">",
"           Causes and evaluation of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/9/6294\">",
"           Epidemiology and pathogenesis of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/760\">",
"           Management of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30423\">",
"           Steroid 5-alpha-reductase 2 deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21050\">",
"           Use of androgens and other hormones to enhance athletic performance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pituitary tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22489\">",
"           Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8857\">",
"           Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31561\">",
"           Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prostate disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Puberty",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19546\">",
"           Definition, etiology, and evaluation of precocious puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4889\">",
"           Treatment of precocious puberty",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F272DADF6A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_53_31582=[""].join("\n");
var outline_f30_53_31582=null;
var title_f30_53_31583="Hormone levels reproductive age";
var content_f30_53_31583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Hormone levels: Older and younger reproductive age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 440px; background-image: url(data:image/gif;base64,R0lGODlhBgK4AeYAAP///wAAAAAz/4iIiP8AAO/y/zMzMxEREczMzP/v75+y/+7u7n+Z/0Bm/0RERP9/f7/M/1VVVf8wMP+/v/+fn9/l/3d3dzBZ///f32CA//9gYP/Pz1Bz/8/Z/yBN//9AQKqqqhBA/6+///8QELu7u/8gII+l/3CN/yIiIv9QUP9wcN3d3WZmZv+Pj/+vr5mZma8QUM8KMM+5348WcN/V72Agn88qUL9dkJBGn3Adj+9jcJ+S3yA972BQz0BW7xAw75+i74CJ78/J798GIN8XMO8DEDApz9+1zwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAGArgBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIJy1wECCAgQUASBwIgAKBIIYBWCTcyNHaCgcLFqAYAOAASQsGAAxAsWDFARAdY8qEZmAAggAQSQQAEMHCRZIzgwotNiClTkE6PwJ1oHGo06e7WDwEcDPnzp4/CTXcyrWr169gw4odS7as2bNo06pdy3anrbZw/+PKnUu3rt2vm1YYaCrIJACUKlm6hKnILVRZhmklPvxqsaUXXFFEnFjxYkO+iRwzZqUZVufNqT57Bj36LenGuUSfJqWa8+pWrWG/dm16tqrYtMEJMIc7tO3bqVkNOABRloAK5XqjUj5KJ2FWBMgxX17oZspBEyGCcIgowtYIJXGqDOBzEArw4Yuz6iAAQvJbi29yRfCxoQOS3mEuaKie0ICtB/AUAEzWERKBZAI+Z8oGBGwwznSnxMcdduJtd90hFgQAVHbjlQfAdoRx2AoEAojwXm2DFDiIAQFYBIIDCQKwn3iHbIdeflRNKOMB5eGIygQETPBgcISo2FeFOhqS4f+G4v3n4YEU9qcKiQycWIuEF4bHAlAxzijlIDYKgqOR/60g5oCptEDAA0PigiUhE3GVZSFLHgmRk4Is4JedrlBpZSc62SfIfw59WYiEAAIA2VYweteVoR8GcCOaRhoA45kKlvLAmm3CV12SHFqYSJ3pdThoAGby2YoJHjTw5yeD3WSRAR4i8mZ1FqAQAAk4eolImDGqeNMLg/h4SgopfNApioIYWaqoOtX6l4aWkQAACwEQCwAKl6rKCgMNuCrdKDetUNSg3dr66YULacviCr3yV9KcwP5HEmRNsRBgsWii8sEDEix75afzhcrdfxbx2xB49TUElHNwcsUlKgxw4MH/q53oStIAl660yK2CWICRATDFi5NOExMawL7YLoxdrY66XAoBCUQnDoSm4OwAepGwgCAtDDCw27iiiPTCuSqlC9YmHksCWcKuRDcCBjcTKclLk/BoCwcKCFAA0Z5sCYBLNrUIAK0fb+KAtI44MOcqEwT8gZDh4FyK3cw0AIHeYHfygq6Snlpo2uFMoKwGLVTtZjh68y0wYuI8oAIAD7BZt9Xe6H1ClY/HgjczKrBJQQqKe6pbAUH3Pcvny8wNgOGlM9vNbgpwoDrk4UggZM2xD6wbAHvf7rk4NgNA8+WL/w7BxZ2X9g3vgrgODuuhUH8MBBcIMnTvuH8DuyApUIC8/+neBA/A9uMrFs7og1Sevu/li3uBe9wPD477grSgwfvqf2O+4/yz3zcQN4jvfcN6n0BgMRhwAkFkwATNQw04pAcADIwggN3rRuoAsEEMSvAbJXDQIIrnDQV2woTD2KAJMhBBV6BwGCQEgO6mhzlubE4Q5vOgC8GxgRIU4gMuoGHyMkc/7LVQNt5TFiHwV8IabgOA6Dsg+bqhv0JITohT5AYUj5ibbjBREAbsxgs1MUZgzG8QHqAfFvvnjfAVoodrhN/sCAFAKcpuGxQcYRzZOMdBcK1+zuvG8QoxwyYOsY+C6KAd5ciNGIIvcYbMojYKgD4GAvKD3IjbIa4YyTtmI/+HwBPXHgWYSSUWIozbKCMmVNkLUIKyk6v7BicLAT0xOvGTogQAJS+5Q2+EDhEjECE3WGkJYu6idoWIoi09iY08EgKIsOTjNhQJAA90QIdI7EYhDfFFbRiTEt/MBTXruExPIIBFGRHcVArzDUcOwgWmTOUtsTFOBWCzEi/wiaxkdTa2HcobtTTEBi5YTmZe44GFoOYwR7EfBCCNY4QrpSIGKc9DPlGNieTcIkGxtqQN6mfq6gb7EuFMbIRTEie9BTlFkMuCdmIBexnUdSA6iKV50XKI+OVCLaoNcr5yp56QiLZyNCt/asUbBExEC0gHVINaw5qFqEAI7kmJll1mPIP/YycqqCaIBMCipITQZFMZqQ1lno+qwHkEVysBJAK4lQAaWOsqQqiImgkzGybcziAkQpGEYQQzIUUkIaC60VgSwquIYJD4KDHQxVZQA3CVqyEQ+wl3WjFgFdUERrBzkpSspCVY0yo3jGgIcmaWjxhoECKSRQDHQqKxhsAAZOOKgQm4oHIf+MAIWvsJODJCAjg1KaDcUpWIXKU894noNlZ4iBsWNoMuIEAJKFvAESSAAryFRAJKMDlEyJYAI8ht5VwwAQwMVAPUzQQqE6vaZKRXtJo4inGRgqrkAoApytUGQg1hyeeSUgUqQJYh/iUI7JbgA6GbwAbeO4gESGB/i2Bw/1c/IAHJXqKKjQBYMlJr4cDGl7jiOQpW7jsxm3IjjYdg6SgDKQEXbBeSBfbhIMw7Acl9oATtpeWDM6GCEdAtE91UBHCRAVkY5xcT8i1JZwMD2kwZIqW02OUhSBtNAdbMqwwSZglcewgKTM0QGpCAhCXh5eBawo2OYFCHf5FaDTdCgRjJ1mT6apl0HvkaVDaEWfFKPhdgFgAtmC7l4pkIFYiZEGEe8yQ2IIEUKNoRYE1Ei42hgf19mRFQfkSmZdHfQ4QAOVV2HoAJgawE+NgRAhaECgTdiQSkQAJ3nQRFGzFqYnAYABro7p0zmI0/IsK0fEbRpBtcgkY/wsGT83KsOf/xgBFwORKWTYSfebHmSoNRxrsmZTYIe4j9uhR3Vz5ljhthQQ0EcxQTGIGuIyHWY8/aFthVQXpvLYgS/Dgz86SGlBGh0GD7btqxlQSQ7h0KDEjgA48+xHp/G0RcYLcFujWytQehAgjDl6zW+CkhVBxqCdY6E2v+RALMTXBGzPIRH68Fdhc7gRLYu4IEkKsFMZ3vaXR6ytnreC+HPQzsllwROoUEwFWe3UG0ILwpsPggJPDsf/LUGr5GxL7HCrlwF8PNkP75IlK77Fes/BAJUEHMDbHUbAcSGyG4piK8pnPZDL0YQ3bENiHh5ZCrQrF1PURqjfzkmkejAnumI0a96an/lBMDSGZORLQZYeiEm+IBSofEEYbgaA9jnBocV0TUTxtLnhsjbrCO8OIZkepXmLrrjWCAD2xA174/nRr9TqhGOY8YqydjU4kPK6HPB2pGIBsWFNj9IzwgggLcgABCcL0kq9EAEy0Cmd/23NuTwejQd5mpg/CTIyzYdFSUoOGSEAHzAAAEth/19dP4NCM0fo1Nf8zwysD9Js3MgAuE4Gtpli6CH6Bgx2vCBdgmCRwwe/h3fss3DVLVCFNHeG/hecxQfbGWVH6kAA1gT8e2ATWmAjc2bqLwAd3HCIDXe5YnTdWQeYtgfrTnOe/WDPI3CM6UdgowfpTgZf5nCQNVgwll/ztmh0nWEHuGcEZUp23QAIH1dlcJWE2DJwlhRgoakHuOQHw0h37R0HyOQIVB6BkoKA2b8laFwHEm0FKTsGOg8F2oxwji92Z+9wzH4Qg+SA3uVxibJw0S5lwFoH6WYGofWAnfFVeVMIBoKIXP0AFT5QjMdYWaIDKDQCjrlBnQ1w1WCAAnwEKXkGWbsAGzZXeNsIZReIDR0IjrB4btVz0BcCn8hDaFQUkFuA0oCHipOIPWlQnYxYeXcISb6FTP4FyNQIsMCAo09VDpcgg7EYfYsDyF4IeYsIQXdmqZwH7KZ4vOYFq2RwiB54ai0IsdA1LACACemA2FmH0yaAliSAnmVv+G4QeK2QiIzpCFghBdPweEu/gJvThTSoMXqMgN3jYIF2CBl4CHkzByFcYJbWiAzsgMHfCNggBZufeI/gaPpGg2pohvACCMT5WECpBzmMAgEqACLuYIDnZoADl7F0eC0rCN9aYBwoeLC3lCW2EmiggpNSUIJFkNC4hGSUgJGOAChkYAGbmR3vVgOFiFzleLlwcNKCkIFpRah3BzwlUb9WgKEJABAhCVUhmVF3ACCiCCoWCChFAxnpAAOCkBOqmR1HVeoABs58iJz+CORkc6rUcIzDgNbwiREamPolCRIcAAWKlLEAAuAuABHGACavcJSjkIlJSXm+CVObmTLjACfMf/CXYolCIZDeoIACmQOJVpCAW5DQUQl4EVk5tQAQwQAvnoCB1gAhYjAA3AABDQipegkIWQAQ1ECogJlnl4CV1jmGc5kMpAjIbwZWWnZw1gArj5C8OJmQLAmWcJeBBkCQVQARCwlwyQAeESlRlQk7moACdwAQLAAUF5CY9pCFLFmqKAiZZgAiFgnbk5lLggnoQoiWElY75VCAWgABkQAh5wAuipC12Tn4TJAwqAnM3YARfQAOzJCF2Dmg2QAUHznMUZCRXAKh6Al5YgiIsQnMlQn4H5h2hpCyYgABkKCfcoCJA3QnYHASfgASGQAQpQoLXQNQ1gkYqAAzQDoE5HmCcQ/wLdyYZpdwpPiZp0CQme6Y3HUAAZcAEN2ozqGWUWE5osmghqKQg854G5+IUCkAEfagtdY08XAJKGoAPnRqMCOQgiEAIn0KSEUKRXSgoFYAL2dwJH+ppcagge8KPAUAAXcAFmiqSRWQsFyQFfU6SSwB6taHsnB4KhaZawkKWCwB5pCgCuRgRcBaYveQgF8KL8qUt3mqeh0AH1mY+a+qSHQIHEUAEXkAGaWqO66QodupyCUKqQUAAewKrv9GevQ6uOsKYeMKctKgB0WX96JwEwQAOTqp4d2qiL6qqxMJ/2Z6XPN5mGUIfGmguC6J4olYaMcKq3SpgW86F1SKeJwAE6WP8ITXhYK+gIFHiX2BoKiloIW/pGIzADdCmpgqAaGUCthSCIcfoKFXCjF2AC4omhbGivvAABISCr1YqOioA6VRqtj1ABUMk1y+Onh8AefRkuDbA5C/qc18Qq4vlyhDB3kgABHJCib6quvDqxHjoI2FUD9iqvAKAaIRiqJ5sLFFilamSneNqwU1mqJnCpq1CaDTCzleCy8yqfhFCc4qc3h5qjkOCwC1s7AmCwRtsBzwmdDGSxHhCVaTpzhRB0leCwIcABPqsJEKAA4JK13ppIOddjPQCjReuM9cpfO8oLoJmrJjCmAgsJELBC2smzYwsKBSACGZCrGSACDKuhzEKxU+n/rRXQAFAoCPOZqyvatFCZASKYronAnr9JCMGnCagTAhUYCg8atK3CAAoAAQ16AUHwajtwf3oqhOCpiQ50AYdbCyLAAUK7jHy7nWmblbgbnLWraVZjp7K6rpArNAwgnix1l4Z5u1NJnSXLCZdZCEjJCTEYq9jKoh2QnWE7uZAgAzEAAz+Qsq97dogQt5ias8OAuY+wpsv6t5Swr3bLvpBpWJAIhuuatA3KqQLgt3UboZfLCpdWCG25CXvDvGV7ts/7vJbbhYPrAYVLCenWXezpsrERggKat+Qgv/cZvbd6rsxaPUQypuLZNV/4uI6wt0W6nUzbCi23Wo2pCfxbuqeb/whOa6W1I5onELyIACS1+bIbOgjSeZfv8JSi6a+YwKmg672iQLRAXIctDJMCkLzLMKKHsLmw4LTB6cGJ5WyIa7+LAHi9qw5QW5VXGQm42sEREhwXG8bN4ICDEJ+yQL+TVQIxnJ68lrD3sJcjG7aqiUPPaQJBI50vGpXcmVbwwaZ0LAwukALlKghj1wwOFnkhCbsEUQHYqZ39Gy4KygA9+5y9BB/kOw0YsGp2rGhS2gyl98V5/Buj4MQBsMi9cF26pQHk2D7rlgyJBgkW7MrUgbDFYInhRQE12G7JEGg/2cu+nDOp8Ff1Ows/2WCBxl3kOVngJV4PQF7VDG/nFgnKvP/MrIEKnzUYdRUADxDNoTABFPAAG9h0CZAAE2BblaOBFOZWKQB+NinP7Kxb1/wv2VxetaDO7IxjtzyClgzOJ4QKI2ZfmXFj+GwJ21xA67yBB/YAFKBgIxB5aqKTuRU6/zwB6AwJtXVb+7xbBJBbTch/AJ0J1+XIB5ZgDiLQFP0vFx3S34zQInwK9oVf7ASAHxByjoddbzXURE3UFX3RYCcBh+ZqBTwLtVVjkJdbb4XSlRPP1dzSBBA+CYCBNoZjR611k3DTOJ1ACo1cJYYXjropH9ACsbYpWp0IX+cJ5kYBJVB5wfDUlWOSHzDVH5DSVo3Vb+0bqTrWYS3OghFacln/QS6gAS6nAeSl1OrsyIGtskXnCQ/nDHgd1Xud1cScTXtK2KvUzFe1axsAcZzSYKNT1JX9CRGtD2IN2psAyxG2fbAdptXYEIto0LV9CbK925zwTaVoVMPq25nQ28Rd3Kbgizt43MILzMy93JrQi9hYvs/Ny6lxF9id3dq93dxdFsktj1rR3eI93uRd3nJhrdVdyZ8Q3NCd3omdpO6t3vCI2y75tvF9sEF833h80Pr93p/d3/ttvgAu3wI+4LrNgwbu32Cc4Ape4Axu2wseCsaCCAewL5igNfbw2uSA4SnIa/KxFU6GJ5CQH8BiCBWeCQjDCCLCG1n04aMINZ0g4riQ/+KLsOJSJwzG3SxJYggy7ggTfggnjgkG8DZATiMsLjsFohNEjuLkoQtD3gg2bpyH/As5niNZck5b4eL7cQAMoSffIQgtMxEgcBPggeWjaCZBriQO0RA+UR8VTiPDIggs4igcMzhRzkWr8CZbvuVd/gJxgh6EMhE+8TcuY+YtwhULQOiBYyFPniEOMy0OMBGAvhUTQwhz/uhuLiJxfjaS4jAMMRV3PgiCKMi5ygA8HMpI/igsMlR4MiPyIgi6QgL/AR75QebbQhxKXhIWTifUwiK8Qi0iYgEW7us6IRnYQiyhjlaCnSLcARkR4OqH7lnkcROS4SQFcuyrnohNfu3Zsv8duI0nDAECdTIRDtXkupIqhUDsKyMgJBHsw74rxX4tcpbsdqpRzsvFeV5DzrIohdLq6x4yXCHu1FLrklIgXpLmvI4fA0LupbItfMEiCFAg427kGKNtLv7sW34qPmEhs94hKsPm/P4QePLx5AEsOJIhFlAnEB8zDeFknI4AGc/wIoICD98iEg/sFE8IyEoIJxCu6J3vRbLjcp4t/6ERGT8ejTIg4D4gto4CuM4dJx4thLAkItEi4V4qkGEtQx/x3DHx9d12XWTlhHD0BeIkuW7tQs/pR5NOzlIvTR7uKt8iRe8f/bL1GX/1HJL1K2LzXY/zhgKoz3qeu1DlLr7wW2H/9Oh09DC1MiwCEwxxAI1v62buAGgeIDQO8HFCLFhuABziNpbO9ykx8ZRe8WfnLEevKHHSFI7OIoMOOBoSJ+m0+Dih6BpS4o7uF3FvER+PAA6AjRCf8Zvf+VkC8Tff7hIzCPXHnuAy+D+PCjuT8IcQ7ytALfmg4ZXAEEP1CnvSCNJP/ZWgAHOLCLra/MtOC4gN8BPj7Q6h+8Th2vnNCOjU5LEgEV8fKbjN/vWvCIz6fAYJCACCg4SFhoeIiYcBio2Oj42MkJOUlZaXmJmam5OSnJ+EnqCjpKWQFwyPDammoKKtmq+ws7S1tq63lrK5vL2DDBeQECEFvp2mDpIkBwEo/wiCyQEsjrvG1tfYmNXZANvc35kdAh2THCfgi6UsAZIHAwAWBgADKAsrByCR6Pv8397Y//oJPISKUgUBFQYGpBRvACMEARYAIMEoggVo7xQtHMixozaFHkMeAmaJgwKQoOiteMGIoiCKKxxkdDBNo8ibOHWhzOnxILlKCjjs5ISCnVGIEl1axBjKqFOeUKMa2uiLqlRfQS8VEFCsn1VILAW5gyePnj18+q6qzfk1V9u1tUxikuvVVNiJzJxBY1fTJty/Hd/aEgy41NaulrLW5Ui4sONWjWdFfrxJsVaEi4dS3mxsMmTO1uhiysBqn2dYp0GrhpS6EAIDfAU5DGBAov/f1bcOa+pAjF/rUr9xJiCAATen4IJeXISIgDkAAxdvG6clItimBidNB55uiAIBFdwzISe0IACCAfLmOUgbHtaJc5tEePC9vb2gFCpGJLBfafwgBxcNsN48KLDHHykXiPCJBwqi499x/A2XwAcPHHgMLAsYUBN6sg0oiFNPWTiKbpwo0IB2jPFHQQoATFCCiI+Mt8wLgzgHnYEwalIdKAWE8JM/9bWXAgWClEBkjomMt45R08xWG45IXvLeKAxk4GCQ3EkoCAUvRpmOQA9yl+AoByUEZIrtuSABISVM4OVUmr05CYmgZAAfN2HGYp8GFQ7ywAdyhhJnoI7sSEoFveH/ieV0JWxASAIjOEponpdQuhpppnBQGkCL4rbBCIaooAGh3QxKaiIeQGDKMIhdY2ml7bXAYiEYEEDqq5TguhmisGCnKJrcDXmIBG4Gqitrp0JiglCtQDBfNsdeyB1xh6jQp5zRUpPsIxyYMIsH2bnaqWpqIrLipKZuS0gIZraiwLPiAmucCuAdggGoxqarLgDO1pIqp/LiJoELiYxQHLb6qltlLSYCnLBjtSoiLMJg7pvImLT0qKo12cbI3bmJPFDvmx1LZ/EgdM7CALOdjctZCi0oMsGaFGd28iCG1tJju72UDCVokTZia8303UzIlLecYGXLAYO2QZeKNEo0ikYL/4KxLQe16pbLlD0waiMfFOulz4iQLVXKtVzNi9llTzewI9ZOfWXVAOSc9J1rc/0YAfs1IrLc4LANFdK52L1105wN3cgEgJL8MKlq24L2YHo7prgiTwN+ptGTp91g3ohvdrkio+couKBVG353VZUXVjoiUo/9eKCE86J6LacXkjssrx8StuMVVx15blz13PpftfbdSNyyB39z57aIdsvug1BfigZfO/J38zZbfPstlk1//Fq1HuwI48B3v2/tvUD/WeiOYT9J5twXffPwvEiP+/hXlU9J7weinvU44j5bhG9/8AOM/ChBLGwoL3Cz81LDsFGmw0UwKv6jhAZiZowEPP+AAJKCoPMslgFvZeMEJxIfKBYQjSctoxnPAEA0+pIk1SyQEi3I3iYeeAjluaAEH1ABzUQICwt4yEm2qeHN2AUJ5fFwExpT4SdisoAFoOAdY4kHgc6SD5NBjFqVmNknPkiAMprxjGXUAONKQDAASOBav4JMAAZko+go0WL9csQGNIBGDoLCBPCiBXIMMACkTKQi0ZHJzxSow/9tYgMSkEAIEYEBPj5AeRsAIRFbISDZpKeTXkwW+w6RSQ2Y72kpeGImPGBCQZqCQy45ZExmQsMvUSaDlmggJj4Ix0aYz09DhBYtQEnMAoXyVP8CWy8BkIAUtAkUrELgKFjwJEMqJZH/GfkQiNjBmRtaYoOXgKQkOfHGzXFyQBxST1O2eTJeNeKHqgRACwggtuvg7X1T1BAhsliWetyji3f84i8rkUNL8BIUmZwkx4ZJR/M8x45ts5gJlpaIBLBRES0oQTwrUUHJjIIlRinQC/Uiw9gsci3etIQY5xdJhW7iAcFcKGqMsoJ5sONJxySUrxTxJ0ekYFac0B9w+IcTXGICgIY4qCnK6TD7bauAmRxoD0vgR00ccKgJlEpKL6FLmbUUFgltKtW29T1BJEACVcUcGDVRwE0McICXMComwCkzAiyzFDAV69zUNUpCqKBxkNjqJYQ6irc+RrCWKGgiPnWkWjCVaeqD/9znDOEC/VBCrpe4amGJGhLMXmKlpBxBY2sRVsg69VTQg1QbNdjIy3g0qzxB7CV6Z9GR3SKvph3rqcoaxLiudZUbM4VhAeNZRGjNEF0dxFlba4vHgi6ytLvnIFoggY02QraT2KlwOdsR7BbCJ4qgq3IlwFxbTIAAo5XiaSVrL01ioriTYMCmSDFcuMDXEA0IgXQJodhBaKC615jACMqLmgseqHNeeylgMTHB7cL2Jt4lhHx4c9xBgBYA/7WuLc76AQ1vdoSkuh2kXFoJi672Enl0sIEHcl9CFIBBAFhFRd2rAo1+IwEaiJ001xvdQ1BgwZmAZya2wrMPr1ggEf5FCv9TfIi8UiBo6GiBaCkHYkLh76KfoJAmMkBR+nK3Hx8k8SE6CoALhGtYH4DyPgR8Vy9XWU6T++EoaiXmR5DZyG/GiTjr2QgZD+JddeUzOiCZytdCV4IpLMQH0ruJJ3s4EVxWcZ5FolRIyEdrME6EVPfRzHHik8dvKqEhPvVoDcaUEuJopYvF82VuYOADnobEiycriAZL5QEjEPQnBLgtJhaCT60gbyacxQHEiIAD4/jIg/khZdtCggGJdnEIgiuVJ6d110fmDpMF0WJMQIrRc+IAgxjgAQ/I1wMV1taywdHMZ3IUMyPpslSepoFSI2vSSBplgsH6W0uYQAAc+BwHWJb/q1Ybo7L1voSfD0FkuEwIwLjAd46SSYhc0+KvUCzEi1V972z3AscjODElLq2ISP9FA2p2q8dx405CUODUpYCUrneT7IKvO8AlKLRWMp2IrAHGO+RtwQQ23XFQI2miyAV3KTJqCkCmO6Irt0V+rk0JaD8CU4BJwARyKAF6KvvQOdKuIAScC6pmiuDqjvosIPkBoj+75o2IpiWergi6k+LJdc6pMAkljiID+xYCtresWSktifcCAxN4QAq63mZIdOACF6B2n8+sLAFY/vKYz7zmT2B3UOBdJ4Y/UEEI0e1R9LYUfS862M1Lgb+OYARBpMAEBG8IBghgvoUKpCMK0IAL//zIIPnlOCwy3B+1b4YkhVD84d1LCsLaMvRzTvziCSCBFDxg6KB4vO8vAS5L67fzinAWxWdB/MLrFkni+H2RRG4LR5dCs89fPSRckAICANFaE3DUBFqfZtirQPatYHu4NwkKYB11dwIhQGuZYAIh0ABFZgofAGQntXdvMnqEIGfG8F+oJwCUB3XQR0kPUAIl8AAYsAGJ91clQH3Wh32zoH3qZwnjZwiP1wDgNycnIACcNwvLZX57FSXIVwjWdw3CRgoKwIFp94GDgAGt13UpwH7GIICfYHWI8G/CBwoVEHw6OIRHeH4i8m+SBwBRdQ3f9n5GqHdxBAAE0ISkJCspSP8hs/cNLsgjvuZivfeCpSB+X4hQU7aFPSgiBSBuXziG2HBel0SEZeiBNoMBITiCJvgn9gczefeEt1cKSlMIIvB9ucCADtgKjMWHm2QhHeABxTYsBMYLG/ABWKYJylOEF3ACInBc9XWB9ScB/+d22BCHG8gKBYCACqgzN9iKIvCAmjABRUAAEWh9DyB7b1gqSPgYBSACJ3ABAlCFGAZz1/BDbZcJZGRGMQADOWAEAjA6sdgRHZABmjeA2Qd5BUiD11AB0CiNDFCDjlCEmpd5zCh/oCEAwCiMAOB+nPZBVOdLsBaJqDMU8mg7+cUAPHOQmGB71GgMHdAAMXgJGeAjnmj/TiKyAS3wAWjEfPyASvb2ZCogePW1FXZoDQXwLuDCkGTSDww4iloBeeDHaxaSAC6QYyWgAS7wQLT3cc5EkM1kccUnLwqQKBTEAA3YiznyhyHwkInAG/JmhvFyIMbYAgTJEfOkhoggYDo3lJqRAQaYMRAAAQogXxzQAA1geRlwkl7iLA3AloZQhB0olTJFN+igiCJIgo+SH0rnMU1zARR1bALQgJpiAhAAl4JQAGNZliuDlpeHlprCAAowlixpIQVge8BIdxWJmHDSjHZ5C/RHfSrgAjOTjazWND1iAuRmbhXQARCgmmcZAoPZAIV5mCmJbAIAmfI1mRBQmafijtGo/4+u2CoFIJOgh4+f2UEuIER2BSGIIw4B1wiuCZv5BXAK4JvJ+YzBCYzDEJWq14fJ2Q89GX+2MEMXiZ3hySPveIjHaQtINIHp+Re4Yhb/BJ/xyQ3oaSl1ZJ/3eRW4shQylE2I2J+FYSnpBEoBRaAF2guKJEO11JkK6hgGik7GlKARChf/iU3rtE0c2qEe+qEgGqIiOqIkWqImeqIomqIhmgsH6iHdoKIwGqMyOqM0WqM2KqK9QJ9oQZcXihP66VA3wqM9KhK6Yp78OaREygvvKaRIanBU1qRqQZNQ6p9OOqVnyIVWehPjmKU+anxcyjo396WfCJ5i6hFb6giwEUOFUP8eB4AOFAFQdCOlk5Cmh8Cm+3AAEFUJWwEj4zgbAdCmh0Cng2ABATAAdjoIIBAAEfAIhBoAJJAIEWAUi8oMEuEQEBUBFZoIEJEeI1I8ayGnNsUOgGoIgioIhGqof0oIibqoigARRmEAaqoJDhGriECphiACcMcfW7qqiVCq5JGql1AU0qAIpyoWEWFTdrQAeOoIm0qGSskWccKriOCrg3ColNCsDsGqm2AAnKoItloI5piH3LGriioIsBGphfocisoO7+AQqHoAyeAMELGo58quhZCoBnAAB5BEhlCsAGCrljoIDlFTbBqv9FCuzdp8HrBfPAGqACCt9ZquEduuhVr/sDA0r+qKrgKKrel6CIQKGwFwETHxp98KETSSseyaDE/yrYTgAQunq50CsY5KEW0KGyRAszb1rg87RxhrszhLCJE6AEGbCP4KsCE7CAYwIHbqENNQFCuQsDzCgWEpFQ4rszebqj6bqu5qp4nqAD07s8AqCK56UyfbrxLrqEP7rRYwqllbIOtAIywrCIiyMBZCrqyapnaKt1pbsam6qV+LANYKACsAIt1aCEV7rAELACYrCEt7tGkKtZ8QFG0VElVbruoKuFhrHo2rs35brno7qopLG4LgtB6brpEKAszwDN+KAn3xuKJbrHELAMsCAdFmH3ZrrpqbuZjbplu7txHw/7eBm62jC7Z56q/J8KhvKwgsMKqNexGuW7ibIBf4A61VJrO7e7mb27i/67m5C7rNakUBsAIUAVGnCr4IkAz5YKss8ai42xyvm66xaxItB7MB46c1273Yu7eoahQOsADAG7YAUBRdRKgsMKtAK6mCGw0d+6/JurfOax5jyw60OnfF01fU2z32m7/3e729y7/+y73XWyNOgQI0YsCD+qfsQCOvQRu26gDd+rzwAL9OkRGYIQAicqbo4ADaSgksMcE80giKUVZa6qWtoMOGu8CEQBEFMrgCagl5FHl1W6W0sKOV4MKw0HCJQBeTK8Wf1g9UbKpInKg39QwDsK+agDQN8P+suIHDpwIBAuCdiempZabGlEvEj4Ex8hXFtHAP7Du4RtHEECpRacmP4WPBQ/wJjUpSRrqkFookeyoISBdAw8QOfRy+37kt3WJyhiA9QlzHn/C7ABABi6qjILCfTModDUa7eixIlcwOOzyg25IqdxbHxCnHUPEbFrCoACoTLXqk7SFqcmvDkow77FsjY3HKMPLImvxnaDfHVDoKy1BTDUoTxeTL4WGRg2DL4ZEnjmoIDapN7HQyqgwAsyxUhuzJn/ACJLXLA9DL1cOhgcIbhdAA4rrGg8G+A7AcB1DMsHwqDHAnmnyZ8CZhU3vBm+DCSUTKptzIMBLJg+B89jwLfjr/DSQgrHlKnskiGhUkH5toCFvsmYfgxzRVUsMaqjjF0CIidgCQx/Rrx7jhAb+XAWfJcwRBx2FqQV6izfAX0S6tGgfxXbdnd+fMxZKGJKozzrZL1MYhArULAODXyTetXvkmXY+c1FF9IP+MCeJQz0rtZl4ykQAw0Nvc1auRxplQlJyJnGCKE+jpCD99CPTc0iDNGXY3h5mFzV0619ZwEHMJCvAHzO3Bxu0xy4Qwv5hwAuhm0Fg6EAMXAugYVNTI0oFN1leBq02NM5dtCWBJd/xYl0bXD6zyeHC8CXYtYZm9GoIdHqQxbYhwAo9dCZuNCEWY1lJNpijZZ7ponKMQiokA/wEFbRypzR0wDWhwbdOyBpiHUITdN6bMbQwHkYPJrXtg+SOd/WyjHdZyrdaqwdsxNoBiDUXITQhyudNr/dm8cAKNPYDLTQhISZbI1tenoMalDdyUHRWRLHeDwN0jsrB/ZoQfvWOLzQs9Qg60u94rndlFaBKX6JSNoM3zzNWcEdzGYdaCsMwAQN5aHQInIZcPDd/Go9dUEm3vEtdRZFz5HQLX/ZS6ZwhYN9ZX7Rh0UuKC4NqtAJXsieE4HeC5MJFIyQEyPQkVAJgMydSNkNWT/eKFQeTsHW1x3Szs6dQOnlu2zQvE7dE3WN0erdvP9tr8ctqgIeGXInzrHeVWeAgQ/f9c5m0LBu7RcweWWE4IgI0I+j2u9c0TMG0I0bRt4NPMUt7cuaDndYLXfQbh2H3kPc0Tc04IMrYsxvDfBQbinPCypcCAhB7WnXfnLn7oOeHQhSAOChDn+ePhte3ntkBhtDDbjVDVitDkdI7kf0HhyT2YlW4KOA7gU24LdoLrXI7UikDjmQ7pa1FARfjmreDoRX3rp56rsGDqicDpiUC3rT4LfPwfJoXMjqHkikDssHDmT5rmrYCAtB3pHi7Z4eflm/Egs4HP/vTFGM0doN4PtW5o3k4Kf3gB2v4J8rHqxm3YPC0Z7MvO1kwZmE5AZD7qGFkLQQ6TvEDThTDwDW7o/s7/FA4a8I6R6Iwt6q4E7JPAGwzLMKctzI8AxdEe8aGsoe8czvzh7AMR712M7KPA4Sgp6Pm94okA6/RNzLKx7nDa7hNu3PhZ8LZO6qMA7tkA7aYdX1z+GOjOJHtR0tb+F8Z+Ddwu7zrOCfV+78v+5Cud9IOg8qoB5pSB7SHB8lil3ZaQ8G2dfSgOrgxOCLze72ZfGO9O8GkPKxov5/rFD8V5AYjB6m4N8jev6SHh8CEx9S0v9Bv/mo0pmxhvDZspCEBvCJEvoXXuERbvEWSPZ1W/e7NZmx1Q97Aw7KquCrMun5XfEV7fEVHvnHF/q79d+JNp7pvc+IAB9o5h8zdh+GU//++9zvXwnsmVQO6offoDsfrZkPnYBuwizxNb4esEyOcRTvwCIfZsPfm7v/nZDvg8gWw+Pwhv//XS3w9zLxLTS/WaMO1NvyE3xa88Dwm2xhOoTgmjD/6uHhWEjxNGjuaySsk5DwgLKwcgCAEIAAYWAIyNjgABj5KTjxkmlJiZmpucjwUCnY8CFaGlpqeokairpqqsr7CrHR6xtagQF7ahrrUBJIwRiwAOAwMGjAMOmryoHh260NGPDRDS1rHM16vZ2t2hJhne3QIF4o7crL6MxOssycgoy68VIeb2oZb3+pLo+5T9/sw1EBHQVgMF+gCeUgcg2LpixwC8axSgosWKr/9McCjIEQADBh3vKew4MiS0T+VMrmIQTiQ0hgNQCCJkCJEieaw4XFKpT0QDnt5KFhQK9JXPoqdmJbQ1wCKLdRWfSqxoYAHOVSFIIRWHa+skCAoYNPAAqpVXRkTPlsqnllNWl1vTPlLaVltZtZ88NGCgoNpCtXLranImWBMHhPYCm1PMCFxha2/VasQG+HEsupYnOU7slTGAg5mhUWt7gSAsz+JQZ94cem49znFZjWptKwPIsx1en65M+9TA3o9CPFvceVVX4LAYnFB7Yjnls6otk0PeiG3q4qiU88TgD8LPs8J76VtxccBV6pqOo1ewkXhsVKVVUiBAYR9mpCJyib//R35Fp+iFsUYdPbAhlRYE4FwwXUjzaUCfPp8Mh5ROtgAYCnkVRbCJhXVZhx5h173HiQAXWOIXgw/OV989JniQElAoVRgQAgeYlwmHpJ2Inm3uGdibio0AeQ8H7QE1mYwBsUPRRRaht4kCszkJgALfBYVdaEIG+aA9BXiwE0/xIWnPAIvQ+MuNUmKiQAg6ovdJj0XhWAsGBBAgwQcfqPDAAy5MMEECWToSqDcdCCBhSLm9pA8JKFQkDJppSpJBeJECcEGb1sgpJk8PaJCAny7sqQKeEtS54iSDdtPiix01pyh0lTqSwQVaVXrCbd1ouh9QI0ygCXeZpKoNkSpRuqmP/7EWcMEFrEaaX4jI8kSBBLXMV8IHD1DwpzZdftmsPc++emWaynLwLSoJEAAsUBUIgJg2uj7HkwSnwoLBBBQ88EEJW1pTqAAAG+oPheKKKOUsLVVLgApb5ebcNfHuxtMEI2izwQgPcNsIA/rdE2PB0TqZG66/TtCCBqUmMEkKGoygMlIVXGAuxOOGpEHGFpeggTkXkCzOkSDHmeaa72oygZ0atDBBCi1Moi62XhXAAa2Z1hwQoCmo600Cd76sTaG1ihNm0EBFvA/RnVxc77SSuEDtBCUwZ6wuZqfDEQYUZJ0CBV53kwDK615zmD2JSlP3K4ebw8Dcmaj9SAIjBA7Azf+MlFAvI4H3fXbAAHNgGuJW27MBAXtrbk7LG3TD3jVhA+Cq4bwhlwGImzguCeWOjJA6ABTELWidwBOw+ySmR/NiBQx44AEDrZeS+F/+QH75PhSM4II27WbQPCxQMvAi48cKDZzUzHaSQAkMT+KC74zA7UgJvjISaPWSyy/8PiJwcBf0Id/zwc4hccEIpqeLCmRAANqzBZRMMBaChAt2sOqNssrHCa4BkBK6a4QK0scIfdlveiqQgOZUMAKUheZ5ZtlHCIvnj4td0BoGROD2SgElxIhALw34UjRQyL/QxCxhm7CgJjbYCPg5AnIbEBYAUpCCRiQgBRLgjgRw9hge7oL/epEDCgYk4KluxDCBqKihIwrAgChBMHSCyQ0QNSFETVyMEW98RAj7JQmuMWyLKXjZ6IYnGCv+Rx8Xix9QEvABEXrjizNUk7smca7wla01EAhB0TaBMhY+ogTX65QkRkdAR2AAYyPgYAepVUU0WoNrVESKBkrAR9YdEIxPWuQ+/HjFWBSAPQLw3CPyx7le+vKXv5ykJirZCU1K4HqSqN8kODmJKZbSYN5gYlseoDuToYwAlpzHKxPJCDH6g5Z/ZMUt9XeYDiRveRA4J/MKWApiduKTo4MFC0cXPGxGsH/aeIAh2zIfLirtA52sBSIp4c1vxq4U48ylAprFS11yRAUl/8hmMyXQxGv0jWn3FJ83KNbKs/StBRXF3gGBKcuAgJMTQvHlYRoprQyaogV07AbbTEkScXwyoG35pDkayU1oQTNN1etoBe1pD5fiUyV1syNwjhmrcNIUOEF9jAZE+cifRkMDH0COCl7YVEycdENSwpe++CVIwWyAfafcxlNRsa7qSbQuZ+0qWPXhgKjMNTQbmMADRsWva2VrAspsCyZPqQKipvCorzha8IQaGlbKFVJjkskgQHCeFvrpsnvK7KjwhCd+1elaepoAYzOjyWhQMwWBvatGa2E7ALy1MFN9rFf14ZBh2Gi2nainbnfL23pei7N5yuyeLuun0aKHTq/tRP/vPlDWHlaVtQOMlduSiRTJJRey5lCSA6SCW9kWBqC1mMC+cOrU1b7ifFRNUxYx5yANpHYfiq2ncVFKW2EoCS1Mwoh3C0OBrIbCdBhIAcYcaRIAtbGpGMVAeyfQ3veao7WMaEFEQXePmMyEstjdr1rSZV1KwHS3Kriuap/LigM3dVoNboSCCeDegnyyaZKQpt3oatfKavgsuMMc6fjmxBQ49nE7XCsl99lVOrU4mQ6i6AMAmzaTPSAFHxgBAUC75A1Y0sRHLAGMU3HQG59lfY74X952DLc8wskbTQlAVWxsCnc+VqKfosCoRjCCPGkLAHltwZOjTIA6p+ABSktdXvf/uq+YMgLLj9ijWjPq5bP8mGIvwxoBtuzTbtQkEY/6xysgKuIb3+vJpfIzoEUbioul180enrBzzdvorWy1cpQ+9FLMYQxkKCPDpYhqq/2BR6+hGhMyPqxVd82TN0q4wGO6dUzYzAldE3sfT4wiAFqw3iBqedUkfnZRJEDt5pp0TBGZCH7zGwrdelvb9iAhNeebaMOWF7Ho7gi1/RuS5136Jrh+Z7wLMp9zsxHbPPnqvpOpNWSPiSpWyffA1eJgunV54R3pNLyEDHEvC/xG+c24xjfO8Y57/OMgD7nIR07ykps84505ucpXzvKWu/zlMCc3o7+N1IDXnOK5svnN692W/4tfHC065znOJ75zoRt96DQrek0NPuxZM/3oHPl5d6MedKgPZeYGVTrVn950uHB961av+tW1PvawZ5vmXy/70rteILNn3e0Vj7vc5073utv97njPu973zve++/3vgA+84AdP+MIb/vCIT7ziF8/4xjv+8ZCPvOQF84IDVOQFUAkAd81hgNvWVfP7IIHlUYCIgAziTCswwOXvYYGKkB4AqV99SCov+89vXhydb4TtQz/60vvj9IyIfQAwb4/WB+D1wie+SSyA+QEcQCKSJYQ5SFARG1l4svqoEQAsEJF9pPlMEdAQCAKQcHFEABHhb4j4yR8S5kvk+deXvjioHwDrR/8fw/bQPvcD8n1grL/83nB+6jeA4weAJgECz1db9yUOSqKAtyUOhmAV1Bd1ZyJ/DMF6GmKBZ3KACWhfD+gNDeiB9xCBADCBQ1GBGHaBxZeBKbiB+8ACNQZ7KEBZ2nV7ugCDoPcQOjgMNqgNJkh9/mFSZ8IQw7coB+AfRKh894CD3LUCM2hb7XANTKh7NlKD9/CDARCE3zSEQ6iE83eEkNCFPEEjxOeA9xCCO2gOJGiCQsgIGngPL/B6APCGIUGGwCCC9oCGUGgPa3hSDEGH5hCHpQeIHRETvhd/+MeA9ndh2Wce+3eC/gcABZiHaxaJk1iIcgh9jJiHi4h996B/3bf/hZbIftlViQRIiiHRKBaBebs3fRYRD8MQg/Ygesfne/qQZqCXfPaAIRaxArqYihfBirLYDfR3fJnXg8TYe/znFLCnekVoDrxYEb7ojF44edZ4jdiYjdq4jdzYjd74jeAYjuI4juRYjuZ4juiYjuq4juzYju74jvAYj/I4j/RYj/Z4j/iYj/q4j/zYj/74jwAZkAI5kARZkAZ5kAiZkAq5jxFwCJ3QkIm4kAXRkLaYCRApkdIAAs4YihbpkJxwkRhpCxpJFQ/pkZsAkiFZC9RnAP5BJh9pkpqAkinJCivZkpmGCRRZkhE5k6sAg0pYV+ZRVwiAAJ9HfjmJix+Ig5ZX/wjlMYcOeQCwyJOT4JOOAJSxOJRFuQBHaRFJWRFLaQhc6ZSIAJVSmQmqZ4vjx5IBoAwocAC+R5FNsQiNooVNoSEoaQjP13rMV39lOQln6QhpSR5s6ZaNAJcBIJdZ2Ah12RABgH94uX2H+QJ82ZeT0JBe2CgQaQihSJENeRH413rmAZEr0JkVsQCGgAIOcAAGSJmW+QiY2Zia6QicySSfyZeiSZrkd5qpuZqUWYJqZpNTYYwA0JZveQhN0YNxGYsg0JDmYXlW0ZnIWJY1KRGLkGawSJyFaZw5+AjJWVfLyZfOyZjb2ZuPMJJqxggLYHk2QpQWoZUOiYswWVcHoHqFYIF5BhCe4weT5CmJG4me6skI7FmaW2kRtiif9EkjaoafFVGR+0kJ6fl84jB+t9agmPCg5iChFLoJycmAjZmhmLChINihHjqiJFqiJnqiKJqiKrqiLNqiLvqiMBqjMjqjNFqjNnqjOJqjOrqjPNqjPvqjQBqkQjqkRFqkRnqkSOpdgQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean daily levels of gonadotropins, sex steroids, and inhibins in older (ages 35 to 46 years; n = 21), shown in red, and younger women (ages 20 to 34 years; n = 23), shown in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;from: Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84:105.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_53_31583=[""].join("\n");
var outline_f30_53_31583=null;
